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The generation of new chemical entities (NCEs) for use in chemical biology and 
drug discovery is of wide interest to both academia and the pharmaceutical 
industry. In order to generate NCEs, this project focused on development of 
new synthetic methodologies using transition-metal mediated [2+2+2] 
cyclotrimerisation of alkynes and unsaturated molecules to form bi- and tricyclic 
heterocyclic derivatives, some with structural resemblance to the quinocarcin 
family of natural products. Three different dialkynes (1,5-di(prop-2-yn-1-
yl)pyrrolidin-2-one 2.117a, 1,6-di(prop-2-yn-1-yl)piperidin-2-one 2.118a and 4-
benzyl-1,6-di(prop-2-yn-1-yl)piperazin-2-one 2.120a) were successfully 
synthesised. Several cyclotrimerisations were attempted, with the best yields 
being obtained when diethylacetylene dicarboxylate 2.113a was used as the 
monoalkyne and Cp*Ru(cod)Cl as the catalyst in refluxing toluene. New 
heterocyclic compounds with potential for diversification were synthesised using 
a diversity-oriented synthesis approach; specifically the build/couple/pair 
strategy for the synthesis of small molecules. Racemic nitrogen and oxygen 
building blocks were coupled with acrylonitrile, bromoacetonitrile and acyl 
chlorides. The pair step involved the intramolecular ring closure using transition-
metal catalysed [2+2+2] cyclotrimerisations using microwave assisted radiation. 
The best catalyst for this approach was found to be CpCo(CO)2 at 150 ºC (300 
W) in chlorobenzene. This provided a new methodology with potential for 
synthesising a diverse set of small molecules for biological testing. 20 
compounds were subjected to chemosensitivity testing using the MTT assay. 
Several compounds were shown to possess activity in bladder (RT112) and 
breast (MCF-7) cancer cell lines. As these two cell lines are known to express 
extra-hepatic cytochromes P450 enzymes, it is possible that these are involved 
in generating cytotoxic metabolites that may damage DNA. 
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Chapter 1 Development of new methodologies to generate 
new chemical entities 
 
1.1 Chemical biology as a recent field for the development of 
small molecules as new chemical entities 
 
Chemical biology is a broad field of study that involves the multidisciplinary 
collaboration of synthetic organic chemists, medicinal chemists, computational 
chemists, molecular biologists, physicists, mathematicians, engineers amongst 
others. Although it does not present a simple definition, one can extrapolate that 
chemical biology is the use of chemical tools to uniquely interrogate human 
health and disease affording a much deeper knowledge of complex biological 
systems.1,2 
 
 
Figure 1 – Valley of death.3 
 
Chemical biologists aim to identify small molecules that can target or modulate 
each of the individual proteins that are the cause of disease. As a field chemical 
biology aims to bridge basic and clinical research, which has been described as 
crossing over the so called “valley of death” (Figure 1). Significant work has 
been done by academic research groups to provide a better insight into 
complex biological systems and how pathways may be related. However from a 
pharmaceutical point of view, this research has not yet revolutionised validation 
of new targets and generation of new chemical entities (NCE) with therapeutic 
value.3 
 
Pharma     Novel      
Drug 
 
Identify drug candidate, 
Perform clinical trials 
2 
  
 
Figure 2 - A schematic representation of the overlap of chemical space occupied 
by natural products, drugs and combinatorial libraries in total small molecule 
chemistry space.4 
 
It is believed that the chemical space encompasses 1060-10200 molecules and it 
is proposed that screening new small molecules will cover more of the chemical 
space than natural products or molecules screened from high-throughput 
screening (HTS) approaches as depicted in Figure 2. Natural products and hits 
from HTS, in general, only cover a small amount of the chemical space due to 
the complexity of their structures, decreasing the chances of finding NCEs with 
true potential of being developed into drugs with clinical prospective.5,6 
 
1.2 Diversity oriented synthesis – a strategy used by organic 
chemists and chemical biologists for small molecule synthesis 
 
 
 
 
 
 
 
 
3 
  
 
Figure 3 – Top: TOS and DOS focused library synthesis.7 Bottom: The molecular 
diversity spectrum.8 
 
Biologically active molecules have given chemists the challenge to develop 
efficient methods for their synthesis. Target oriented synthesis (TOS) and 
combinatorial chemistry have often been used for the design and synthesis of 
drug-like compounds that resemble natural products. Although these techniques 
provided a solid foundation for generating biologically active compounds, the 
chemical space they occupy is often very limited (Figure 3a).9,10  TOS is based 
on a retrosynthetic approach (it moves in the direction of complex to simple), 
the objective is to synthesise the biologically active molecule (natural product or 
known drug) and closely related molecules; as shown in Figure 3a the chemical 
space is poorly populated. In combinatorial chemistry the synthesis is 
developed based on an active pharmacophore or scaffold, and medicinal 
chemists explore a certain region of the molecule that is known to provide the 
biological activity. Although this technique allows access to some degree of 
diversity, as Figure 3b illustrates, the chemical space covered is still not 
significant. 
Accordingly, successful generation of truly NCEs may therefore not be 
achieved, and there is the demand for developing new and powerful 
methodologies for the synthesis of small molecules. Therefore, diversity-
oriented synthesis (DOS) appeared as a new synthetic tool to synthesise broad 
libraries of small molecules with highly substituted scaffold diversity (skeletal 
and stereochemical), with the potential for encompassing several chiral centres, 
but with no single target.10,11,9 This methodology is a divergent synthesis 
(contrary to the two methods described previously) that in a few steps (3-5), 
using robust synthetic methods, provides access to an immense number of 
different compounds leading to a highly populated chemical space (Figure 3c, 
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the synthesis moves from simple and similar to diverse and complex).9 This 
method can either start with a building block (commercial or synthesised), which 
can be reacted with different reagents (branching pathway) or use different 
building blocks (commercial or synthesised) reacting with a common reagent 
(folding pathway). Regardless of the strategy used, the aim is to always provide 
a short, modular and diverse synthesis strategy.7 
 
 
Figure 4 – Application of a B/C/P approach starting from proline 1.1 yielding 
bicyclic compounds 1.6–1.9.12 
 
Despite all the advantages of this methodology, the original DOS approaches 
still afford molecules that mainly contain heterocyclic rings with a high number 
of sp2 hybridisations. Therefore, there is the need  to acess more diverse 3D 
molecules, i.e., with higher number of sp3 hybridisations and better physical 
properties, in order to cover even more of the chemical space that may include 
more challenging unknown or “undruggable” targets. Consequently, within DOS 
the concept of the build/couple/pair (B/C/P) strategy was born (Figure 4).12,13 
The build phase involves obtaining stereochemically diverse building blocks 
(chiral, commercially available molecules are preferred) that have groups that 
can be further derivatised, i.e., that can be coupled intermolecularly with other 
building blocks (couple step) in order for all combinations of stereoisomers to be 
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covered. Finally, in the pair step the molecules are joined together 
intramolecularly, ideally using diverse reaction conditions (frequently transition 
metals (TM) catalysts) to form a higher number of products. 
 
 
1.3 Tetrahydroisoquinoline alkaloids as a starting point for 
small molecules synthesis 
 
  
Figure 5 – Examples of a THIQ alkaloids. 
 
Tetrahydroisoquinoline (THIQ) alkaloids appeared as a class of anti-tumour 
antibiotics with the discovery of naphthyridomycin in 1974 by Kluepfel.14 To date 
more than 60 compounds within this family have been isolated and biologically 
evaluated. THIQ alkaloids often possess both antimicrobial and anti-tumour 
activity, which is derived from a variety of different biological processes 
including: deoxyribonucleic acid (DNA) alkylation, DNA crosslinking, oxidative 
nucleic acid damage by superoxide formation and protein inhibition.15 
The family of THIQ alkaloids as anti-tumour antibiotics can be divided into three 
different sub-classes according to their specific structural features: the 
saframycins (e.g. 1.10), the naphthyridomycins (e.g. 1.11) and the quinocarcins 
(e.g. 1.12) (Figure 5).15 
The saframycin family is the largest family and can be further subdivided into: 
saframycins, renieramycins, safracins and ecteinascidins. All the compounds 
belonging to this family share a core formed of five condensed six-membered 
rings, where the two terminal rings can exist as quinones and/or hydroquinones. 
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They also contain a THIQ motif and a piperazine ring, which shares the nitrogen 
with a second THIQ moiety. These molecules are sometimes also described as 
bis-tetrahydroisoquinoline structures. 
Naphthyridomycins can be separated into two subfamilies with closely 
intertwined natural products: the 
naphthyridomycins/cyanocyclines/bioxalomycins and the dnacins/aclidomycins. 
Naphthyridomycins present a core of five to seven condensed rings, four six-
membered rings and up to three five-membered rings. The aromatic component 
of the THIQ can also be present as a quinone moiety (tetrahydroisoquinoline-
dione). 
 
 
Figure 6 – Yondelis® 1.13 and Zalypsis® 1.14. 
 
THIQs anti-tumour antibiotics have a remarkable broad spectrum of biological 
activity, with Yondelis® (ET-743 1.13) and Zalypsis® 1.14 (PM00104) currently 
drawing most interest due to their ongoing clinical investigations as anticancer 
agents (Figure 6). The ecteinascidin-based ET-743 1.13 was approved by the 
European Union in September 2007 for the treatment of advanced and 
metastatic soft-tissue sarcoma and in September 2009 for platinum-sensitive 
recurrent ovarian cancer in combination with Doxil,16 it is currently approved in 
56 countries within and outside the European Economic Area. Zalypsis® 1.14 is 
also a potent cytotoxic agent that displays high in vitro and in vivo antitumour 
activity in a wide variety of solid and haematologic tumour cell lines and human 
transplantable breast, gastric, prostate and renal xenografts tumours. It also 
binds to DNA but does not activate the DNA damage checkpoint. Thus, Zalypsis 
1.14 exerts cytotoxic effects dependent on DNA binding, but that is not 
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associated with DNA damage per se.17 Zalypsis 1.14 is currently in Phase II 
clinical trials for endometrial and cervical cancer.18  
The last family of the THIQs anti-tumour antibiotics is the quinocarcin family, 
which can be divided into three subfamilies: quinocarcin itself, tetrazomine and 
lemonomycin. This family of natural products contains a tetracyclic core, also 
bearing the characteristic isoquinoline fragment, a piperazine moiety and a 
condensed five-membered ring. The aromatic part can also exist as a quinone 
or a hydroquinone. 
 
 
1.3.1 Quinocarcin family 
 
  
Figure 7 – Examples of THIQs anti-tumour antibiotics belonging to the 
quinocarcin family. 
 
Quinocarcin 1.12 (DC-52) is the THIQ anti-tumour antibiotic with the simplest 
structure and, as a consequence, has often been used as the starting point for 
exploring the chemistry of these biological compounds (Figure 7). 
The biological activity of quinocarcin has been demonstrated against Gram 
positive bacteria, Staphylococcus aureus, Bacillus subtilis and Klebsiella 
Pneumoniae and against P388 lymphocyte leukaemia in mice.19 As an anti-
tumour antibiotic it appears to inhibit ribonucleic acid (RNA) synthesis over DNA 
and protein synthesis.19 Its monocitrate derivative (KW2152) and its cyano 
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derivative 1.16 (DX-52-1) were the first agents identified by the National Cancer 
Institute (NCI) for displaying activity against the 60 human cancer cell line 
panel.20 KW2152 showed potent anti-tumour activity against St-4 gastric 
carcinoma, Co-3 human colon carcinoma, MX-1 human mammary carcinoma, 
M5057 sarcoma, B16 melanoma and P388 leukaemia.21 KW2152 underwent 
Phase I clinical trials in Japan, but failed due to toxicity following daily treatment. 
The more stable analogue, DX-52-1 1.16 underwent Phase I clinical trials in the 
USA, however this analogue was also abandoned due to gastrointestinal 
toxicity.22 
More recently, it has been shown that DX-52-1 1.16 and KW2152 can also 
target Hypoxia Inducible Factor-1 (HIF-1), a transcriptional factor which is 
induced under low levels of oxygen and is crucial for tumour progression, 
invasion and metastasis.23,24 DX-52-1 1.16 also appears to inhibit cell migration, 
which is common to both normal cells and cancerous cells and is required for a 
range of biological responses including embryonic development, tissue repair, 
immune cell function, inflammation, angiogenesis, cancer cell invasion and 
metastasis. Recent studies have shown that DX-52-1 1.16 targets the 
membrane-cytoskeleton linker radixin followed by binding the multifunctional 
carbohydrate-binding protein galectin-3. The targeting of galectin 3 seems to be 
via formation of a covalent bond between DX-52-1 1.16 and the C-terminal 
region of radixin, causing radixin to dissociate from actin.25,26  
 
  
Scheme 1 
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The antiproliferative effect of quinocarcin 1.12 and DX-52-1 1.16 could be 
explained through a DNA alkylation event via an iminium ion 1.19. The 
presence of an unstable oxazolidine at C7 would allow formation of an 
electrophilic iminium intermediate 1.19 in a similar fashion to DX-52-1 1.16 
(Scheme 1).15 It was proposed that the iminium ion could be attacked by the N2 
residue of guanine 1.20, forming a covalent bond generating adduct 1.21 as 
shown in Scheme 1. The alkylation would occur via protonation of the nitrile 
group or by ring opening of the oxazolidine. Despite the proposed mechanism 
of action, DNA alkylation via the iminium ion intermediate has never been 
substantiated experimentally. 
Quinocarcinol 1.15 which does not possess the oxazolidine component or the 
nitrile (Scheme 1) is devoid of biological activity.27 This provides an opportunity 
for bioprecursor development by targeting cytochrome P450s (CYPs) 
overexpressed in cancer tissues including CYP1A1, 1B1, and 2W1 (which will 
be further discussed in Chapter 4). Recent reports by Patterson, Pors and co-
workers show duocarmycin bioprecursors to be selectively activated by 
CYP1A128 and CYP2W129 in bladder and colorectal cancer tissues, 
respectively. Similarly, quinocarcinol 1.15 may be a suitable substrate for CYP-
bioactivation in cancer tissues and is in part subject to investigation in this 
thesis (Chapter 4). 
 
 
1.4 Transition-metal mediated [2+2+2] cyclotrimerisations of 
alkynes and nitriles 
 
 
Scheme 2 
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 [2+2+2] cyclotrimerisation of alkynes and nitriles has appeared as a new 
methodology for the synthesis of carbon and heterocyclic benzene derivatives 
(Scheme 2) as an alternative to the electrophilic aromatic substitution (EAS) or 
ortho-metallation.30,31,32,33,34,35 
The first report of [2+2+2] cyclotrimerisations dates back to 1866 when 
Berthelot described the cyclisation of acetylene to yield benzene at 400 ºC. 
Despite the reaction being exothermic, the reagents need to overcome a large 
entropic barrier when associating three molecules, which gives rise to the need 
for such high reaction temperatures.31 These harsh conditions precluded alkyne 
cyclisation methodology from being applicable to a wider range of molecules. 
Consequently, in 1948 Reppe developed the use of transition-metals, 
demonstrating for the first time the use of a Ni catalyst for the synthesis of 
benzene from acetylene.36  
In the last 60 years, research has advanced sufficiently to allow the use of a 
diversity of transition-metals, which nowadays includes at least 17 different 
metals.33 The main ones used in  [2+2+2] cyclotrimerisations are Co, Rh, Ru, 
Ni, Pd, Ti, Ir, Pd and Zr, with the cobalt catalysts the most explored and widely 
used.37,38,34,39,40,41,42 
 
 
Figure 8 – [2+2+2] cyclotrimerisation of dialkynes with an unsaturated molecule. 
 
More advances within the field led to similar reactions where one of the alkyne 
contributors is replaced by another unsaturated substrate including nitriles, 
isocyanates, alkenes, imines, isothiocyanates leading to diverse and highly 
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substituted 6-membered ring derivatives (pyridines, pyridones, thiopyridones, 
1,3-cyclohexadienes, iminopyridines, indolizidinespyrones, etc) (Figure 8).  
 
 
Figure 9 – Different types of [2+2+2] cyclotrimerisations of alkynes and tethered 
alkynes. 
 
There are three different types of [2+2+2] cyclotrimerisations of alkynes, and 
alkynes and another unsaturated substrate (Figure 9). To simplify the 
explanation the types of cyclotrimerisations will only refer to alkynes, but the 
same applies to heteroatom containing compounds. Intermolecular 
cyclotrimerisations happen between three distinct alkynes, while in partially 
intermolecular reactions only two alkynes are tethered. In fully intramolecular 
cyclotrimerisations a single molecule contains all three alkynes. 
Transition-metal mediated [2+2+2] cyclotrimerisations of alkynes is an elegant 
and versatile convergent tool for the construction of densely (poly)substituted 
benzene products and related heterocyclic derivatives, although less is known 
about the latter. It is a very important reaction in terms of atom economy, 
because it involves the formation of several C-C or C-heteroatom bonds in a 
single step. It is also possible to synthesise chiral systems using chiral transition 
metal complexes as catalysts,33,35 however this topic will not be covered in the 
present work. 
Emerging evidence indicates that [2+2+2] cyclotrimerisations have a wide 
application in both academia and industry, mainly in the synthesis of various 
organic compounds such as cyclophanes, biaryls, organophosphorus 
compounds, helicene-like molecules, organic materials and complex biologically 
active compounds (see section 1.4.3).34 
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1.4.1 Transition-metal catalysed [2+2+2] cyclotrimerisation reactions 
for benzene derivatives 
 
1.4.1.1 Mechanism 
 
 
Scheme 3 
 
The mechanism for the transition-metal catalysed [2+2+2] cyclotrimerisations of 
alkynes depends significantly on the metal of the catalyst, the ligands and 
substrate. The generally accepted mechanism that describes these types of 
reactions is shown in Scheme 3. Initially, two molecules of alkyne coordinate 
with the catalyst surface (1.41), then by oxidative coupling the 
metallacyclopentadiene adduct 1.42 is formed. The third alkyne coordinates 
with the metal centre and here the reaction can be driven in two directions 
(depending on the metal). The metallacyclopentadiene adduct 1.43 can react in 
a Diels-Alder fashion [4+2] cycloaddition (path b) to form adduct 1.45, which 
happens for example with cobalt based catalysts.33 Alternatively the third alkyne 
can insert at the M-C bond with ring expansion leading to the formation of 
complex 1.44 (path a) which happens with ruthenium catalysts.43 The final 
benzene 1.36 is then formed by reductive elimination of either complexes 1.44 
or 1.45 followed by metal de-coordination with recovery of the catalyst 1.47. 
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1.4.1.2 Regio- and chemoselectivity 
 
 
Scheme 4 
 
In the [2+2+2] cyclotrimerisations the regio- and chemoselectivity is a major 
problem, paticularly in the intermolecular trimerisation, where typically mixtures 
of products are formed (Scheme 4).  
The chemo- and regioselectivity can be controlled in two steps: first during the 
formation of the metallacyclopentadiene adduct 1.42 and secondly during the 
insertion of the third alkyne component.  
Chemoselectivity depends on the ability of the catalyst to preferentially 
coordinate with the first two alkynes vs the third: alkynes with similar electronic 
and steric properties will react in a similar way. Initially, to avoid the formation of 
regioisomers, stoichiometric amounts of catalyst have been used with the third 
alkyne added at the end, thus forcing the first two alkynes to bind to the catalyst 
before the third is introduced.44 However, such methods are unattractive due to 
the cost of the catalysts and low yields obtained, and chemoselectivity still 
remains a challenge. In the partially intramolecular approach, there is still the 
potential for dimerisation of the diyne but large amounts of monoalkyne and 
diluted solutions of the reaction mixtures are often used in order to reduce the 
likehood of dimerisation. 
 
 
Scheme 5 
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Regioselectivity depends on the orientation of insertion of the third alkyne and 
isomers can be formed if it is not symmetric. Some useful strategies have 
emerged to overcome this problem, for example full control of regioselectivity 
can be obtained through a fully intramolecular reaction (Scheme 5).45 Usually 
only one isomer is obtained, since other isomers would result in a highly 
strained ring system.46 
Regioselectivity can be obtained in a partially intramolecular way affording a 
bicyclic product. Selected examples are described below (for reviews 
see30,31,32,33,34,35). 
 
 
Scheme 6 
 
In order to avoid isomer formation in a partially intramolecular reaction, a group 
can be added to the diyne that directs the addition of the alkyne, which can 
induce regioselectivity by steric hindrance. Dialkyne 1.55 reacts with 
monoalkyne 1.56 in the presence of Cp*Ru(cod)Cl to give products 1.57 and 
1.58 with meta/ortho selectivity 98:2 (Scheme 6). The bulky Cp* group directs 
the insertion of the monoalkyne in the less substituted Ru-C bond (Scheme 6), 
therefore avoiding a steric clash between the butyl group and the Cp* group.47  
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Scheme 7 
 
The ligand on the catalyst can also play an important role in isomer formation. 
An example is illustrated in Scheme 7, where the use of 1,2-
bis(diphenylphosphino)ethane (DPPE) favours the meta regioisomer while 1,1'-
bis(diphenylphosphino)ferrocene (DPPF) favours the ortho regioisomer.41 When 
DPPE is used the reaction has been proposed to occur via a Diels-Alder 
pathway (Scheme 7, complex 1.66). Bidentate coordination of DDPE affords a 
5-membered ring which gives the most stable chelation, allowing for the 
coordination of the monoalkyne to happen above the plane (complex 1.65). The 
meta isomer is more favoured due to less steric hindrance with the methyl 
group. On the other hand, when DPPF is used the reaction follows the ring 
expansion pathway (complex 1.69). DPPF has a large bite angle, therefore 
when the iridium catalyst coordinates with dialkyne 1.62 to form 
metallacyclopentadiene 1.67 a steric clash between the methyl and the PPh2 
groups will force the complex to dissociate, allowing for the formation of a 
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vacant site on the iridium centre for monoalkyne coordination (complex 1.68). In 
this situation the ortho isomer is more favoured because the iridium complex is 
bulkier than the methyl group. 
 
 
1.4.2 Transition-metal catalysed [2+2+2] cyclotrimerisation reactions 
for pyridine derivatives 
 
Transition-metal catalysed [2+2+2] cyclotrimerisations to form pyridine 
derivatives involves the reaction of two alkynes with a nitrile. This reaction was 
first reported by Wakatsuki and Yamazaki in the early 1970s, where a Co 
catalyst was used in a stoichiometric amount.48 Nowadays this reaction uses a 
substoichiometricamount of a wide range of transition-metals.34,35,49,50 
 
 
1.4.2.1 Mechanism 
 
 
Scheme 8 
 
The mechanism of the cyclotrimerisation to give pyridine derivatives is very 
similar to the one described above for benzene derivatives (section 1.4.1.1). 
The cycle starts with coordination of two alkynes to the transition-metal to form 
the metallacyclopentadiene 1.71 by oxidative coupling. The next step involves 
coordination of the nitrile 1.73 followed by insertion into the M-C bond leading to 
the formation of the azametallacycloheptatriene 1.74, which undergoes 
reductive elimination to give the desired pyridine derivative 1.75 (Scheme 8). 
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1.4.2.2 Regio- and chemoselectivity 
 
 
In the [2+2+2] cyclotrimerisations of alkynes and nitriles there will always be 
competition between the alkyne cyclotrimerisation and pyridine formation. In 
order to avoid alkyne cyclotrimerisation, a large excess of the nitrile is usually 
used. The catalyst of choice can play an important role in the chemoselectivity, 
as the ligand can predetermine which reactant coordinates first. Nitrile 
trimerisation is generally less favoured due to the instability of the 
diazametallacycle that would be formed. Nitrile trimerisation is also much slower 
than the formation of the desired product or the trimerisation of the alkyne. 
There is still the possibility for the initial coordination of the metal to an alkyne 
and a nitrile via intermolecular reactions, but density functional theory (DFT) 
studies have shown that this pathway is very unlikely.35  
 
 
Scheme 9 
 
 
Intermolecular reactions usually lead to mixtures of products (Scheme 9) and 
the formation of isomers depends on the chemoselectivity of the catalyst in the 
oxidative step. Theoretically, the insertion of the nitrile can take place in two 
orientations, however, experimentally it is observed that the nitrogen atom is 
placed near the bulkiest group.50 The same applies for tethered dialkynes and 
alkynenitriles, where the bulkiest group is placed near the nitrogen (Scheme 10 
and Table I).50 
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Scheme 10 
n R
1
 R
2
 Yield (%)
a
 
Product ratio 
(1.83:1.84) 
3 Me Me3Si 70 >95:1 
4 CO2Me Me3Si 82 1.1:1 
4 CO2Me Et3Si 78 1:1 
4 CO2Me 
i
Pr3Si 67 1.7:1 
4 CONEt2 Me3Si 87 1.4:1 
4 OMe Et3Si 43 >95:1 
4 H Et3Si 26 >95:1 
4 Me Me3Si 70 >95:1 
5 Me Me3Si 66 >95:1 
Table I –Regioselectivityfor the cyclotrimerisation of alkynenitrile 1.81 with 
different unsymmetric monoalkynes. a combined yield. 
 
 
 
Scheme 11 
 
Completely intramolecular reactions are generally associated with greater 
regiocontrol (Scheme 11).51 
 
 
Scheme 12 
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The cyclotrimerisation of tethered dialkynes and alkynenitriles also depends 
strongly on the electronics of the tethered component, i.e., electron deficient 
alkynes will react with the electron rich carbon from the nitrile and vice versa 
(Scheme 12).52 
 
 
Scheme 13 
 
Recently, a new strategy has been developed to overcome this regio- and 
chemoselectivity problem through spatial separation of the substrates by 
adsorption of the diyne onto a solid resin. This solid-phase methodology is a 
great tool for the construction of small libraries for combinatorial chemistry, and 
permits easy automation, parallelisation and purification. The first example of 
this approach was carried out by Sun and co-workers for the construction of a 
variety of isoindolines catalysed by Wilkinson’s catalyst (RhClP(Ph3)3), Scheme 
13.53 
 
 
Scheme 14 
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Deiters and co-workers carried out a more thorough study, initially using 
Wilkinson’s catalyst and a broad variety of substrates (examples can be seen in 
Scheme 14).54 
 
 
Scheme 15 
 
Later, the same group used Vollhardt’s catalyst to study different immobilisation 
strategies using different diynes with different unsaturated molecules (alkynes, 
nitriles, carbodiimides and isocyanates) (Scheme 15).55 This also involved the 
development of microwave-assisted [2+2+2] cyclotrimerisation reactions, which 
will be the subject of investigations in Chapter 3. 
 
In summary, there is emerging evidence that [2+2+2] cyclotrimerisations of 
alkynes and other unsaturated molecules can be used for facile access to highly 
functionalised (poly)substituted carbo- and heterocycles, that might not be 
possible by other synthetic methodologies. It is a complementary strategy to the 
well-known Diels-Alder reaction and permits the synthesis of one-, two- or 
three-membered ring(s) in a single step, which tolerates different functional 
groups such as alcohols, amines, alkenes, ethers, esters, halogens and nitriles 
to be used.32 Finally, regio- and chemoselectivity strongly depends on the 
reactants presented in the reaction mixture and hence provides a tool for 
controlling the diversity of the target molecules. 
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1.4.3 Applications of the transition-metal mediated [2+2+2] 
cyclotrimerisations in natural product synthesis 
 
The implementation of the transition-metal catalysed [2+2+2] cyclotrimerisation 
of alkynes with other unsaturated molecules is increasingly being employed as 
a part of the “synthetic chemistry toolbox”. This approach can be incorporated 
into a variety of syntheses including organic compounds such as cyclophanes, 
biaryls, organophosphorus compounds, helicene-like molecules, 
supramolecular and polymer chemistry and natural product synthesis.34 Natural 
products and their derivatives are rich in highly functionalised aromatic rings 
and their syntheses are often long, cumbersome and with low yields. [2+2+2] 
cyclotrimerisations have the ability to form mono-, bi- and tricyclic systems in a 
single step as described previously; therefore they may provide an advantage in 
key steps of syntheses towards natural products. A few examples of the 
synthesis of natural products and derivatives that use this methodology are 
described below. 
 
  
Scheme 16 
 
One of the first applications of [2+2+2] cyclotrimerisations applied to natural 
product synthesis was reported by Vollhardt56 during the synthesis of the steroid 
estrone 1.110 (Scheme 16) based on the cyclotrimerisation of 1,5-hexadiene 
1.106 and bistrimethylsilylacetylene (BTMSA) catalysed by CpCo(CO)2 
affording 1.107 which underwent retro [2+2] to afford estratrienone 1.108, 
followed by Diels-Alder cycloaddition under the reaction conditions to give 
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tetracycle 1.109  in 71% yield. Consequent treatment of 1.109 with 
trifluoroacetic acid (TFA) and lead acetate afforded estrone 1.110. 
 
  
Scheme 17 
 
Vollhardt’s group over the years has made a strong contribution to the 
application of [2+2+2] cyclotrimerisations. For example, they developed a novel 
strategy for morphinoid derivatives such as morphine, codeine and thebaine, 
where the key step involves a [2+2+2] cyclotrimerisarion of furan derivative 
1.111 with BTMSA catalysed by CpCo(C2H4) to form the tetracyclic core of 
these alkaloids (Scheme 17).57 
 
 
 
Scheme 18 
 
 
Another example of the application of this methodology is in the synthesis of 
colchicinoids. Colchicine, a natural compound with anticancer properties, 
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possesses an interesting ABC tricyclic pharmacophore, which makes these type 
of compounds very attractive for biological screening. An example is the 
synthesis of colchicine derivatives, 6-oxa-allocolchicinoids 1.116, that have 
been obtained through a fully intramolecular reaction of triyene 1.115 catalysed 
by Wilkinson’s or Vollhardt’s catalyst under microwave irradiation (Scheme 18); 
subsequent analysis of these [2+2+2] cyclotrimerised colchicine alkaloids 
showed they possess the capacity to induce apoptosis.58 
 
 
 
Scheme 19 
 
 
The key step in the synthesis of the indole-based anti-tumour antibiotic 
lavendamycin 1.119 (Scheme 19) is the construction of fused pyrrole and 
pyridine rings, which have been generated via [2+2+2] cyclotrimerisation from 
the reaction of 1,6-diyene 1.117 and methyl carbonocyanidate and catalysed by 
Cp*Ru(cod)Cl, in an elegant regioselective approach (Scheme 19).59 
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Scheme 20 
 
Nicolaou’s group devised a strategy which implemented transition-metal 
catalysed [2+2+2] cyclotrimerisation in the synthesis of Sporolide B 1.125 
(Scheme 20).60 The regio- and stereocontrolled synthesis of this unusual 24-
carbon polycyclic structure involves, in one of the key steps, a [2+2+2] partially 
intramolecular cyclotrimerisation of alkynes catalysed by Cp*RuCl(cod) to form 
the indene motif (Scheme 20). The other remarkable key step in this synthesis 
is the Diels-Alder cycloaddition to close the macrocycle. 
Other compounds with biologically important properties have been synthesised 
using this [2+2+2] approach, which will not be discussed here, that include 
anthraquinones,61 protoberberines,62 taxanes,63 camptothecin,64 
sesquiterpenes,65,66 steroids,67 unnatural -amino acids and peptides.43,68 
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1.5 Rationale 
 
As chemical biology becomes more integrated in drug discovery there is a 
greater demand for new and efficient strategies for the synthesis of small 
molecules to target different biological pathways (section 1.1). 
The quinocarcins have been shown to interfere with the HIF-1 pathway, cell 
migration and DNA alkylation by quinocarcin salt (KW2152) and DX-52-1 1.16. 
The lack of activity of quinocarcinol 1.15 is interesting and may provide a route 
to bioprecursors development with potential for cancer drug development 
(Scheme 21). CYPs might selectively hydroxylate quinocarcinol to compound 
1.126 which can lead to iminium ion 1.127 by loss of water. Nonetheless, the 
lack of knowledge in understanding the biological activity of the quinocarcins 
provides a reason why further exploration of this family of compounds is 
necessary. As a consequence, the design and synthesis of new truncated 
quinocarcin analogues, similar as well as diverse, could be used to probe the 
biological targets and/or pathways to aid in elucidating structural fragments 
responsible for their biological activity.   
 
 
Scheme 21 
 
There are several syntheses reported for the preparation of THIQs anti-tumour 
antibiotics; most of the methods reported are based on the traditional methods 
for THIQ synthesis including implementation of the Bischler-Napieralski and the 
Pictet-Spengler ring closure reactions where the aryl ring and its substitution 
pattern is set prior to the cyclisation step.15,69,70,71,72,73,74 Such methods are 
generally not amenable to concurrent total synthesis and simultaneous library 
preparation of the natural products and more diverse derivatives.  
In order to prepare structurally diverse molecules it is envisaged that a late-
stage transition metal mediated [2+2+2] cyclotrimerisation of alkynes could be 
used as a key component of the synthetic strategy. This would be contrary to 
the existing literature on THIQs anti-tumour antibiotics synthetic methodology 
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and would allow a unique opportunity for the introduction of various aromatic 
substituents useful for further chemical manipulation. 
 
 
1.6 Aims and objectives 
 
 
The main aim of this study is to apply transition-metal catalysed [2+2+2] 
cyclotrimerisation of alkynes to the synthesis of small molecules that resemble 
THIQs for biological investigation. In order to carry this out, three specific 
objectives will be pursued. 
 
 
i. Design and synthesis of a tricyclic model system 
 
 
 
Scheme 22 
 
The objective is to develop a short and concise synthesis to the three tethered 
dialkyne intermediates 1.128, 1.132 and 1.133 (Scheme 22) and then 
investigate different transition-metals for the [2+2+2] cyclotrimerisation of the 
tethered dialkynes with a small library of commercially available monoalkynes in 
order to generate the simple THIQ tricyclic compounds 1.131 and 1.135 (ring A 
and B) in one step. 
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ii. Diversity-oriented synthesis using microwave assisted radiation 
 
 
Scheme 23 
 
The objective is to synthesise heterocyclic molecules by applying the concept of 
DOS and B/C/P in order to generate NCEs. The transition-metal catalysed 
[2+2+2] cyclotrimerisations will be performed using microwave assisted 
synthesis (Scheme 23).  
As a starting point, racemic building blocks will be generated followed by 
optimisation of the methodology to enable the synthesis of both enantiomers. In 
order to increase diversity in the building block architecture, both oxygen 
(Scheme 23 bottom) and nitrogen (Scheme 23 top) atoms will be incorporated. 
 
 
Scheme 24 
 
To generate a broader library of compounds, the terminal alkyne will be silylated 
before pairing which will potentially allow further functionalisation after 
cyclotrimerisation by (i) removing the silyl group, (ii) oxidation to pyridone 
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derivatives and (iii) performing a cross coupling reaction to introduce a new 
chemical handle for enabling chemical diversity (Scheme 24). 
 
 
iii. Biological evaluation of small molecules 
 
The objective is to biologically evaluate truncated THIQs and other related small 
molecules. In the first instance, new compounds will be assessed for the 
cytotoxic potential in cell lines known to be deficient or proficient in extra-hepatic 
CYP1A1, 1B1 and 2W1 enzymes. Selected molecules will also be assessed for 
their potential to inhibit the HIF-1 pathway and cell migration. 
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Chapter 2  Exploration of transition-metal catalysed 
[2+2+2] cyclotrimerisation of alkynes in the design and 
synthesis of tricyclic tetrahydroisoquinoline-based 
molecules 
 
2.1 Synthesis of dialkynes 
 
2.1.1 Towards the synthesis of (S)-4-benzyl-1,6-di(prop-2-yn-1-
yl)piperazin-2-one 
 
2.1.1.1 Retrosynthetic analysis  
 
  
Scheme 25 
 
 
Retrosynthetically, the model system 1.131 (“ABC” skeleton) was envisaged to 
be constructed by cyclotrimerisation of dialkyne 1.128 and an acetylene 
derivative with a transition-metal catalyst, affording rings A and B in one step 
(Scheme 25). Dialkyne 1.128 was planned to be synthesised from iodolactam 
2.1, which in turn could be obtained from the readily available and inexpensive 
building blocks N-allylamine 2.4 and benzyl bromide 2.3. 
The initially proposed synthetic route is presented below (Scheme 26): 
 
 
 
30 
  
 
   
Scheme 26 
 
 
 
2.1.1.2 Iodolactam formation via halocyclisation 
 
 
Scheme 27 
 
N-allylamine 2.4 was reacted with benzyl bromide 2.3 affording N,N-
allylbenzylamine 2.5 in 82% yield (yield based on benzyl bromide 2.3) (Scheme 
27).75 Treatment of 2.5 with 2-bromoacetamide 2.6 in acetonitrile afforded 2-
(allyl(benzyl)amino)acetamide 2.2 in 98% yield.  
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Scheme 28 
 
Table II – Attempts to synthesise iodolactam 2.1. 
 
 
Entry Reagents Solvents 
Time 
(h) 
Yield (%) 
 
RSM 
2.2 
2.10 2.1 
1 I2 MeCN 20.5 42 10 --- 
2 NIS 
Dioxane/MeOH 
Aq. NaOH 
0.5 Degradation 
3 
TMSOTf, NEt3 
then I2 
Hexane 
THF 
1
st
 step: 0.5 
2nd step: 17.5 
trace --- 25 
4 
TMSOTf,  NEt3 
then I2 
Hexane 
THF 
1
st
 step: 0.5 
2
nd
 step: 2 
--- 18 --- 
5 
TMSOTf,  NEt3 
then I2 
Pentane 
THF 
1
st
 step: 3 
2
nd
 step: 2 
37 5.4 30 
6 
TMSOTf,  NEt3 
then I2 
DCM 
THF 
1
st
 step: 3 
2
nd
 step: 2 
Did not react 
7 
TMSOTf,  NEt3 
then I2 
Et2O 
1
st
 step: 3 
2
nd
 step: 2 
Degradation 
8 
TMSOTf,  NEt3 
then I2 
Pentane 
THF (50 ºC) 
1
st
 step: 3 
2
nd
 step: 2 
Degradation 
9 
TMSOTf,  NEt3, 
DMAP 
then I2 
Pentane 
THF 
1
st
 step: 3 
2
nd
 step: 2 
--- trace --- 
10 
TMSOTf,  NEt3, 
then I2 
Pentane 
MeCN (80 ºC) 
1
st
 step: 3 
2
nd
 step: 2 
Degradation 
11 
TMSOTf,  NEt3 
then I2 
Pentane 
THF 
1
st
 step: 3 
2
nd
 step: 24 
Degradation 
12 
LDA, 0 ºC 
then I2 
THF 
0.5 
52 
Did not react 
13 
TMSOTf,  NEt3 
Br
+
(collidine)2P
F6
-
 
Pentane 
DCM 
1
st
 step: 1 
2
nd
 step: 21 
--- --- --- 
14 I
+
(collidine)2PF6
-
 DCM 2 Did not react 
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The subsequent step was to ring close amide 2.2 via iodolactamisation to form 
the desired piperazine-2-one 2.1 (Scheme 28). Halocyclisations are more 
commonly described for lactones rather than lactams, because cyclisation of 
amides often produce lactones as well.76,77,78 There are several methods 
described in the literature for iodolactamisations, for example the use of 
I2/MeCN,
79 NIS,80 N,O-bis-silylation81. The use of LiOH, nBuLi and LiAl(OtBu)4 
as the base has also been successfully applied in iodolactamisation 
reactions.82,83  
 
 
Scheme 29 
 
  
 
 
Figure 10 – 1H NMR of lactone 2.10 (top) and lactam 2.1 (bottom). 
 
 
                  2.10 
 
 
                  2.1 
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In the first attempt, I2 (4 eq.) in acetonitrile (MeCN) was used as this is the most 
straightforward method of iodocyclisation.79 After 20 h, 42% of starting material 
2.2 was recovered and 10% of a new compound was obtained (Table II, entry 
1). NMR and mass analysis revealed that this compound was lactone 2.10 
instead of lactam 2.1 (Scheme 29). 1H NMR analysis (Figure 10 top) showed 
that the terminal alkene signal at 5.20 and 5.24 ppm (CHH’) had disappeared, 
so the double bond had reacted. In the product a new signal appeared at 4.46 
ppm (H) and 77.8 ppm (C) consistent with H-6 being  to an oxygen rather 
than a nitrogen atom. The iodo-cyclisation was further confirmed by the 
appearance of the CH2I signal at lower chemical shifts, characteristic of a 
methylene group  to iodine (C = 3.6 ppm). 
 
 
Scheme 30 
 
As a consequence, it was decided to follow a method reported by Knapp which 
uses trimethylsilyl trifluoromethanesulfonate (TMSOTf) and NEt3 to form the bis-
silylated intermediate 2.11. Such bis-silylated intermediates have been shown 
to react with iodine to obtain the desired product (Scheme 30).81 In the first 
attempt (entry 3) amide 2.2 was reacted with TMSOTf affording 25% yield of 
lactam 2.1 and trace quantities of starting material. With this encouraging result, 
the next step was to try to find better conditions to enhance the yield of lactam 
2.1. Different reaction times (30 minutes and 3 h) and different solvents 
(hexane, pentane, dichloromethane (DCM), Et2O) were tried for the 1
st step 
(entry 3, 5 6 and 7, respectively, Table II). Use of 4-dimethylaminopyridine 
(DMAP) in the silylation step has been reported by Moody,84 but did not 
promote lactam formation in this attempt (entry 9). Since the formation of 6-
membered rings is often slower than with 5-membered rings because of the 
greater entropy of activation, the iodocyclisation step was carried out at higher 
temperatures. After addition of iodine, the reaction mixture was heated in 
tetrahydrofuran (THF) at 50 ºC or in MeCN at 80 ºC (entries 8 and 10), however 
the elevated temperatures led to decomposition of the reaction mixture. The 
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best result was obtained when the bis-silylation was carried out in pentane over 
3 h and the iodocyclisation was carried out in THF during 2 h (entry 5). Using 
these conditions lactam 2.1 (30%) and lactone 2.10 (5.4%) were obtained as 
products, but 37% of starting material 2.2 was also recovered.  
 
  
Scheme 31 
 
Since this approach proved to be capricious, other cyclisation methods were 
investigated. In a first approach lithium diisopropylamine (LDA) was used to 
generate the amide anion of 2.2, followed by addition of I2 (Scheme 31). No 
reaction occurred after an extended reaction time (52 h) (entry 12).  
 
 
Scheme 32 
 
Knapp has also investigated the use of iodonium bis(collidine) 
hexafluorophosphate 2.16 as a source of iodine for the cyclisation step.81 With 
that in mind, iodonium bis(collidine)iodine hexafluorophosphate 2.16 and 
bromonium bis(collidine)iodine hexafluorophosphate 2.17 were synthesised 
from the reaction of silver nitrate, collidine  2.14 and potassium 
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hexafluorophosphate (Scheme 32), followed by halogenation of the resulting 
silver salt 2.15.85 
Using Knapp’s protocol,86 the bis-silylation step was performed with TMSOTf 
and NEt3 in pentane (entry 13) and bromonium bis(collidine) 
hexafluorophosphate 2.17 in DCM was used as the electrophile in the 
cyclisation step. The resulting mixture was stirred for 21 h and the reaction was 
stopped after all starting material had been consumed (Table II, entry 13). After 
purification, the compounds isolated weremixtures and none matched the 
desired product. Iodination with iodonium bis(collidine) hexafluorophosphate 
2.16 in DCM was also investigated, based on the use of this salt for the 
preparation of medium-ring lactones and lactams (entry 14).77 After 3 h, the 
reaction was stopped because the starting material was no longer visible by tlc, 
however after an aqueous work up, only starting material was recovered, 
indicating that an intermediate had been formed, but was unstable to the 
extraction conditions leading to reversal of the reaction. 
 
 
  
Scheme 33 
 
Literature reports on the formation of 6-membered ring iodolactams in good 
yields from cyclisation of the lithium salt derived from an amide-carbamate with 
an iodine source (Scheme 33).83 
 
 
 
Scheme 34 
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Entry Reagents Conditions Time/h Observations 
1 
1.BuLi (2 eq.) 
2.CBzCl(1.2 eq.) 
THF (-78 ºC) 
0.5 
1.5 
Degradation 
2 
Ethyl chloroformate (2 eq.), NEt3 
(1.3 eq.) 
THF 24 Did not react 
3 
1. (COCl)2 (1.2 eq.) 
2. 
t
BuOH (2.1 eq.) 
1,2-DCE, reflux 
0 ºC 
2.5 
1.5 
Degradation 
4 
1. (COCl)2 (1.2 eq.) 
DMAP (0.2 eq.), NEt3 (2 eq.) 
2. 
t
BuOH (2.1 eq.) 
 
1,2-DCE, reflux 
0 ºC 
5 
 
17.5 
Did not react 
5 
(Boc)2O (1.5 eq.), DMAP (0.2 
eq.), NEt3 (2 eq.) 
1,2-DCE, reflux 24 Did not react 
Table III – Attempts to protect the amide group of compound 2.2. 
 
Consequently, it was decided to protect amide 2.2 with benzyl chloroformate 
(CBzCl) (Scheme 34), prior to cyclisation with the reported methods. The 
protection was attempted using nBuLi in THF and CBzCl at -78 ºC (Table III, 
entry 1).87 After 1.5 h the starting material was consumed but the reaction 
mixture degraded. Deducing that the use of a strong base led to decomposition 
of the starting material, NEt3 was employed as the base in a reaction with ethyl 
chloroformate (entry 2)88,89 but no reaction was observed. In the last attempt the 
amide 2.2 was Boc protected90,91,92 using oxalyl chloride/tBuOH or Boc2O 
(entries 3-5), however these attempts were also unsuccessful.  
 
 
Scheme 35 
 
Entry Reagents Solvent Time/h Observations 
1 m-CPBA (1.2 eq.), -20 ºC-rt DCM 5 Did not react 
2 m-CPBA (1.1 eq.), reflux DCM 1 N-oxide  
3 
 
1. BF3.Et2O (1.5 eq.), -78 ºC 
2. DMDO (2 eq.) 
 
THF 
2 
2 
Did not react 
4 1. TCA (5 eq.) 
2. m-CPBA (1.1 eq.) 
DCM 
0.08 
24 
Did not react 
Table IV – Attempts to epoxidise compound 2.2. 
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Another strategy attempted involved generation of an epoxide from amide 2.2, 
followed by ring closure and conversion of the alcohol 2.23 into the 
corresponding iodide 2.1 (Scheme 35). When meta-chloroperoxybenzoic acid 
(m-CPBA)93 was used for the epoxidation at rt (Table IV, entry 1) the reaction 
was not complete after 5 h. Increasing the reaction temperature to reflux (entry 
2) led to the consumption of all the SM and formation of a very polar compound 
which was believed to be the N-oxide formed by the oxidation of the tertiary 
amine (1H NMR showed that the alkene had not reacted). Epoxidation of 
compound 2.2 using dimethyldioxirane (DMDO)94 in the presence of BF3
.OEt2 
was also attempted (entry 3).95 It was believed that the non-protic Lewis acid 
would form an adduct with the tertiary amine, protecting it from N-oxidation 
during epoxidation of the alkene. Trichloroacetic acid (TCA) was also employed 
towards the same outcome (entry 4)96 however in both reactions the starting 
material did not react. 
 
 
 
Scheme 36 
 
 
An alternative route to the epoxide employs N-bromosuccinimide (NBS) for 
bromohydroxylation of the double bond followed by epoxide ring closure97 
(Scheme 36). Despite the use of H2O in the solvent system the bromohydrin 
2.24 was not obtained; instead lactone 2.25 (21% yield) was isolated. 
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2.1.1.3 Iodolactam formation via Garner’s aldehyde 
 
Scheme 37 
 
Since all attempts at forming the lactam via halocyclisation had proven 
unsuccessful, another strategy was developed in order to produce lactam 2.1. 
Garner’s aldehyde98 2.27 was subjected to a reductive amination, followed by a 
cyclisation to produce alcohol 2.23,  which could then be transformed into the 
corresponding iodolactam 2.1, (Scheme 37). 
Garner’s aldehyde 2.27 was obtained in good yield by reduction of the 
commercially available ester 2.26 with diisobutylaluminium hydride (DIBAL) in 
toluene. Reductive amination of aldehyde 2.27 with N-benzylglycine ethyl ester 
2.28 and sodium cyanoborohydride afforded amine 2.29 in a moderate yield 
(60%). Deprotection of the isopropylidene and Boc groups under acidic 
conditions followed by cyclisation generated hydroxylactam 2.23 in quantitative 
yield and high purity.98 
 
 
Scheme 38 
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An alternative approach to Garner’s aldehyde 2.27 involved reduction of the 
commercial ester 2.26 using LiAlH4 (Scheme 38) to the corresponding alcohol 
2.30 followed by Swern oxidation.99 Garner’s aldehyde 2.27 was obtained in 
52% yield, making this route less viable.  
 
 
Scheme 39 
Entry Reagents Solvents 
Temperature 
(ºC) 
Time/h 
Yield 
(%) 
1 PPh3, Im, I2 Benzene/MeCN rt 3 
a
 
2 CDP, Im, I2 PhMe, MeCN rt 0.5 --- 
3 Me
+
P(PhOMe)3I
-
 THF rt 2 47 
4 
, Im, I2 
Toluene 50 5 86 
Table V – Attempts to convert alcohol 2.23 into lactam 2.1. a Product difficult to 
separate from PPh3O 
 
Conversion of alcohol 2.23 to iodide 2.1 (Scheme 39) was first attempted using 
PPh3, I2 and imidazole (Table V, entry 1),
100 but the desired product proved 
difficult to separate from the triphenylphosphine oxide generated in the reaction 
mixture. Chlorodiphenylphosphine (CDP)/imidazole/I2,
101 methyl triphenoxy 
phosphonium iodide100 and a polymer-bound triphenylphosphine101,102 were 
used to perform the direct conversion of alcohols into alkyl iodides without the 
purification issues arising from triphenylphosphine oxide as a side product. The 
best result was achieved when a triphenylphosphine polymer support was used 
(entry 4); iodolactam 2.1 was obtained with a yield of 86%.  
 
 
Scheme 40 
 
Finally, a Finkelstein reaction was investigated for the synthesis of iodolactam 
2.1 (Scheme 40),103 affording the desired compound 2.1 in 96% yield. 
Comparing the Finkelstein reaction with the use of polymer-bound 
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triphenylphosphine, both provide similar yields, however the product is quickly 
obtained using polymer supported triphenylphosphine and the oxidised polymer 
is easily removed by filtration. The disadvantage with the latter approach is that 
the polymer is quite expensive and therefore not ideal for scale-up reactions. 
 
 
Scheme 41 
 
With iodolactam 2.1 in hand, the next step was formation and coupling of the 
corresponding organozinc reagent. Alkylation of the organozinc with propargyl 
bromide was used as a model reaction to test the organozinc formation, prior to 
investigating its cross-coupling with alkenyliodides. A copper-mediated 
nucleophilic substitution of the organozinc 2.32 with propargyl bromide 2.9 was 
carried out. Insertion of activated zinc (Zn*) into the C-I bond in 2.1, followed by 
transmetallation to copper (CuCN.2LiCl as the copper source) in THF, gives the 
organocuprate reagent, that should react with alkyne 2.9 to give 2.33 (Scheme 
41).103,104,105,106 The product distribution from the model reaction with propargyl 
bromide indicated that zinc was inserted (Scheme 41), however after addition of 
propargyl bromide 2.9 the desired product was not obtained. Instead, two other 
compounds were obtained, the unsaturated amine 2.2 (17%) which resulted 
from -elimination (a known side product described for this type of reactions)103 
and methyl lactam 2.34 (61%). This reduced species may be formed as a result 
of self-quenching of lactam 2.32, i.e. slow deprotonation of the amide 
functionality of 2.32 and/or related copper compound which yields 2.34 after 
work up. The same reaction was repeated with (iodoethynyl)trimethylsilane 
affording the same results in a similar yield, suggesting it is not a problem of 
alkyne reactivity but a problem in the transmetallation step. Therefore, a Negishi 
cross coupling reaction was attempted using Pd2(dba)3 as catalyst, Sphos as 
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ligand (1:2 molar ratio), (iodoethynyl)trimethylsilane and DMF as solvent.107 
Unfortunately, no product was formed and no starting material was recovered, 
indicating degradation of the reaction mixture.  
 
 
2.1.1.4 Towards alkyne synthesis by nucleophilic substitution 
 
 
Scheme 42 
 
The cross couplings described in the section above are air sensitive and are 
often described as providing low yields. Consequently it was decided to go back 
to alcohol 2.23 to see if it was possible to convert the alcohol into alkyne 2.8, via 
displacement of a leaving group (Scheme 42). 
 
 
 
Scheme 43 
 
 
Given the lack of steric hindrance of the leaving group (LG) (Figure 11), both 
tosylate 2.31 and iodide 2.1 should be easily displaced by lithium acetylide-
ethylenediamine complex 2.36 (LAED) to afford the desired alkyne 2.8 
(approach of the nucleophile indicated with a green arrow). However no desired 
product could be isolated from either reaction due to degradation of the reaction 
mixture (Scheme 43).  
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Figure 11 – Minimised energy conformations in vacuum for compounds 2.1 (top) 
and 2.31 (bottom). * Structures modeled using ChemBio3D and minimised to give the 
lower energy state. 
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Scheme 44 
 
The failure of the tosylate displacement may also have been due to 
deprotonation of the amide proton by lithium acetylide, so it was decided to 
block this position by reaction with propargyl bromide 2.9 (Scheme 44). 
Unfortunately, the desired propargylation was not achieved. Instead three new 
compounds were obtained, bromolactam 2.38, bromoalkyne 2.39 and 
bromoallene 2.40. Their formation can be explained by the mechanism shown 
below (Scheme 45). 
 
 
 
Scheme 45 
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Figure 12 – 1H NMR of tosylate 2.31 (top) and bromolactam 2.38 (bottom) and 
mass spectrum of 2.38. 
 
 
As per normal procedure, these structures were assigned by NMR 
spectroscopy as well as mass spectrometry. A change in chemical shift of the 
sidechain methylene protons to ~3.5 ppm is consitent with formation of 
bromolactam 2.38, which is more shielded than in the starting material (~4 ppm) 
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(Figure 12). Mass spectrometry shows a molecular ion characteristic of 
bromine-containing compounds (m/z (ESI+) 283 (100% C12H15
79BrN2O), 285 
(98% C12H15
81BrN2O) [M]
+) since the two bromine isotopes have a natural 
abundance of 100:98.  
 
 
 
 
Figure 13 – 1H NMR of bromoalkyne 2.39. 
 
 
 
Compound 2.39 differs from compound 2.38 due to the presence of the alkyne 
moiety. The 1H NMR shows the appearance of a triplet (2.22 ppm, C≡CH), 
characteristic of terminal alkynes, as well as two double doublets further 
downfield (3.88 and 4.53 ppm) which correspond to NCHH and NCHH’ (Figure 
13). The presence of the alkyne was also confirmed by 13C and DEPT NMR. 
The quaternary carbon from the triple bond appears at 73.2 ppm as expected 
for alkynes and the terminal carbon appears at 78.0 ppm. Mass spectrometry 
also revealed a characteristic isotope pattern indicating that bromination had 
taken place. 
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Figure 14 – 1H NMR of bromoallene 2.40 (top) and bromolactam 2.38 (bottom). 
 
Finally, when comparing bromolactam 2.38 with allene 2.40 it can be seen that 
one of the H3 proton signals had disappeared and there are two new signals, a 
multiplet at 4.90-4.80 ppm (2H) corresponding to =CHH’ and a double triplet 
(1H) corresponding to =CH (Figure 14 top). The coupling between H3 and =CH 
can be seen in the COSY spectrum (Figure 15 top) and the correlation between 
allene carbon and =CHH’ and H3 can be seen in the HMBC spectrum. 13C 
reveals the presence of the quaternary allene carbon at 210.5 ppm (Figure 15 
bottom). 
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Figure 15 – COSY (top) and HMBC (bottom) spectra of allene 2.40. 
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2.1.1.5 Towards dialkyne synthesis by alkylation of lactam 
 
 
Scheme 46 
 
The results obtained above suggest that the amide NH needed to be 
functionalised prior to activation of the hydroxyl group. Alcohol 2.23 was 
protected with t-butyldimethysilylchloride (TBDMSCl) and the crude product 
2.45 propargylated with NaH and propargyl bromide 2.9 in THF affording alkyne 
2.46 in 90% yield (Scheme 46).108 Deprotection of alkyne 2.46 was successfully 
achieved using tetrabutylammonium fluoride (TBAF) yielding alcohol 2.47 in 
near quantitative yield without any need for further purification.109  
 
 
Scheme 47 
 
To insert the second alkyne, it was planned to convert alcohol 2.47 into a good 
leaving group, as previously shown (section 2.1.1.3), and then react it with 
LAED 2.36. This time a mesylate was chosen to see if this leaving group would 
afford different results to those obtained when tosylate 2.31 and iodide 2.1 were 
used (Scheme 43). Thus, alkyne 2.47 was reacted with mesyl chloride and NEt3 
in DCM and the resulting product 2.48 was used in the next step without further 
purification (Scheme 47).110 Reaction of mesylate 2.48 with LAED 2.36 as 
previously described, yielded allene 2.49 rather than the desired dialkyne 1.128. 
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Tosylate was also employed as a leaving group, but the reaction mixture 
degraded. Based on these observations, triflate was chosen as a better leaving 
group. Reaction of alcohol 2.47 with triflic anhydride, 2,6-lutidine in DCM, at -78 
ºC during 30 min led to reaction mixture decomposition.111 Pyridine was also 
employed as a base instead of lutidine, but again the reaction mixture 
decomposed. Therefore, it was not possible to synthesise the triflate derivative. 
 
 
2.1.2 Towards the synthesis of 1,5-di(prop-2-yn-1-yl)pyrrolidin-2-one 
 
 
Figure 16 – Towards the synthesis of 1.132. 
 
 
The synthetic obstacles in forming the dialkyne intermediate 1.128 prompted 
the investigation of a simplified five-membered ring system 1.132, without a 
tertiary amine (Figure 16). 
 
 
2.1.2.1 Towards dialkyne synthesis by initial nitrogen alkylation 
 
 
Scheme 48 
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The first route investigated was based on that used to prepare the 6-membered 
ring system: functionalisation of the lactam, conversion of the alcohol into a 
leaving group and displacement of the leaving group by an alkyne nucleophile.  
Ethyl-2-pyrrolidinone-5(S)-carboxylate 2.51 was obtained from the acid-
catalysed cyclisation of commercially available L-glutamic acid 2.50 in 90% 
yield (Scheme 48).112 Reduction of ester 2.51 with sodium borohydride 
generated alcohol 2.52 in very good yield. Subsequent protection of the alcohol 
2.52 with TBDMSCl, propargylation of the amide N-H with propargyl bromide 
2.9 and deprotection of the alcohol 2.54 with TBAF afforded alcohol 2.55 in 
quantitative yield.  
 
 
Scheme 49 
 
With alkyne 2.55 in hand, the alcohol group was converted into three different 
leaving groups: mesylate, tosylate and iodine using the same conditions as 
used for the 6-membered ring. Each resulting compound was reacted with 
LAED 2.36. The mesylate and tosylate derivatives decomposed when treated 
with LAED in DMSO, THF or hexamethylphosphoramide (HMPA), revealing that 
the solvent does not play an important role in the course of the reaction. Iodide 
2.56 did not degrade, instead alkenes 2.57 and 2.58 were obtained (Scheme 
49). 
It is likely that the acidic H5 was abstracted by the lithium complex that acted as 
a base instead of acting as a nucleophile, subsequently expelling iodine to 
create the exocyclic alkene. The allene was also formed as a result of 
isomerisation of the triple bond in basic media. 
The results with iodide 2.56 suggested that a change in the solvent system may 
modulate the reactivity of LAED 2.36. Only starting material 2.56 was recovered 
when THF was used as the solvent. The reaction was also attempted with 
sodium acetylide in THF and HMPA,113 and after 24 h only starting material was 
recovered indicating that the use of another nucleophile did not change the 
reactivity of the starting material. 
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2.1.2.2 Initial alkyne insertion via SN2 or cross coupling at the alcohol 
 
 
Scheme 50 
Entry 
Cross coupling reaction 
 
SN2 
reaction 
 RSM 2.60 
Zn* Reagent/catalyst/solvent/time 
Reaction 
conditions 
1  
LiCl, CuCN, IC≡CTMS 
THF, 24 h 
X Degradation 
2  
Pd2(dba)3, Sphos, DMF 
IC≡CTMS, rt, 18 h  
X 81% 
3 X 
Bu3SnC≡CH, Pd2(dba)3, o-
tolylphosphine, DME, rt, 24 h 
X 38% 
4 X 
Bu3SnC≡CH, Pd2(dba)3, o-
tolylphosphine, MeCN, 80 ºC, 
 24 h 
X 69% 
5 X X 
NaCCH, 
HMPA, THF, 
-78 ºC-rt 
24 h 
Only SM
a
 
6 X X 
LiC≡CTMS, 
CuI, THF, 
 -30 ºC-rt 
o/n 
30% 
7 X X 
BrMgC≡CH, 
CuI, -30 ºC, 
THF, 24 h 
Only SM
a
 
Table VI – Attempts to convert iodide 2.60 into alkyne 2.61. a Analysis of the crude 
reaction mixture by NMR. 
 
In view of the results described in the previous section, it was decided to do a 
more detailed study on the insertion of the alkyne motif. The reaction substrate 
was obtained from alcohol 2.52 which was converted into iodide 2.60 via a 
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Finkelstein reaction,103 followed by investigation of different reagents to 
transform iodide 2.60 into the desired alkyne 2.61 (Scheme 50, Table VI).  
The first reaction attempted with iodide 2.60 was the use of zinc insertion 
followed by acethynylation, mediated by the use of stoichiometric LiCl and 
CuCN (transmetallation of organozinc to organocuprate in situ) (entry 1).106 In 
contrast to what was observed with the 6-membered ring system (Scheme 41), 
the reaction degraded. Negishi107 and Stille114 cross couplings gave no reaction 
(entries 2-4), in contrast to the Negishi cross coupling on the 6-membered ring 
2.1 (section 2.1.1.3) which led to decomposition of the reaction mixture. As the 
cross coupling reactions did not work, nucleophilic substitution reactions using 
NaC≡CH (entry 5), LiC≡CTMS or BrMgC≡CH mediated by CuI (entry 6 and 7) 
were attempted, unfortunately also without success. 
 
 
2.1.2.3 Alkyne formation from the corresponding alkene 
 
 
Scheme 51 
 
Conversion of iodide 2.60 into the desired alkyne could considerably be 
achieved by conversion into an alkene, followed by consecutive 
halogenation/dehalogenation to afford the desired alkyne (Scheme 51). 
Treatment of iodide 2.60 with vinyl cuprate, generated in situ from 
vinylmagnesium bromide 2.62 and copper(I) iodide, afforded alkene 2.63 in 
72%,115 which was then brominated with Br2 affording a mixture of 
dibromoalkanes 2.64a/b which could be separated by column chromatography 
(2.64a less polar isomer; 2.64b more polar isomer).116 
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Entry 
Base 
(eq.) 
Time 
(h) 
Temp. 
 (ºC) 
Ratio of products 
1 
t
BuOK 
(4.2) 
24 rt 
 
2.66           
 
2.65            
 
2.61        
0.4ª 0.32ª 1ª 
2 
t
BuOK 
 (2.5) 
2.5 rt 
2.67            
 
2.68            
 
2.61       40% 
0.55ª 0.35ª 1ª 
3 
t
BuOK 
 (6.0) 
0.5 -78 
---  
2.68                
 
2.61  
--- 1ª 1ª 
4 
t
BuOK 
 (6.0) 
0.8 -78 
---  
2.68           
 
2.61      
--- 1
b
 2
b
 
5 
t
BuOK 
 (6.0) 
2.75 -78 
---  
2.68           
 
2.61      
--- 1
b
 2
b
 
6 
LDA 
(6.0) 
6.5 -78  
2.67   
SM      2.64a/b  
2.61   
1.4ª 0.86ª 1ª 
Table VII – Optimization of the dehydrobromination to obtain alkyne 2.61. a ratio of 
isolated products, b ratio estimated based on crude NMR 
 
In the last step dibromalkanes 2.64 a/b were treated with a base and what was 
expected to be a simple reaction was revealed to be quite complex. 
Initially the less polar dibromoalkane isomer 2.64a was reacted with tBuOK (4.2 
eq.) in THF at rt (Table VII, entry 1). The reaction was monitored by TLC and 
after 30 min the appearance of two new compounds more polar than the 
starting material was observed. As the reaction was not finished, it was left to 
react overnight to ensure consumption of the starting material. After purification 
by column chromatography three compounds were isolated (Table VII entry 1). 
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The desired alkyne 2.61 was obtained along with two byproducts, allene 2.65 
and alkyne 2.66 in the ratio of 1:0.32:0.40, respectively. These two latter 
products 2.65 and 2.66 are believed to be derived from isomerisation of alkyne 
2.61. With the desired compound in hand, attempts to optimise the reaction 
were carried out by investigating the role of base and reaction time (Table VII). 
Subsequent reactions (entries 2-6) were performed with a mixture of both 
dibromoalkenes 2.64a/b. Decreasing both the amount of base used and the 
reaction time (TLC showed complete consumption of starting material after 2.5 
h) resulted in three products (entry 2), which were identified as bromoalkenes 
2.67 and 2.68 and the desired alkyne 2.61 in a ratio of 0.55:0.35:1, respectively. 
Based on literature precedent,117 it was then decided to decrease the 
temperature of the reaction and increase the amount of base. Use of 6 eq. of 
tBuOK (entries 3-5) afforded a mixture of bromoalkene 2.68 and alkyne 2.61 
that could not be separated by column chromatography. The ratio of products 
was 1:1 after 30 minutes and 1:2 after 50 minutes, with no further change being 
observed at longer reaction times. Use of LDA (entry 6) as a base also gave a 
mixture of products (starting material 2.64a/b, bromoalkene 2.67 and alkyne 
2.61 in 0.86:1.4:1 ratio). 
Although the desired alkyne 2.61 had been successfully obtained in moderate 
yield, the difficulty of separating it from side products 2.67 and 2.68 prompted 
investigation into alternative synthetic routes. 
 
 
2.1.2.4 Towards synthesis of alkyne 2.61 by reductive ethynylation 
 
 
Scheme 52 
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Contemporaneous to this work, a method that converted an aldehyde to an 
alkyne by a two carbon homologation was published by Danishefsky and co-
workers.118 A reductive ethynylation of aldehyde 2.69 was achieved by addition 
of the zirconia nucleophile 2.70, obtained by hydrozirconation of BTMSA. 
Treatment of the resultant bistrimethylsilyl alkene intermediate 2.71 with a 
mixture of bases afforded selectively the desired alkyne 2.72, via a 
Brook/Peterson transformation (Scheme 52). 
 
 
Scheme 53 
 
Following this approach, it was decided to apply their strategy to the synthesis 
of alkyne 2.61. (Scheme 53). 
 
 
Scheme 54 
Entry Reaction conditions Observations 
1 DMP, wet DCM, rt, o/n Degradation 
2 PCC, MgSO4, DCM, 2.5 h Degradation 
3 DMSO, (COCl)2, DIPEA, DCM, o/n Degradation 
4 DMSO, (COCl)2, DIPEA, THF, o/n No reaction 
5 IBX, DMSO, rt, 22 h Degradation 
6 IBX, DMSO, rt, 2 h Degradation 
7 IBX, MeCN, 80 ºC, 1 h Mixture of products 
8 IBX, AcOEt, 80 ºC, 3.5 h Mixture of products 
9 Tempo-Baib, MeCN, rt, 3 h Mixture of products 
Table VIII – Different reaction conditions for the oxidation of alcohol 2.52 to 
aldehyde 2.73. 
 
However, prior to initiation of this elegant strategy, it was necessary to oxidise 
the previously obtained alcohol 2.52 to the corresponding aldehyde 2.73 
(Scheme 54). A range of oxidising reagents (DMP, PCC, Swern oxidation, IBX, 
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TEMPO-BAIB) were used, however, in all cases the reaction mixture 
decomposed (Table VIII). Therefore, it was decided to protect the amide 
nitrogen before proceeding further. 
 
 
Scheme 55 
 
To ensure chemoselectivity, the alcohol group needed to be protected first 
(Scheme 55). Consequently, alcohol 2.52 was protected with TBDMSCl, 
followed by reaction with Boc2O and NEt3 in the presence of DMAP, yielding the 
di-protected compound 2.75 in 75% yield.119 
 
 
Scheme 56 
 
When TBAF in THF was used to deprotect the TBDMS group, the free alcohol 
2.76 was only obtained in 21% yield, along with by-product 2.77 (35%) (Scheme 
56), which is likely to arise from the migration of the Boc group after the 
cleavage of the silyl group.120 To overcome this problem, the reaction was 
carried out in the presence of a small amount of acetic acid (Scheme 56) to 
protonate the alkoxide resulting from silyl deprotection preventing the migration 
of the Boc group.120 Alcohol 2.76 was then easily oxidised to the corresponding 
aldehyde 2.78 (84% yield) with TEMPO-BAIB (Scheme 56),121 confirming that 
the problem in the previous oxidation was the presence of the free lactam. 
Finally, with aldehyde 2.78 in hand, it was possible to try the reductive 
ethynylation described above (Scheme 53). The zirconate intermediate 2.70 
was generated in situ from reaction of Cp2ZrCl2 with BTMSA in the presence of 
nBuLi and pyridine. Formation of the intermediate was confirmed by observation 
of its characteristic deep red colour in solution. Unfortunately, when the 
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zirconate 2.70 was slowly added to the freshly made aldehyde 2.78, after 30 
min the molecule was completely destroyed.  
The compounds studied by Danishefsky and co-workers are in general alkyl 
substituted allylic alcohols (which are protected with a p-methoxybenzyl (PMB) 
group), a conjugated enal and an aromatic aldehyde. In all cases the 
bistrimethylsilyl alkene intermediate is formed in good yield, however there are 
no amides present in any of the compounds reported. In this case the 
bistrimethylsilyl alkene intermediate is not formed. A possible source of 
functional group incompatibility is the excess of the nBuLi used in the formation 
of the zirconate 2.70 which is likely to react with aldehyde 2.78 by addition to 
the aldehyde carbonyl. Less likely but possible, side reactions are addition to 
the amide or the Boc groups, or removal of the acidic protons at H4 
 
 
2.1.2.5 Alkyne formation via Grignard addition to the aldehyde 
 
 
Scheme 57 
 
Alkyne 2.61 could also be obtained from aldehyde 2.78 via a Grignard addition 
of ethynylmagnesium bromide 2.79 followed by reductive removal of the alcohol 
2.80a/b (Scheme 57). 
 
 
Scheme 58 
Entry 
Alylating 
agent (eq.) 
Additive 
(eq.) 
Solvent 
Temp. 
(ºC) 
Time 
(h) 
Yield 
(%) 
RSM 
(%) 
Isomer 
ratio  
280a/b 
1 
 
(1.5) 
--- THF 0 - rt 4 19 14 1:1.3
a
 
2  --- THF 0 - rt 24 ---
 b
 ---
 b
 ---
b
 
58 
  
(1.5) 
3 
  
(2) 
--- THF 0 1 42 --- 1:1.6
 a
 
4 
  
(3) 
LiCl 
(3) 
THF 0 1.5 40 12 1:1.4
 a
 
5 
  
(3) 
BF3
.
OEt2 
(3) 
THF 0 -  rt o/n ---
 b
 ---
 b
 ---
b
 
6 
 
(3) 
CeCl3 
(2) 
THF 0 - rt 6 16 17 3:1
 a
 
7 
 
(5) 
--- 
Et2O, 
dioxane 
0 -  rt o/n ---
 b
 ---
 b
 ---
b
 
8 
 
(5) 
--- 
Et2O, 
dioxane 
-78 - rt 16 31 13 1:1.6
 a
 
9 
 
(3) 
--- THF -40 - rt 1  ---
 b
 ---
 b
 ---
b
 
Table IX – Attempted optimisation of the Grignard addition to the aldehyde 2.78. a 
Isomers ratio 280a: less polar fraction, 280b more polar fraction, b degraded. 
 
 
Aldehyde 2.78 was reacted with ethynylmagnesium bromide 2.79 in THF 
affording alcohols 280a/b in 19% yield (as a 1:1.3 ratio of isomers, 280a less 
polar isomer and 280b more polar isomer; the stereochemistry of the 
diastereoisomers was not assigned) along with 14% of RSM 2.78 (Scheme 
58).122 It is well known that Grignard reactions are often accompanied by side 
reactions such as enolizations, reductions, condensations and conjugate 
additions resulting in lower yields of the desired products.123 Accordingly, in 
order to optimise the reaction, the effect of solvent, temperature and additives 
was investigated (Table IX). Since the starting material was not all consumed in 
4 h (entry 1), the reaction time was increased to 24 h (entry 2), however this led 
to decomposition of the reaction mixture. Use of 2 eq. of the Grignard reagent at 
0 ºC gave complete reaction after 1 h and the products were obtained in 42% 
yield (entry 3). Addition of LiCl to the Grignard reaction had no effect (entry 4). 
LiCl and BF3
.OEt2 are Lewis acids known to coordinate with carbonyl groups to 
make them more electrophilic for Grignard additions, but in this case they did 
not help to improve the product yield.  
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CeCl3 is also a known additive for these type of reactions by forming an 
organocerium complex that is generally less basic than the parent Grignard and 
is a stronger nucleophile.123,124 
 
 
Scheme 59 
 
It is noteworthy that although the addition of CeCl3 does not increase the yield 
of the products, the ratio in which the products were obtained changed from 
~1:1.5 to 3:1 (see Table IX). This can be explained based on the chelation 
transition state that can form by the lone pairs of the nitrogen and the carbonyl 
co-ordinating the cerium ion when CeCl3 is used (Scheme 59).
123 Usually, when 
there are no atoms that can coordinate, the nucleophile will attack the less 
hindered face in the transition state (blue arrow in Scheme 59). On the other 
hand, in the presence of a metal that is able to chelate, in order for the 
coordination to occur, the molecule has to rotate affording a different 
conformation in the transition state. Addition of the nucleophile at the less 
hindered face of the new transition state (green arrow in Scheme 59), would 
afford a different isomer. 
The Grignard reaction did not afford the expected results. As a consequence it 
can be concluded that the addition of additives does not increase the reaction 
yield. As low yields were obtained and the products were difficult to isolate from 
the reaction mixture, no further work was carried out in respect to this approach. 
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2.1.2.6 Synthesis of racemic alkyne from succinimide 
 
 
Scheme 60 
There is precedent for racemic alkyne 2.61 being obtained from the reaction of 
allenylstannanes with ethoxylactams derived from succinimide.125 Partial 
reduction of succinimide 2.88 with sodium borohydride in ethanol, followed by 
ethanolysis at pH ~3-4 of the intermediate N,O-hemiacetal afforded 
ethoxylactam 2.90 in 41% yield (Scheme 60). In the original report126 the yield 
for ethoxylactam 2.90 was 88%, however in this work after many attempts the 
product was never obtained in such a good yield. The same problem was also 
reported by Sy and co-workers.127 Furthermore, it was observed that compound 
2.89 was obtained as a side product, resulting from over-reduction of the 
intermediate.  
 
Scheme 61 
Entry 
scale 
(mg) 
2.91 
(eq.) 
Time 
(h) 
Temp. 
ºC 
Yield (%) 
2.90 2.61 2.65 
1 100 1.2 2 0-rt trace 38
a
 trace 
2 100 1.5 2 -40 b  b trace 
3 50 2.5 7 -40 --- 
70
c
 
(32)
a
  
5 
4 200 2.5 7.5 -40 --- 
60
c
 
(47)
a
 
5 
Table X – Formation of racemic alkyne 2.61 with allenyltin 2.91 in DCM with 2 eq. 
of BF3
.OEt2. 
c isolated yield, b 1:1 ratio 2.61/2.65 analysis of crude NMR, c estimated 
yield by NMR. 
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The next step was formation of racemic alkyne 2.61 (Scheme 61). This reaction 
has been reported as producing an excellent yield (94%) for a six-membered 
ethoxylactam.125 In this system, ethoxylactam 2.90 was reacted with 
tributylallenylstannane 2.91 (1.2 eq.) (Table X, entry 1), and the target racemic 
alkyne 2.61 was obtained in 38% yield. Recovered SM and the corresponding 
allene 2.65 were also observed in trace quantities. Due to the low yield 
obtained, it was decided to subject the ethoxylactam 2.90 to other reaction 
conditions. The reaction was slower when it was performed at -40 ºC even with 
a slight increase in the amount of the allenyltin 2.91 (entry 2). When stopped 
after 2 h, the ratio between SM 2.90 and alkyne 2.61 was 1:1. This reaction 
proved to be difficult to purify as both the SM 2.90 and product 2.61 had the 
same Rf, meaning that the reaction had to be forced to completion to facilitate 
isolation of the product. Accordingly, 2.5 eq. of allenyltin 2.91 was used and the 
reaction time extended. 1H NMR spectroscopy of the crude product revealed 
that all the SM 2.90 had reacted. Purification of the reaction mixture proved to 
be difficult, due to the polarity of racemic alkyne 2.61 and the corresponding 
allene 2.65 once again being very similar. 
 
 
Scheme 62 
 
With alkyne 2.61 in hand, dialkyne 1.132 was easily prepared (83% yield) with 
NaH and propargyl bromide in DMF (Scheme 62). 
 
 
Scheme 63 
 
During the course of the work on the transition-metal catalysed [2+2+2] 
cyclotrimerisation studies, an alternative route to the synthesis of the racemic 
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alkyne 2.61 was published. Nicolai and co-workers reported an intramolecular 
aminoalkynylation of olefins with a hypervalent iodine reagent catalysed by a 
lithium palladate catalyst (generated in situ) (Scheme 63).128 This is an 
interesting alternative to the previous synthesis mainly because it would avoid 
the use of tin, which is very toxic and carcinogenic. Nicolai and co-workers 
mention that there are several factors that make this method widely applicable 
including the use of inexpensive LiCl, PdCl2 (the most common palladium 
catalyst) and triisopropylsilylethynyl-1,2-beziodoxol-3(1H)-one (TIPS-EBX), 
which is commercially available. However, the drawback is that this 
commercially available hypervalent iodine is expensive (£134/g), although it can 
be synthesised in a good yield over three steps. 
 
  
Scheme 64 
 
Comparing this method to the one presented in Scheme 60, it involves more 
steps for the synthesis of lactam 2.61 (Scheme 64), making this route less 
viable (7 steps compared with 4). 
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2.1.2.6.1 Synthesis of tributylallenyltin 
 
 
Scheme 65 
 
 
Allenyl tin 2.91 can be synthesised from 2-mercaptobenzothiazole 2.101 
(Scheme 65).129 As such, 2-mercaptobenzothiazole was reacted with propargyl 
bromide to afford alkylated compound 2.102 in 89% yield after recrystallisation. 
However, the reaction of alkyne 2.102 with tributyl tin oxide and polysiloxane in 
the presence of azobisisobutyronitrile (AIBN) was prone to polymerisation 
during the reaction itself or on purification of the product.  
 
 
Scheme 66 
 
 
Therefore, allenyl tin 2.91 was prepared via a Grignard reaction, Scheme 66. 
Propargyl bromide 2.9 was added to a solution of tributyl tin chloride, 
magnesium and a substoichiometric amount of lead bromide in THF, yielding 
the desired compound 2.91 in 81% yield after purification by column 
chromatography on alumina.130 
 
Obtaining tributylallenyl tin 2.91 in high yield allowed the scale-up of the 
synthesis of 1.132 and therefore start the [2+2+2] cyclotrimerisations of the key 
alkyne intermediates (section 2.2). However, before discussing these 
investigations, the synthesis of two more compounds as substrates for the 
cyclotrimerisations is reported. 
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2.1.3 Synthesis of racemic 1,6-di(prop-2-yn-1-yl)piperidin-2-one 
 
 
Scheme 67 
 
Following the synthesis used for dialkyne 1.132, glutarimide 2.104 was partially 
reduced with sodium borohydride in HCl/EtOH to give the corresponding ethoxy 
lactam 2.105.125 Reaction with allenyl tin 2.91 afforded monoalkyne 2.106 in 
55% yield. Treatment of monoalkyne 2.106 with sodium hydride and propargyl 
bromide 2.9 afforded the desired 6-membered ring dialkyne 1.133 in 82% yield 
(Scheme 67). 
 
 
2.1.4 Synthesis of racemic 4-benzyl-1,6-di(prop-2-yn-1-yl)piperazin-2-
one  
 
 
Scheme 68 
 
Unsuccessful approaches towards the synthesis of (S)-4-benzyl-1,6-di(prop-2-
yn-1-yl)piperazin-2-one 1.128 have already been outlined (section 2.1.1). Since 
it was very important to obtain this dialkyne to produce model THIQ tricyclic 
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adducts by [2+2+2] cyclotrimerisation,  it was decided to apply the synthetic 
route of dialkyne 1.132 towards molecule 1.128 (Scheme 68). 
Imide 2.108 was synthesised from N-benzyliminodiacetic acid 2.107, which 
underwent ring closure with ammonium formate in refluxing DMF yielding the 
corresponding imide 2.108 in 65% yield.131 Partial reduction of lactam 2.108, 
applying the same conditions used for lactam 2.88 (Scheme 60), afforded 
alcohol 2.109 (67% yield) instead of ethoxylactam 2.110. Alcohol 2.109 was 
converted to the desired ethoxy lactam 2.110 in quantitative yield by heating in 
ethanol with substoichiometric p-toluenesulphonic acid (PTSA). Reaction of 
ethoxylactam 2.110 with allenyltin 2.91 did not go to completion at temperatures 
between -40 ºC and rt. When the reaction was performed at reflux in DCM 
product 2.8 was obtained in 54% yield. Alkylation of alkyne 2.8, was done easily 
with NaH and propargyl bromide, affording dialkyne 1.128 in 93% yield. 
 
 
2.2 Transition-metal catalysed [2+2+2] cyclotrimerisation of 
alkynes 
 
2.2.1 Studies on the [2+2+2] cyclotrimerisation of 1,5-di(prop-2-yn-1-
yl)pyrrolidin-2-one 1.132 
 
 
Scheme 69 
 
Entry Temp. (ºC) Time (h) Yield 2.111 
1 reflux o/n 0 ª 
2 rt 24 0 
b
 
3 
50 
reflux 
14  
o/n 
0 
b
 
0 
a
 
Table XI – Attempted reactions for the cyclotrimerisation of dialkyne 1.132 and 
BTMSA. a Unidentified mixture of products, b Did not react. 
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Investigation of the transition-metal catalysed [2+2+2] cyclotrimerisation of 
alkynes started with investigation of the reaction of dialkyne 1.132 and BTMSA 
(an alkyne commonly used in this type of cyclisation) catalysed by Wilkinson’s 
catalyst (Scheme 69, Table XI).132 However, the expected cyclisation did not 
take place as dialkyne 1.132 did not react at either rt or 50 ºC. Indeed, it only 
seemed to react at reflux in toluene where it afforded a mixture of unidentified 
products. 
 
 
Scheme 70 
Entry 
Catalyst 
(mol %) 
Temp 
(ºC) 
Solvent 
Time 
(h) 
yield (%) 
2.113
a
 2.114 2.115 2.116 
1 
A 
5 
reflux Toluene 18 44 21 25 30 
2 
 A 
5 
reflux Toluene
b
 7 ---
 c
 ---
 c
 ---
 c
 --- 
c
 
3 
 A 
5 
reflux Toluene
d
 5.5 7 
e e 
17 
4 
A 
10 
reflux Toluene 2.5 ---
 c
 ---
 c
 ---
 c
 --- 
c
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5 
B 
10 
reflux Toluene 4 11 4 8 42 
6 
B 
10 
rt DCE 24 ---
 f
 ---
 f
 ---
 f
 ---
 f
 
7
g
 
B 
10 
reflux Toluene 4 11 3 7 44 
8
g
 
B 
5 
reflux Toluene 8.5 14 2 8 15 
9
g
 
B 
10 
50 Toluene Incomplete after 3 days 
10
g
 
B 
10 
100 Toluene 24 10 1 7 15 
11
g
 
B 
10 
reflux Dioxane 8.5 7 6 5 29 
12
g
 
B 
10 
reflux Benzene 9 8 3 4 2 
13
g
 
B 
10 
reflux THF 24 10 2 4 14 
14
g,h
 
B 
10 
reflux Toluene 24 8 trace 3 27 
15
g,i
 
B 
10 
reflux Toluene 19 2 --- --- 45 
16 
C
j
 
10 
reflux Toluene 6.5 32 18 7 18 
17 
D 
10 
reflux Toluene 2.5 24 trace 16 70 
Table XII – Optimisation of tricyclic adduct 2.116 synthesis. Reactions performed 
with 0.310 mmol of dialkyne 1.132, 5 eq. of diethyl acetylenedicarboxylate 2.112a in 2 
mL of solvent. Catalyst: A - RhCl(PPh3)3, B – CpCo(CO)2, C - [Ir(cod)Cl]2, D – 
Cp*Ru(cod)Cl. 
a yield based on the amount of diethyl acetylenedicarboxylate 2.112a 
used, b Pre-mixing of RhCl(PPh3)3 with dialkyne 1.132 followed by syringe addition of 
diethyl acetylenedicarboxylate 2.112a, c degradation, d syringe addition of diethyl 
acetylenedicarboxylate 2.112a, e mixture 2.114:2.115 1:15, f did not react, g stock 
solution of catalyst (0.23 M), h  2.5 eq. diethyl acetylenedicarboxylate 2.112a, i 1 eq. of 
diethyl acetylenedicarboxylate 2.112a and 2 eq. of dialkyne 1.132.j DIPHOS 10 mol%. 
 
 
Next, the reaction of diethyl acetylenedicarboxylate 2.112a with 1.132 was 
investigated under the same reaction conditions. The desired tricyclic product 
2.116a was obtained in 30% yield along with the hexasubstituted benzene 
2.113a resulting from trimerisation of monoalkyne 2.112a (44%) and two other 
products, compound 2.114a (21%) and compound 2.115a (25%) which resulted 
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from the reaction of two molecules of monoalkyne 2.112a and the individual 
alkyne branches on dialkyne 1.132 (Scheme 70). NMR spectroscopy revealed 
that, for compound 2.115a, the cyclotrimerisation happened on the alkyne 
branch attached to the nitrogen. In this structure the NCHH’ and NCHH’ are 
more deshielded (4.17 and 5.10 ppm) than in the starting material (3.67 and 
4.55 ppm). The 13C NMR spectrum of products 2.114a and 2.115a and their 
corresponding derivatives often show superimposition of the CH3 and OCH2 
carbons, nevertheless it can be confidently stated that it is the right compound; 
all other characterisation matches the desired structure. 
As shown in Table XII, it can be seen that the chemoselectivity of Wilkinson’s 
catalyst for dialkyne 1.132 is quite low, i.e., the ability for the catalyst to 
coordinate preferencially with dialkyne 1.132 is very low, which explains all the 
by-products formed. Table XII summarises attempts to optimise the reaction of 
dialkyne 1.132 with diethyl acetylenedicarboxylate 2.112a in order to increase 
chemoselectivity. The formation of 2.113a could have arisen from the addition 
of diethyl acetylenedicarboxylate 2.112a into the reaction vessel as a bolus, 
providing a high localised concentration to co-ordinate with the catalyst and 
trimerise. However, pre-mixing of Wilkinson’s catalyst with dialkyne 1.132, 
followed by syringe addition of monoalkyne 2.112a over 7 h, led to 
decomposition of the reaction mixture (entry 2) and addition of diethyl 
acetylenedicarboxylate 2.112a over a period of 5.5 h did not increase the 
amount of product 2.116a (entry 3).44 When Vollhardt’s catalyst (10 mol %) was 
used the desired tricyclic adduct 2.116a was obtained in 42% yield (entry 5) 
with a corresponding decrease in the amount of by-products formed. A stock 
solution of catalyst was used during this study to minimise catalyst exposure to 
air and allow accurate dispensing of small quantities. It was confirmed that the 
use of a stock solution did not affect the yield of the reaction (entry 7). The 
literature reports high yields from similar reactions using DCE as a solvent at 
rt.43 However, dialkyne 1.132 did not react under these conditions (entry 6). 
Decreasing either the catalyst loading (entry 8) or reaction temperature (entries 
9 and 10) decreased the reaction rate and overall yield of product 2.116a. To 
investigate the stability of dialkyne 1.132 during the course of the reaction, a 
reaction was carried out using an excess of dialkyne 1.132 (ratio 
dialkyne/monoalkyne 2:1) (entry 15). Compound 2.116a was obtained with the 
same yield as before (45% yield) and 53% of the starting monoalkyne 2.112a 
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was recovered. However, because twice the amount of dialkyne 1.132 was 
used it means that 75% of the compound 1.132 had decomposed. 
 
 
Figure 17 – Minimised energy conformation in vacuum for dialkyne 1.132. * 
Structures modeled using ChemBio3D and minimised to give the lower energy state. 
 
Examining the minimum energy conformation of dialkyne 1.132 can suggest 
why there is the need for higher temperatures. In the lowest energy 
conformation (Figure 17) the two alkynes are not in close proximity (3.2 Å 
distance between the reactive carbons atoms) when compared with the average 
C-C bond distance (1.5 Å). Therefore, it is likely that the reaction will not occur 
unless more energy is put into the reaction system to allow it to access higher 
energy conformations where the two alkyne branches are close enough in order 
to coordinate efficiently to the catalyst. 
In summary, for this reaction system Vollhardt’s catalyst is more chemoselective 
than Wilkinson’s catalyst for the formation of tricyclic adduct 2.116a. It has also 
been shown that the yield of product 2.116a decreases with reduction of the 
catalyst loading, the temperature of reaction and the amount of monoalkyne 
2.112a used. The best solvent is toluene at refluxing temperature.  
The attempts to optimise the reaction of dialkyne 1.132 with diethylacetylene 
2.112a in the presence of Vollhardt’s catalyst were not successful, therefore in 
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an attempt to increase product formation, two more catalysts ([Ir(cod)Cl]2 and 
Cp*Ru(cod)Cl) were used with the same monoalkyne system (entries 16 and 
17). [Ir(cod)Cl]2 is widely used in [2+2+2] cyclotrimerisation reactions
41, and 
here it was used in the presence of DIPHOS affording the product 2.116a in 
18% yield. Although, it did not increase the product formation, it notably altered 
the ratio of byproducts obtained, affording byproduct 2.114a in higher yield 
compared with byproduct 2.115a, which did not occur before. It is possible that 
the presence of a bulky ligand that coordinates with the metal limited the 
second addition to the alkyne branch of compound 2.114a. When Cp*Ru(cod)Cl 
was used as the catalyst under refluxing toluene it afforded the desired product 
2.116a in very good yield, making this catalyst the most chemoselective of the 
four catalysts used. 
 
 
Scheme 71 
Entry Monoalkyne 2.112a-h 
Time  
(h) 
Yield (%) 
2.113ª 2.114 2.115 2.116 
1 
a        
2.5 24 trace 16 70 
2 
b          
1 22 --- 17 34 
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3 
c              
20 Degradation 
4 
d         
20 Degradation 
5 
e          
4 days Did not react 
6 
e          
3 days
b
 Did not react 
7 
f             
24 Degradation 
8 
g       
24 32 --- --- trace 
9 
h 
           
24 Degradation 
Table XIII – Monoalkyne screening. Reactions performed with 0.310 mmol of 
dialkyne 1.132, 5 eq. of monoalkyne in 2 mL of toluene under reflux with 10 mol % of 
Cp*Ru(cod)Cl. a yield based on the amount of monoalkyne used, b reaction carried out 
in DMF at 110 ºC. 
 
 
Having identified an effective catalyst for the [2+2+2] cyclotrimerisation, the next 
step was to investigate the reactivity of dialkyne 1.132 with monoalkynes 
2.112a-h (Scheme 71, Table XIII), in order to explore the steric and electronic 
effects of the substituents. 
The monoalkyne screening showed that electron withdrawing monoalkynes are 
more reactive towards [2+2+2] cyclotrimerisation (entries 1, 2 and 8, Table XIV) 
whereas the electron donating monoalkynes (entries 3-6 and 9) led to 
decomposition of the reaction mixture. Alkyne 2.112e did not seem to be 
soluble in toluene and the reaction formed two phases even after four days 
under reflux conditions; dialkyne 1.132 did not react or decompose (entry 5). 
Subsequently, the reaction was repeated in DMF at 110 ºC (entry 6). Although 
the problem of solubility was overcome, the problem of reactivity remained, 
even after 3 days there was no product formed. BTMSA 2.112h did not react 
with dialkyne 1.132 in the presence of Cp*Ru(cod)Cl or as previously shown 
with Wilkinson´s catalyst; this was quite disappointing because BTMSA is 
widely used in [2+2+2] cyclotrimerisations of alkynes due to the absence of 
competition for the homotrimerised product.56 
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2.2.2 [2+2+2] Cyclotrimerisation of 1,6-di(prop-2-yn-1-yl)piperidin-2-
one 1.124 
 
 
 
Scheme 72 
Entry Monoalkyne 2.112 Time (h) 
Yield (%) 
2.113 2.117 2.118 
1 
a 
 
0.5 19 46 8 
2 
b 
 
1 26 28 8 
3 
g 
 
24 31 5 -- 
Table XIV - Monoalkyne screening. Reactions were performed with 0.310 mmol of 
dialkyne 1.133, 5 eq. of monoalkyne in 2 mL of toluene under reflux with 10 mol % of 
Cp*Ru(cod)Cl. [a] yield based on the amount of monoalkyne used. 
 
 
Monoalkynes 2.112a, b and g were most reactive with dialkyne 1.132, therefore 
they were used in subsequent reactions with the 6-membered ring dialkyne 
1.133 under the previously optimised reaction conditions using Cp*Ru(cod)Cl as 
the catalyst in refluxing toluene. 
The 6-membered ring scaffold dialkyne 1.133 gave a similar pattern of results 
compared to the 5-membered ring 1.132 (Scheme 72 and Table XIV). Better 
yields were obtained with the diethyl ester than the corresponding methyl ester. 
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Diphenylacetylene was much lower yielding; although it is an electron 
withdrawing alkyne, there might be a steric clash associated with the insertion 
of this alkyne to the metallacycle adduct during the catalytic cycle (see Scheme 
3 in section 1.4.1.1). 
 
 
2.1.3 [2+2+2] Cyclotrimerisation of 4-benzyl-1,6-di(prop-2-yn-1-
yl)piperazin-2-one 1.119 
 
 
Scheme 73 
 
Entry Catalyst Solvent 
Temperature 
(°C) 
Time 
(h) 
NMR 
% yield 
2.119a 1.128 
1 Cp*Ru(cod)Cl Toluene reflux 0.5 39ª -- 
2 Cp*Ru(cod)Cl Toluene reflux 0.5 32 -- 
3 Cp*Ru(cod)Cl DCE rt 24 10 75 
4 Cp*Ru(cod)Cl DCE reflux 24 12 59 
5 Cp*Ru(cod)Cl Toluene rt 24 25 60 
6 Cp*Ru(cod)Cl Toluene 40 72 26 40 
7 Cp*Ru(cod)Cl Toluene 60 5 37 -- 
8 Cp*Ru(cod)Cl Toluene 100 5 38 -- 
9 Cp*Ru(cod)Cl 
DCE/Toluene 
1:1 
85 24 28 10 
10 Cp*Ru(cod)Cl DMF 85 24 7.3 --
b
 
11 Pd(PPh3)4 Toluene reflux 2.5 --
b
 --
 b
 
Table XV – Optimisation of the [2+2+2] reaction conditions for dialkyne 1.128. 
Reactions performed with 0.310 mmol of dialkyne 1.128, 5 eq. of monoalkyne 2.112a, 
40 mol % of 1,3,5-trimethoxybenzene in 2 mL of toluene under reflux with 10 mol % of 
Cp*Ru(cod)Cl. a isolated yield; b degraded. 
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The last dialkyne substrate to be studied in the [2+2+2] cyclotrimerisation 
reactions of alkynes was 4-benzyl-1,6-di(prop-2-yn-1-yl)piperazin-2-one 1.128. 
Dialkyne 1.128 was reacted with diethyl acetylenedicarboxylate 2.112a (5 eq.) 
and Cp*Ru(cod)Cl (10 mol %) in refluxing toluene, affording 39% yield of the 
desired cycloadduct 2.119a along with 4% of by-product 2.120a (Scheme 73, 
Table XV, entry 1). Quantitative NMR spectroscopy was used to estimate the 
yield of the products during optimisation of the reaction of dialkyne 1.128. 1,3,5-
trimethoxybenzene was selected as the internal standard, because this 
compound generates two singlets in the 1H NMR spectrum: one at 6.02 ppm 
which corresponds to the three aromatic hydrogens and another at 3.75 ppm 
which corresponds to the three methoxy groups, both of which do not overlap 
with the peaks of product 2.119a. Additionally, 1,3,5-trimethoxybenzene is non-
volatile, so can be included in reactions under reflux, and samples can be 
concentrated without risk of losing the internal standard. To prove that the 
transition-metal catalysed cyclotrimerisation reaction was not affected by the 
addition of the internal standard, dialkyne 1.128 was reacted with diethyl 
acetylenedicarboxylate 2.112a (5 eq.) and Cp*Ru(cod)Cl (10 mol %) in refluxing 
toluene, affording 39% yield of the desired cycloadduct 2.119a along with 4% of 
by-product 2.120a  (Scheme 73, Table XV, entry 1). Next, dialkyne 1.128 was 
reacted with diethyl acetylenedicarboxylate 2.112a under the same conditions 
with the addition of 40 mol % of 1,3,5-trimethoxybenzene (entry 2). On 
completion of the reaction, the toluene was removed under vacuum and a 1H 
NMR spectrum of the crude reaction mixture was recorded, which was analysed 
to give an estimated yield of 32% of product 2.119a. It can be stated that the 
yield estimated by NMR spectroscopy is an acceptable approximation of the 
isolated yield (isolated yield of 38% vs NMR yield of 32%), which indicates that 
the internal standard does not affect the course of the reaction. Next, attempts 
to optimise this reaction were performed and the results are shown in Table XV. 
The best solvent for this reaction was found to be toluene at reflux (entry 1). 
The use of lower temperatures resulted in decreased yields and extended 
reaction times (entries 5-8). Use of DCE instead of toluene gave even lower 
yields than reactions in toluene at the same temperatures (entries 3 and 4), and 
the use of DMF caused substantial decomposition (entry 10). It is noticeable 
that a maximum yield seems to be reached for a particular set of reaction 
conditions, i.e. ~10% for reactions in DCE, 25% for those in toluene below 60 
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°C and 38% for those in toluene above 60 °C. Increasing the reaction time or 
temperature within these conditions only decreased the amount of SM 
recovered rather than increasing the yield. This suggests that the product may 
be decomposing as the reaction progresses. 
 
Entry Dialkyne Product (% yield) By-product (% yield) 
1 
 
 
 
 
1.132 
 
 
 
2.116a                   70% 
 
2.115a                    16% 
2 
 
 
 
1.133 
 
 
2.117a                   46% 
 
2.118a                     8% 
3 
 
1.128 
 
2.119a                   38% 
 
2.120a                     4% 
Table XVI – Products and by-products obtained from the reaction of dialkynes 
1.132, 1.133 and 1.128 with diethylacetylene dicarboxylate 2.112a (5 eq.) 
catalysed by Cp*Ru(cod)Cl (10 mol %) under reflux toluene.  
 
Comparing the [2+2+2] cyclotrimerisations of the three substrates (1,5-di(prop-
2-yn-1-yl)pyrrolidin-2-one 1.132, 1,6-di(prop-2-yn-1-yl)piperidin-2-one 1.133 and 
4-benzyl-1,6-di(prop-2-yn-1-yl)piperazin-2-one 1.128) when reacting with 
diethylacetylene dicarboxylate 2.112a and Cp*Ru(cod)Cl in refluxing toluene, 
reaction of 1.132 is higher yielding than reaction of either of the 6-membered 
ring dialkynes, and 1.132 also produced more of the byproduct resulting from 
intermolecular cyclotrimerisation of each alkyne sidechain. This suggests the 
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configuration most frequently adopted by dialkyne 1.132 holds the two alkyne 
branches closer, allowing it to react faster and affording a better yield of 2.116a. 
There was no significant difference in reactivity between the piperidinone and 
piperazinone skeletons.  
 
 
2.3 Conclusions 
 
 
Scheme 22 
 
Three dialkynes, 1.132, 1.133 and 1.128 have been prepared using amide 
reduction and aminal substitution to introduce one propargyl sidechain, followed 
by amide N-alkylation with propargyl bromide to introduce the second. 
The study of the transition-metal catalysed [2+2+2] cyclotrimerisation of alkynes 
started with dialkyne 1.132. Several reaction conditions were screened and the 
best conditions found was using diethylacetylene dicarboxylate 2.112a as the 
monoalkyne, Cp*Ru(cod)Cl as the catalyst and toluene as the solvent under 
refluxing conditions to afford tricyclic compound 2.116a in 70% yield. With this 
optimised reaction condition, other monoalkynes were reacted with dialkyne 
1.132. It was concluded that electron withdrawing alkynes react efficiently with 
dialkyne 1.132, since the reaction mixture decomposed when electron donating 
monoalkynes were employed. Dialkynes 1.133 and 1.128 afforded the expected 
tricyclic adducts 2.117a and 2.119a when reacted with diethylacetylene 
dicarboxylate 2.112a, albeit in lower yield. 
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Chapter 3 Diversity-oriented small library synthesis via 
transition-metal catalysed [2+2+2] cyclotrimerisations 
under microwave irradiation 
 
 
3.1 Microwave Assisted Organic Synthesis 
 
 
Radiation Quantum Energy (eV) Bond type 
Bond Energy 
(eV) 
-Rays 1.24  10
6
 C-C  3.61 
X-Rays 1.24  10
5
 C=C 6.35 
UV 4.1 C-O 3.74 
Visible 2.5 C=O 7.71 
IR 0.012 C-H 4.28 
Microwave 0.00126 O-H 4.80 
Radio waves 4.0  10
-9
 Hydrogen Bond 0.04-0.44 
Table XVII – Radiation energies compared to bond energies.133 
 
Microwave radiation is an electromagnetic radiation located between the 
infrared and radio frequency waves, with a wavelength of between 1 cm and 1 
m (0.3 GHz to 300 GHz). Domestic and industrial microwave ovens operate at 
2.45 GHz which corresponds to 0.00126 eV of energy. Such a low energy is 
unable to cleave C-C bonds (3.61 eV) or hydrogen bonds (0.04-0.44 eV) (Table 
XVII), therefore microwave radiation itself is not capable of initiating chemical 
reactions.134,135,136 
First reported by Gedye in 1986137 and later by Giguere and Majetich,138 
microwave assisted organic synthesis (MAOS) uses microwave radiation to 
dramatically accelerate the rate of the reactions, reducing the reaction times 
from days to hours to seconds, enhancing the yields and improving 
reproducibility. It is a powerful tool in organic synthesis, as it accelerates the 
rate of the reaction; high temperatures are reached in a few seconds, therefore 
reactions are shorter and cleaner, with less side products. The reaction is not 
controlled or limited by the boiling point of the solvent, since superheating 
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conditions can be achieved within closed vessels, for example methanol can be 
heated to temperatures above 100 ºC. 
MAOS is an established method used in many labs in academia and industries 
and it appears as an alternative to the use of isomantles, oil baths and hot 
plates and other energy sources (ultrasonic, high pressure and plasma) and it 
has often been used in different areas of chemistry not only in organic but also 
in medicinal and combinatorial chemistry and also in biochemistry139,140 In the 
early days of the application of microwaves in organic synthesis, domestic 
microwave ovens or cavities designed for analytical science were used, 
however, problems associated with the use of flammable solvents, safer 
containers and reproducibility of results (accurate power and temperature 
measurements) led to equipment improvements. Nowadays microwave reactors 
are equipped with built-in magnetic stirring, temperature, power and pressure 
controls as well as cooling options (CO2 or N2 streams), and automation. The 
cooling option is very important since it allows that the bulk heating generated 
inside the reaction mixture is minimized by the use of simultaneous cooling in 
order to avoid thermal degradation of certain substrates. 
 
 
Figure 18 – Inverted temperature gradients in microwave heating (left) versus 
conventional heating (right). Temperature profiles (finite element modeling) after 
1 min are shown for both heating methods. In microwave the temperature of the 
whole volume is raised simultaneously (bulk heating, left), whereas in a 
conventional heating tube the reaction mixture in contact with the vessel wall is 
heated first (right).134 
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Conventional thermal heating is usually slow and is associated with inefficient 
energy transfer, being dependent on the conductivity of the reaction vessel and 
on convection currents of the solvents resulting in a heterogeneous distribution 
of heating in the reaction mixture (Figure 18 right). Usually the temperature of 
the oil bath is 20-50 ºC higher than the internal temperature of the reaction 
mixture and sometimes reagents (mainly catalysts) can decompose in contact 
with the vessel wall. Conventional heating is usually limited by the boiling point 
of the solvent, unless the reaction is done in a sealed tube, which can present 
the risk of explosion of vessels under pressure.141 
 
 
Figure 19 – Dipoles and ions trying to align with the applied electric field by 
rotation (a. dipoles) and by moving back and forth (b. ions). 
 
Microwave heating (also named as microwave dielectric heating) transforms 
electromagnetic radiation into heat, by taking advantage of the properties of 
materials (liquids and solids) in absorbing microwave radiation. Like all types of 
radiation, microwave radiation has an electric and a magnetic component, and it 
is the electric component that is responsible for the heating. Microwave 
dielectric heating depends on two mechanisms: dipolar polarisation and ionic 
conduction.142,143 In dipolar polarisation, when an electric field is applied to a 
system the molecules (induced or permanent dipoles) will tend to align with the 
field by rotation. As the electric field oscillates the molecules rotate with it 
(Figure 19 a), however they cannot always change orientation at a rate equal to 
the field’s which induces friction and collisions between molecules ultimately 
leading to heating. In ionic conduction, microwave energy is absorbed by ions, 
that will also move back and forth with the electric field (Figure 19 b). The kinetic 
a 
a b 
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energy will increase due to collisions between ions and other molecules and 
energy is released in the form of heat. 
 
Solvent tan  Solvent tan  
Ethylene glycol 1.350 DMF 0.161 
Ethanol 0.941 1,2-dichoroethane 0.127 
DMSO 0.825 Water 0.123 
2-propanol 0.799 Chlorobenzene 0.101 
Formic acid 0.722 Chloroform 0.091 
Methanol 0.659 Acetonitrile 0.062 
Nitrobenzene 0.589 Ethyl acetate 0.059 
1-butanol 0.571 Acetone 0.054 
2-butanol 0.447 THF 0.047 
1,2-dichlorobenzene 0.280 DCM 0.041 
NMP 0.275 Toluene 0.040 
Acetic acid 0.174 Hexane 0.020 
Table XVIII – Loss factors (tan ) of different solvents.136 
 
The ability of a material (reagent, catalyst or solvent) to convert microwave 
radiation into dielectric heating is determined by the loss tangent (tan ) at a 
determined temperature and frequency. Solvents are considered as high 
absorbents when tan  > 0.5 and weak when tan  < 0.1, so the higher the tan  
is the more efficient the heating (Table XVIII), however, this does not mean that 
weak absorbent solvents cannot be used in MAOS. For weak absorbing 
solvents, polar additives such as ionic liquids, or passive heating elements can 
be added.144 Dielectric heating does not depend on the conductivity of the 
reaction vessel (usually made of a material transparent to microwave radiation 
such as quartz, borosilicate glass or Teflon (where tan  < 0.01) but on radiation 
interacting directly with the reaction mixture, therefore affording a higher degree 
of temperature homogeneity (bulk heating, Figure 18 left). 
 
Sometimes differences are observed in reaction rate and product distribution 
when MAOS is compared to conventional heating. Despite all the work 
published using MAOS, there is still a big controversy on why and how 
microwave enhances chemical reactions. Initially it was thought that these 
differences were only due to specific or non-thermal microwave effects as a 
consequence of the radiation-material interaction (which would decrease the 
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activation energy or increase the pre-exponential factor in the Arrhenius 
equation). Nowadays most researchers appear to agree that the main reason is 
just based on thermal/kinetic effects due to reaching elevated temperatures 
more quickly. The Arrhenius equation          
  
  
 ] relates reaction rate to 
temperature of the system: reactions that take hours at reflux temperatures will 
be finished in just a few minutes in superheated solvents.  
 
 
Scheme 74 
 
MAOS has a wide application in different reactions such as organometallic 
(Heck, Suzuki, Stille cross coupling), cyclisations (Diels-Alder, RCM), 
heterocyclic (indoles, pyrroles, quinolines, quinolones, furans, lactams), 
oxidations, reductions, condensations, nucleophilic additions (Michael additions, 
Mitsunobu reactions) amongst others.145,146 The example described in Scheme 
74 illustrates the influence of the temperature and the solvent on the reaction 
rate of an intramolecular hetero Diels-Alder reaction.144 Under conventional 
heating the reaction was done in refluxing PhCl (bp 132 ºC) over 24 h to obtain 
product 3.2. Under microwave irradiation, the reaction took 1 h to completion in 
DCE (bp 83 ºC) (reaching a maximum temperature of 170 ºC). With addition of 
a small amount of an ionic liquid (bmimPF6) to improve absorption of radiation, 
the reaction mixture reached 190 ºC in less than 1 minute and the reaction was 
finished in just 8 minutes. Microwave irradiation was also used to reduce the 
time for the hydrolysis step, which took place under standard conditions at rt in 
wet chloroform over 18 h (74%). After the first step under microwave irradiation, 
water was added and the reaction mixture heated for an additional 5 minutes at 
130 ºC, affording compound 3.3 in 77% yield. Although both methods afford 
similar yields, it can be seen that using MAOS the time is reduced from 2 days 
to 13 minutes being a one-pot reaction in a microwave. This approach also 
shows how a low absorbing solvent can be combined with ionic liquids to give 
an enhanced reaction rate. 
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MAOS is a tool that has also been applied in drug discovery for NCEs. Some 
examples of its use in pharmacologically active scaffolds are shown below. (For 
reviews of synthesis of pharmacological scaffolds using MAOS 
see147,148,149,150,151)  
 
 
Scheme 75 
 
MAOS in combination with solid-phase synthesis was used for the multi-step 
synthesis of Imatinib 3.15 (Gleevec), an anticancer drug approved by FDA 
(Scheme 75).152 Carroti and co-workers described the synthesis of Imatinib 3.15 
applying microwave irradiation in 5 steps of the synthesis, which includes 
preparation of the linker 3.6, nucleophilic substitution, reduction of the nitro 
group, formation of guanidine 3.13 and cyclisation to obtain the final product 
3.15. It is noteworthy that using MAOS, 3.13 was obtained in both higher yield 
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and purity and the cyclisation reaction time was reduced from 20 h to 50 
minutes when compared to conventional heating. This elegant synthesis also 
opens the possibility for library preparation with molecular diversity as depicted 
in Scheme 75 in blue. 
 
 
Scheme 76 
 
Conejo-García and co-workers investigated the synthesis of purine-based 
compounds to be used as cyclin dependant kinase (CDK) inhibitors that are 
associated with cancer and degenerative diseases.153 The authors used a one-
pot Vorbrüggen condensation of cyclic acetal 3.16 and purine bases 3.17 which 
formed a mixture of isomers 3.18 and 3.19 using conventional heating (Scheme 
76). However, when using microwave irradiation, if the temperature was 
controlled (100 or 130 ºC), each isomer could be selectively formed. 
 
 
Scheme 77 
 
Müller and co-workers have synthesised a small library of anthraquinone 
derivatives as antagonists of platelet P2Y12 receptors.
154 As a key step, an 
Ullman coupling reaction of 1-amino-4-bromoanthraquinone 3.20 derivatives 
was employed with different anilines. The short reaction times (5-20 minutes) 
allowed for the synthesis of diverse derivatives in up to 90% yield. 
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Scheme 78 
 
Compound 
Time MW 
(min) 
Yield MW (%) 
Time conv. 
(h) 
Yield conv. 
(%) 
3.24 3 80 8-10 36 
3.26a 3 78 4-5 53 
3.26b 3 80 4-5 62 
3.26c 3 95 4-5 53 
3.26 3 95 4-5 48 
Table XIX – Time and yield comparison between microwave (MW) and 
conventional heating (conv.) for indole synthesis 3.24 and 3.26a-d. 
 
Microwave irradiation has been used to shorten the reaction times in Fischer 
indole synthesis, while considerably improving the yield when comparing to 
conventional heating (Scheme 78, Table XIX).150 The reaction carried out by 
microwave is a one-pot synthesis compared with a two step conventional 
method. 
 
The examples above show how microwave irradiation is helpful in the synthesis 
of small libraries of compounds. However, MAOS also plays an important role in 
big biological library synthesis when applied to high-throughput microwave 
synthesis: automated sequential library synthesis (integrated robotic devices 
with a single-mode microwave cavity) and parallel microwave library synthesis 
(reactions usually done in 96-well microtitre plates).155,156 
The use of MAOS influences at least three stages of drug discovery: library 
generation, conversion of hits to leads and leads optimisation.155 
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Scheme 79 
 
Condensation of 1,2-diketones 3.27 with the appropriate partner can afford 
1,2,4-triazines, imidazoles, fused pyrazines (for example, quinoxalines), 
pyrazin-2(1H)-ones and canthine derivatives in only 5-10 minutes in high yield 
under microwave irradiation, compared to  30-65% yield  in 8-24 h with 
conventional heating (Scheme 79 a).155 One of these compounds (3.33) was 
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found to be a hit against AKT (serine/threonine kinase) which regulates the 
apoptotic machinery of cells and plays a crucial role in cancer therapy (Scheme 
79 b). To perform structure-activity relationship (SAR) studies and hit-to-lead 
conversion,  a library of 200 compounds was quickly synthesised using MAOS; 
therefore bromomethyl functionalised 1,2-dicarbonyl building block 3.34 was 
reacted with 200 different amines followed by treatment of each intermediate 
3.35 with 1,2-diaminobenzene 3.36 under microwave irradiation generating 200 
different products 3.37 (Scheme 79 c). After HTS, lead I 3.38 was identified and 
a ten-fold increase in potency was observed in relation to the initial hit 3.33, 
however due to poor solubility a second-generation library was developed with 
the aim of modifying the quinoxaline ring. Intermediate 2 3.39 was treated with 
50 different 1,2-diarylamines 3.40 affording 50 different products 3.41 (Scheme 
79 d), which were screened against AKT to identify compound 3.42 as a lead 
structure II with improved potency, solubility and cell permeability. 
 
In summary, these examples show how important the use of microwaves is in 
organic and medicinal chemistry/chemical biology. Its major advantages are 
shorter reactions times and the high temperatures that it can operate. With 
shorter reaction times it is possible to quickly screen different parameters in 
order to optimise a reaction. 
 
 
3.2 Strategy design 
 
 
 
Scheme 80 
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Previously it was shown how DOS contributes to the development of new drugs 
or NCEs (section 1.2). It was also shown how applying a B/C/P strategy can 
lead to stereo and skeletally diverse small molecules in a quick and efficient 
way (up to 5 steps).  
Here it was envisaged to synthesise small bicyclic systems using the B/C/P 
strategy described in Scheme 80. Contrary to chapter 2, retrosynthetic analysis 
is not needed, because there is no specific target, it is important to develop a 
robust method that gives as much diversity as possible. 
Therefore, the building blocks in Scheme 80 were commercially available (in the 
case of X = O) or synthesised in one step (X = Ns), they were then coupled with 
an alkyne side chain (couple step) and in the pair step they underwent ring 
closure through a transition-metal catalysed [2+2+2] cyclotrimerisation of 
alkynes or nitriles using MAOS. 
  
 
 
Scheme 81 
 
Silylation of alkynenitriles 3.47 was also planned in order for further 
derivatisation (1 step) of the bicyclic compounds afforded in the pair step 
(Scheme 81). In this way, more skeletal and stereo-diversity is added to the 
library of compounds. 
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3.3 Preparation of [2+2+2] substrates: Build and Couple steps 
 
3.3.1 Oxygen containing compounds 
 
 
Scheme 82 
The target molecules are alkynenitriles 3.52/3.53 which will afford 
dihydrofuropyridine derivatives 3.54 after the pair step (Scheme 82). 
 
 
 
Scheme 83 
Synthesis of alkynenitrile 3.52 was attempted through the reaction of but-3-yn-
2-ol 3.55 with sodium hydride and bromoacetonitrile 1.139 (Scheme 83).  
Bromoacetonitrile 1.139 had to be used in a large excess (10 eq.) to drive the 
reaction to completion. Unfortunately, due to issues of volatility, the product 
3.52 could not be separated from the excess of bromoacetonitrile 1.139, even 
after normal and fractional distillations were carried out. 
 
 
Scheme 84 
Addition of a silyl group to the terminal alkyne would overcome the volatility 
issue and fulfil the objectives (section 1.6) of allowing for subsequent 
derivatisation after ring closure to increase the diversity of the library. The 
selective silylation of the terminal alkyne was carried out with 
dimethylphenylsilyl chloride (DMPSCl) in the presence of LiCl (Scheme 84) and 
the desired product 3.56 was obtained in 55% yield.157 LiCl coordinates with the 
oxygen anion that is formed by the reaction of BuLi with the alcohol group, thus 
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preventing it from reacting with DMPSCl. The low yield of the product may result 
from an inefficient coordination with LiCl; a less polar compound was observed 
by TLC but not isolated, consistent with formation of the bis-silylated compound. 
 
 
Scheme 85 
 
Alkylation of silylalkyne 3.56 with sodium hydride and bromoacetonitrile 1.139 
was not possible (Scheme 85); all attempts using different amounts of both 
base and alkylating agent led to decomposition of the reaction mixture. Slightly 
weaker bases such as lithium hexamethyldisilazane (LHMDS), 
sodiumhexamethyldisilazane (NaHMDS) and tBuOK or a different protecting 
group such as TBDMS, which is more stable towards basic conditions, could 
have been employed. 
 
 
Scheme 86 
Entry Base (eq.) 
Solvent 
Temperature 
% yield 
3.53 
1 
NaH 
(4.4) 
THF 
0 ºC → - 20 ºC → 
0ºC 
55 
2 
NaHMDS 
(1.1) 
THF 0 ºC – rt 34 
3 
NaHMDSª 
(1.1) 
THF -78 ºC – 0 ºC Degradation 
4 
t
BuOK (1.1) THF 0 ºC - rt Degradation 
5 
NaH 
(4.4) 
DMF 
0 ºC → -20 ºC → 0 
ºC 
Degradation 
Table XX – Optimisation of alkylation of alcohol 3.58 with bromoacetonitrile 
1.139. ªAddition of NaHMDS to a solution of alcohol and bromoacetonitrile at -78 ºC. 
 
90 
  
Due to all the problems reported above, it was decided to change the starting 
building block to 1-phenylprop-2-yn-1-ol 3.58 which is not a volatile substrate. 
Alkylation of this compound was initially carried out with sodium hydride and 
bromoacetonitrile 1.139 (Scheme 86, Table XX, entry 1) yielding 55% of product 
3.53. Other bases and reaction conditions were investigated but it was not 
possible to improve on the original result. 
 
 
 
Scheme 87 
 
Compound 3.53 was silylated with DMPSCl in the presence of LHMDS affording 
the desired product 3.59 in 66% yield (Scheme 87).158 
 
 
Scheme 88 
 
In order to synthesise substrates leading to dihydropyranopyridine derivatives 
3.62 alkylation of but-3-yn-2-ol 3.55 with acrylonitrile 1.138 was carried out in 
the presence of substoichiometric 1,8-diazabicycloundec-7-ene (DBU) affording 
the desired alkynenitrile 3.60 in 89% yield (Scheme 88).159 When the same 
reaction conditions were applied to 1-phenylprop-2-yn-1-ol 3.58 the reaction 
mixture became an insoluble resin, regardless of the reaction temperature or 
mode of acrylonitrile addition. These observations suggest that polymerisation 
of the acrylonitrile is taking place, however it is not clear at present why 
polymerisation does not happen when but-3-yn-2-ol 3.55 is used.  
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Scheme 89 
 
Entry Solvent 
Temperature 
(ºC) 
Time 
(h) 
Yield 3.63 
(%) 
1 THF 0 3 40 
2
 
 Et2O 0 - rt o/n 40 
3 Et2O reflux o/n 45 
4 DMF 0 - rt 3 25 
Table XXI – Attempts to optimise the alkylation of alcohol 3.58 with propargyl 
bromide 2.9. 
 
 
It was decided to compare the reactivity of the transition-metal catalysed 
[2+2+2] cyclotrimerisations of tethered alkynenitrile substrates 3.52 and 3.60 
with a simple tethered diyne 3.63 which would form dihydroisobenzofuran 
derivatives 3.64 (Scheme 89), further contributing to the diversity of the small 
library. The building block 3.63 was obtained in 40% yield from the reaction of 
1-phenylprop-2-yn-1-ol 3.58 with sodium hydride and propargyl bromide 2.9 
(Scheme 89).  Despite several attempts to optimise the reaction conditions 
(Table XXI), none of the modifications were successful in achieving a better 
yield. 
 
 
 
Figure 20 – Isobenzofuranone, isochromanone and dihydrobenzoxepinone. 
 
 
The last strategy to introduce diversity in the oxygen containing bicycles was to 
incorporate a carbonyl group to the non-aromatic ring, in order to afford 
isobenzofuranone 3.65, isochromanone 3.66 and dihydrobenzoxepinone 3.67 
derivatives (Figure 20). 
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Scheme 90 
 
The parent esters were planned to be synthesised by reaction of alcohol 3.58 
with the acyl chloride. Accordingly, pent-4-ynoyl chloride 3.69 (generated in situ 
from the reaction of the corresponding acid 3.68 in refluxing thionyl chloride)160 
was reacted with 1-phenylprop-2-yn-1-ol 3.58 in the presence of DMAP and 
NEt3, affording the desired ester 3.70 in 85% yield (Scheme 90).
161 Next, the 
esterification was attempted with but-3-ynoyl chloride 3.71 (Scheme 90). 
Unfortunately, no reaction occurred when alcohol 3.58 was treated with acyl 
chloride 3.71 under identical reaction conditions. Thinking that the problem 
could have been the formation of the acyl chloride 3.71, the reaction was 
repeated using oxalyl chloride in DMF/DCM at rt,162 but again no reaction was 
observed. A Mitsunobu reaction was also attempted but the reaction conditions 
caused degradation of the reaction mixture. 
 
Scheme 91 
Entry Reactions conditions %Yield 3.74 
1 Propiolic acid chloride, DMAP, NEt3, DCM Did not react 
2 EDCI, DMAP, NEt3, DCM, -78 ºC, 5 h 24 
3 PPh3, DEAD, THF, 0 ºC, 2 h 58 
Table XXII – Attempts on the esterification of alcohol 3.58. 
 
93 
  
1-Phenylprop-2-yn-1-ol 3.58 did not react with propiolic acid chloride, in the 
presence of DMAP and NEt3. Employing peptide coupling conditions (EDCI, 
DMAP and NEt3, Table XXII, entry 2) the desired product was obtained with a 
low yield (24%). Mitsunobu reaction gave ester 3.74 in reasonable yield 
(58%)163 
 
3.3.2 Nitrogen containing compounds 
 
 
Scheme 92 
 
The next point to introduce diversity to the library was to incorporate nitrogen 
containing compounds at the build stage. But-3-yn-2-amine hydrochloride 3.75 
can be protected as the nosylate in high yield (Scheme 92). Unfortunately, this 
required building block 3.75 is scarce and due to its lack of availability it was 
necessary to synthesise it.  
 
 
Scheme 93 
Entry Amine Acid Solvent 
Reducing 
agent 
% yield 
3.79 3.80 
1 NH2Ns 
Acetic 
acid 
MeOH/THF NaBH3CN Degradation 
2 NH2PMB --- MeOH NaBH3CN --- 25 
3 NH2Ns TfOH Nitromethane Et3SiH Degradation 
4 NH2PMB TfOH Nitromethane Et3SiH --- 
a
 
Table XXIII – Attempted reductive amination of ketone 3.78. a observed but not 
quantified 
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The simplest way to obtain nosyl-protected amide 3.77 would be through a 
reductive amination of commercially available but-3-yn-2-one 3.78 (Scheme 
93). When the reductive amination was attempted with nosyl amine and sodium 
cyanoborohydride in the presence of a stoichiometric quantity of acetic acid,164 
the reaction mixture decomposed (Table XXIII, entry 1). Changing the amine to 
p-methoxy benzyl (PMB) amine, afforded alkene 3.80 instead of the desired 
amide 3.79 (entry 2, Scheme 93). Based on the 1H NMR coupling constant (J 
7.4 Hz) it can be concluded that alkene 3.80 is in the cis conformation. Similar 
results were obtained when triethylsilane was used as the reducing agent (entry 
3, 4). Since the initial attack on the ketone by the amine is readily reversible, it 
is likely that the reaction fails due to inability to form the intermediate imine, and 
the small amount of 3.80 formed is the product of a non-reversible side reaction. 
 
 
Scheme 94 
 
Attack on the terminal alkyne could be prevented by the presence of a 
protecting group. Therefore, ketone 3.83 was prepared through the reaction of 
acetic anhydride 3.81 and ((trimethylsilyl)ethynyl)magnesium bromide 
generated in situ (Scheme 94). This reaction has been reported to afford 3.83 in 
75% yield.165 Surprisingly, product 3.83 was obtained in 13% yield, with 3-
methyl-1,5-bis(trimethylsilyl)penta-1,4-diyn-3-yl acetate 3.84 as the major 
product (75%). This by-product is formed from a second addition of the 
Grignard reagent to the carbonyl of product 3.83, followed by reaction of the 
resulting anion with acetic anhydride. In an attempt to avoid the formation of by-
product 3.84, the order of the addition of the reagents during the course of the 
reaction were swapped; therefore the freshly formed Grignard was added 
dropwise into the acetic anhydride to avoid the presence of excess Grignard as 
the ketone formed. The yield did not increase, in spite of the low yields it was 
decided to continue the synthesis. 
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Scheme 95 
 
The reductive amination was then accomplished by treating the TMS-protected 
ketone 3.83 and PMB amine with NaBH3CN (Scheme 95). The TMS group was 
sensitive to the reaction conditions and again alkene 3.80 was obtained. There 
are other alternatives described in the literature for the synthesis of the TMS-
protected ketone 3.83 that could have been employed to improve the yield of 
the product formed, for example: reaction of acetyl chloride either with BTMSA 
in the presence of aluminium trichloride166 or with TMS-acetylene in the 
presence of zinc chloride and nBuLi167 or an oxidation of 4-trimethylsilyl-3-butyn-
2-ol with manganese.168 However, due to the instability of the TMS group 
towards the reductive amination, this approach was not further explored. 
 
 
Scheme 96 
 
An alternative to the reductive amination for the synthesis of protected amide 
3.77 is a Mitsunobu reaction on but-3-yn-2-ol 3.55. Therefore, but-3-yn-2-ol 3.55 
was reacted with N,N-Boc-nosyl amine  in the presence of diethyl 
azodicarboxylate (DEAD) and PPh3 in THF, affording the diprotected amide 
3.85 in 96% yield (Scheme 96).169 Nosyl amine itself was also used for the 
Mitsunobu reaction, however a much lower yield was obtained (38%). 
 
 
 
Scheme 97 
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N,N-Boc-nosyl amine 3.85 was deprotected with TFA, yielding the desired 
amine 3.77 in 90% yield (Scheme 97). Alkylation with sodium hydride and 
bromoacetonitrile 1.139 in DMF afforded alkynenitrile 3.86 in 93% yield 
(Scheme 97). 
 
Scheme 98 
Entry Base (eq.) Solvent Temperature 
% yield 
3.87 
1 
n
BuLi (1.5) THF -78 ºC Degradation 
2 LDA (1.2) THF -78 ºC Degradation 
3 
LHMDS 
(1.05) 
THF -78 ºC Degradation 
4 
NaHMDS 
(1.05) 
THF -78 ºC Degradation 
5 EtMgBr (1.1) THF 0 ºC ---
a
 
Table XXIV – Reactions conditions attempted for the silylation of alkynenitrile 
3.86. a Isolated fractions were mixtures. 
 
Next, it was decided to silylate the terminal alkyne as previously done for the 
parent oxygen compound 3.53 (Scheme 98). Several reactions of the tethered 
alkynenitrile 3.86 with DMPSCl in the presence of different bases were 
attempted, but none were successful (Table XXIV); all the attempts led to 
decomposition of the reaction mixture, even though very low temperatures were 
used, preventing the synthesis of compound 3.87. 
 
Scheme 99 
Entry NaH DBU NEt3 
% yield 
3.88 
1
a
  --- --- --- 
2
a
 ---  --- --- 
3
b
 ---   --- 
Table XXV –Attempted alkylation of amide 3.77 with acrylonitrile 1.138. a rt, b 60 
ºC. 
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Several attempts were also made towards the alkylation of amide 3.77 with 
acrylonitrile 1.138 (Scheme 99, Table XXV). However, as with compound 3.58 
the reaction afforded an insoluble yellow precipitate, therefore it was also not 
possible to synthesise the desired alkynenitrile 3.88.    
 
 
Scheme 100 
 
Dialkyne 3.89 was synthesised in a good yield from the reaction of amide 3.77 
with sodium hydride and propargyl bromide 2.9 (Scheme 100). 
 
 
Scheme 101 
 
Entry Base Solvent 
Time 
(h) 
Temperature 
Coupling 
agent 
Ratio 
3.77:3.90 
1
a
 NaH THF o/n rt --- 1:1.1
d
 
2
b
 NaH DMF o/n rt --- 1:0.6
e
 
3
b
 NaH DMF o/n 60 ºC --- 2.3:1
e
 
4
c
 NaH DMF 9 rt DIC Did not react 
5
c
 NEt3 DCM o/n rt PyAOP 1:1
e
 
Table XXVI – Optimisation of amide 3.90 formation. a acyl chloride formed from 
pent-4-ynoic acid and thionyl chloride, 2 h, reflux, b acyl chloride formed from pent-4-
ynoic acid and oxalyl chloride, 2 h rt, c Reaction with pent-4-ynoic acid, d isolated, e 
analysis of crude NMR.  
 
Acylation of amide 3.77 was initially carried out with sodium hydride and pent-4-
ynoyl chloride 3.69 (generated in situ and used immediately without further 
purification) in THF, affording product 3.90 in 39% yield with 44% RSM 3.77 
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(Scheme 101, Table XXVI, entry 1). Despite several attempts to improve the 
yield of 3.90 (Table XXVI), it was impossible to drive the reaction to completion 
and both 3.77 and 3.90 had the same Rf, which made their separation very 
difficult. 
 
3.4 Pair step: transition-metal catalysed [2+2+2] 
cyclotrimerisations of alkynes and nitriles 
 
3.4.1 Napthyridine derivatives 
 
 
Scheme 102 
Entry Catalyst
a
 T /power 
Time 
(min)
b
 
Sol. 
Mono 
alkyne  
 (eq.) 
% 3.86 % 3.91 
1 CpCo(CO)2 
150 °C,  
300 W 
30  PhCl 
2.112g 
(3.5) 
83  9 
2 CpCo(CO)2 
300 W max  
(93 °C) 
25  PhCl 
2.112g 
(3.5) 
Did not react 
3 CpCo(CO)2 
150 °C,  
300 W 
45  PhMe 
2.112g 
(10) 
54 11 
4  
CpCo(CO)2 
150 °C,  
300 W 
30 PhMe 
2.112h 
(10) 
Did not react 
5 Cp*Ru(cod)Cl 
150 °C, 
 300 W 
15  PhCl 
2.112g 
(3.5) 
c
 
6 Cp*Ru(cod)Cl 
150 °C, 
 300 W 
15 PhCl 
2.112a 
(10) 
c
 
7  
Cp*Ru(cod)Cl 
rt 240 PhCl --- 
c
 
8 Ni(CO)2(PPh3)2 
150 °C,  
300 W 
30 PhCl 
2.112g 
(3.5) 
Did not react 
9 Ni(CO)2(PPh3)2 
300 W max  
(62 ºC)  
30 PhMe 
2.112g 
(10) 
Did not react 
10 Cl2Pd(PPh3)2 
120 °C, 
 300 W 
20 PhMe 
2.112g 
(10) 
Did not react 
11 ClRh(PPh3)3 
150 °C, 
 300 W 
15 PhCl 
2.112g 
(10) 
Degradation 
12 Grubbs’ I 
150 °C, 
 300 W 
30 PhCl 
2.112g 
(3.5) 
Degradation 
Table XXVII – Optimisation of the cyclotrimerisation of alkynenitrile 3.86. a 
catalyst (20 mol %), b total reaction time, reactions were done in cycles of 15 minutes in 
a closed vessel, c mixture of unidentifiable compounds. 
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The work began by following the reaction conditions described by Zhou and co-
workers for the synthesis of naphthyridines;170 alkynenitrile 3.86 was reacted 
with diphenylacetylene 2.112g (3.5 eq.) in chlorobenzene (PhCl) catalysed by 
CpCo(CO)2 (20 mol %). The reaction was performed under microwave 
irradiation in a closed vessel at 150 ºC (300 W) for 30 minutes (15 + 15 
minutes) (Scheme 102, Table XXVII, entry 1). When MAOS is used there are 
two factors that cannot be controlled at the same time: the power and the 
temperature. For example, this reaction was set up to 150 ºC employing a 
maximum power of 300 W, i.e., the microwave would give the system the 
maximum power of 300 W in order to achieve 150 ºC as quickly as possible, 
afterwards the power would oscillate between 50-150 W in order to maintain 
that temperature. Alternatively, the microwave can be set to deliver a fixed 
power throughout the reaction; depending on the power level set and on the 
reaction conditions, mainly the solvent (see section 3.2) the system will reach a 
constant temperature. With the reaction conditions reported by Zhou and co-
workers the desired product 3.91g was isolated in 9% yield. At first, the reaction 
was performed for 15 minutes and after checking that it was not complete it was 
irradiated for a further 15 minutes after which no difference in the SM/P ratio 
was observed (entry 1). 
 
 
Scheme 103
170
 
 
The low yield of the product 3.91g obtained was very disappointing, because 
the literature describes a very similar reaction in very good yield, with the same 
catalyst and same monoalkyne 2.112g (Scheme 103).170 Consequently, 
alkynenitrile 3.86 was deprotected and it was subjected to the same reaction 
conditions and after 15 minutes no reaction had occurred, after two more 
irradiation cycles (15 minutes each) the reaction mixture degraded. Comparing 
both the deprotected 3.86 and the examples described in the literature 3.93,170 
it was not expected that the presence of the methyl group would make such a 
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big difference. Therefore, optimisation of the reaction conditions was carried out 
(Table XXVII, Scheme 102). 
It was decided to apply the maximum power of the microwave (300 W) in the 
next attempt (entry 2). The microwave used has a specific option that allows it 
to apply the maximum power of 300 W whilst the system is simultaneously 
cooled with a nitrogen stream, in this way only a certain temperature was 
achieved (in this case 93 ºC). Unfortunately, no product was formed. Increasing 
the quantity of monoalkyne to 10 eq., while performing the reaction in toluene 
(entry 3) at 150 ºC, did not increase product yield. A smaller amount of RSM 
was observed compared to entry 1, but that might be due its decomposition 
under the increased reaction pressure (entry 3).  
Cp*Ru(cod)Cl was the next catalyst used for the [2+2+2] cyclotrimerisation, 
because it was the one that afforded the best results in the previous chapter 
(section 2.2.1). The conditions used were 150 ºC (300 W) either with 
diphenylacetylene 2.112g or diethylacetylene dicarboxylate 2.112a (entries 5 
and 6) affording the same mixture of compounds. Obtaining the same by-
product from reactions of two different monoalkynes suggested that the product 
resulted from the Ru-catalysed reaction of the alkynenitrile 3.86 alone. It might 
be the case that this catalyst is not chemoselective enough to coordinate with 
alkynenitrile 3.86 and prefers to catalyse its oligotrimerisation. Treatment of 
alkynenitrile 3.86 with the catalyst at room temperature yielded the same 
unidentified mixture of compounds, which could be proven by 1H NMR spectrum 
comparison (entry 7). Other catalysts were also used (entries 8-12) with similar 
lack of success. 
In these reactions only toluene and chlorobenzene were used. These are the 
most common solvents used in [2+2+2] cyclotrimerisations and they are also 
weak microwave absorbers (Table XVIII, section 3.2); the aim here was to use a 
weakly absorbent solvent to try to get the maximum power output from the 
microwave. If a highly absorbing solvent was chosen like ethanol, the reaction 
system would reach 150 ºC very quickly and then the microwave only needs to 
give a small amount of power to maintain that temperature, minimising the 
exposure of the reaction mixture to the radiation. Once the system reached the 
set temperature the power oscillated between 50-150 W, and during the 
complete reaction time the system was subjected to the radiation. 
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3.4.2 Isoindoline derivatives 
 
 
Scheme 104 
 
Dialkyne 3.89 was reacted with diphenylacetylene 2.112g and 4-
fluorobenzonitrile 3.95a under the best conditions obtained above, CpCo(CO)2 
in chlorobenzene at 150 ºC (300 W) for 15 minutes (Scheme 104), affording the 
respective cyclic products in low % yield.  
 
3.4.3 Dihydrofuro[3,4-b]pyridine derivatives 
 
 
Scheme 105 
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Table XXVIII – [2+2+2] cyclotrimerisation of alkynenitrile 3.53 with different 
monoynes (2.112a,e,g,h) catalysed by CpCo(CO)2 (20 mol %). Unless otherwise 
mentioned the reactions were done in a closed vessel. a total time, reactions were done 
in cycles of 15 minutes.  
 
The focus was then turned to the synthesis of dihydrofuropyridine derivatives. 
When alkynenitrile 3.53 was reacted with diphenylacetylene 2.112g (10 eq.) 
and CpCo(CO)2 (20 mol %) at 150 ºC (300 W) in a closed vessel the desired 
cyclic product 3.98 was obtained in 50% yield along with 17% RSM 3.53 
(Scheme 105, Table XXVIII, entry 1). With this encouraging result some other 
monoalkynes were used in the cyclotrimerisation (Scheme 105 and Table 
XXVIII). Reaction with BTMSA 2.112h afforded cyclic product 3.99 in 20% yield 
along with decomposition of the reaction mixture (entry 2). When alkynenitrile 
3.53 was reacted with diethylacetylene dicarboxylate 2.112a (entry 3), after 15 
minutes the reaction was complete affording product 3.100 (29%) along with by-
product 3.101 (12 %). By-product 3.101 results from the reaction of two 
molecules of diethylacetylene dicarboxylate on both branches of the alkyne and 
nitrile. The reaction was then repeated, using open vessel conditions to see if 
the formation of the by-product 3.101 would be suppressed (entry 4). This 
meant that the reaction vessel was set up with a condenser and the 
temperature of the reaction would not go beyond the boiling point of the solvent, 
which also allowed the monoalkyne to be added dropwise. However, no product 
was formed under these conditions (not observed by ultra performance liquid 
chromatography (UPLC)). The reaction in refluxing toluene was complete after 
1 h and afforded only 15% of product 3.100 along with 2.113a and by-product 
3.101 which were not quantified (entry 5). There was no reaction when 1,4-
Entry T /power 
Time
a
 
(min) 
Solvent 
Monoalkyne 
 (eq.) 
Product: yield 
1 150 ºC, 300 W 30 PhCl 2.112g (10) 
3.98: 50%  
3.53: 17% 
2 150 ºC, 300 W 15 PhCl 2.112h (10) 3.99:20%  
3 150 ºC, 300 W 15 PhCl 2.112a (10) 
3.100: 29% 
3.101:12% 
4 
Open vessel 
120 ºC, 300 W 
30 PhMe 2.112a (10) Did not react 
5 Reflux 60 PhMe 2.112a (10) 3.100: 15% 
6 150 ºC, 300 W 30 PhCl 2.112e (10) Did not react 
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butynediol 2.112e was used as the monoalkyne (entry 6), which might be 
associated with poor solubility of 1,4-butynediol 2.112e in the reaction solvent. 
The solubility issue might have been overcome with a small addition of ethanol 
for example using a solvent system of toluene/ethanol 4:1.  
 
 
Scheme 106 
Table XXIX – [2+2+2] cyclotrimerisation of alkynenitrile 3.53 with diethylacetylene 
dicarboxylate 2.112a and BTMSA 2.112h. 
 
Two more catalysts were tested for the reaction of alkynenitrile 3.53 and 
diethylacetylene dicarboxylate 2.112a: Co(CO)8 (20 mol %) and Cp*Ru(cod)Cl 
(10 mol %) (Scheme 106, Table XXIX). When Co(CO)8 was used no reaction 
happened (entry 3) but when Cp*Ru(cod)Cl was used in either chlorobenzene 
(150 ºC, 300 W, entry 1) or toluene (120 ºC, 300 W, entry 2) the entire reagent 
was consumed after 5 minutes, affording only homotrimerised product 2.113a. 
In contrast to alkynenitrile 3.86 (Scheme 102, Table XXVII) alkynenitrile 3.53 
tended to degrade, with no formation of a major compound more polar than the 
starting material. This evidence one more time reinforces the fact that this 
catalyst might not be chemoselective for [2+2+2] cyclotrimerisation of 
alkynenitrile 3.53 and a monoalkyne, and instead might afford only 
oligomerisation of 3.53. 
 
Entry 
Catalyst 
(mol %) 
T /power 
Time 
(min) 
Solvent 
Monoalkyne 
(eq.) 
Products 
1 
Cp*Ru(cod)Cl 
(10) 
150 ºC 
300 W 
5 PhCl 2.112a (10) 2 .113a 
2 
Cp*Ru(cod)Cl 
(10) 
150 ºC 
300 W 
5 PhMe 2.112a (10) 2.113a 
3 
Co(CO)8 
(20) 
150 ºC 
300 W 
30 PhCl 2.112a (10) Did not react 
4 
Ni(CO)2(PPh3)2 
(20) 
120 ºC 
300 W 
30 PhMe 2.112h (10) Degradation 
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Until this point of the work, the highest yields were achieved using CpCo(CO)2 
as the catalyst at 150 ºC (300 W) in chlorobenezene. Unless otherwise noted, 
the [2+2+2] cyclotrimerisation of alkynes discussed in the following section, 
were carried out under these conditions. 
 
 
Scheme 107 
 
Next, attention was turned towards cyclotrimerisation of silylated compound 
3.59, which was reacted with diphenylacetylene 2.112g (150 ºC, 300 W, 20 mol 
% CpCo(CO)2) (Scheme 107), however most of the starting material did not 
react (44% RSM). Isolated fractions only revealed aromatic peaks in the 1H 
NMR spectrum and no product was observed by UPLC of the crude reaction 
mixture. The lack of reactivity of SM 3.59 may be explained by a steric clash 
between the DMPS group and the phenyl group on the monoalkyne. 
 
 
Scheme 108  
Entry
a
 
Monoalkyne 
3.104j (eq.) 
Concentration 
of reaction 
mixture 
(M) 
Ratio 3.59:3.105 
1 10 0.18 1:0.06 
2 10 0.36 
b
 
3 10 0.09 
b
 
4 10 0.018 
b
 
5 10 0.005 
b
 
6 10 0.0025 
b
 
7
c
 --- 0.18 --- 
8
 d
 --- 0.18 ---
e
 
9 
d
 10 0.18 b 
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10 0.5 0.18 1.5:1
f
 
11 1 0.18 2.6:1
f
 
12 3 0.18 1.4:1
f
 
Table XXX – Optimisation of the reaction of silylated alkyne 3.59 and 
phenylacetylene 3.104j. a All reactions were carried out with 20 mol % of CpCo(CO)2 
in PhCl at 150 ºC (300 W) for 30 minutes total reaction time (2 × 15 minute cycles) b 
crude 1H NMR analysis: compounds present but ratio not determined. c CpCo(CO)2 
omitted. d Irradiation for 15 min followed by addition of diethylacetylene dicarboxylate 
2.112a (5 eq.), irradiation for more 15 min, e 2.113a observed, f ratio determined by 1H 
NMR analysis of the crude. 
 
Phenylacetylene 3.104j should bind the catalyst in an orientation to avoid the 
steric clash. For that reason, the reaction of silylated alkyne 3.59 with 
phenylacetylene 3.104j was investigated (Scheme 108, Table XXX), in order to 
see if the addition would happen and if it would be regioselective. 
The reaction afforded the desired product 3.105 in 3.5% (isolated yield, entry 1) 
with selectivity for one isomer. Along with the small amount of product 3.105, 9 
other fractions were isolated, this included 54% of RSM 3.59. Unfortunately, all 
the fractions isolated were mixtures of products and no conclusion could be 
drawn to explain the course of the reaction. 
 
Figure 21 – HSQC spectrum of compound 3.105. 
 
3.105 
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The formation of predominantly one isomer was confirmed by 1H NMR 
spectrum where only one aromatic singlet is observed and by 13C NMR 
spectrum where there is only one peak for each carbon on the molecule.The 
assignment of the isomer formed corresponds to compound 3.105 purely based 
on NMR spectra analysis. In the HSQC spectrum (Figure 21) the carbon C3 that 
correlates with the singlet H3 is the most shielded aromatic peak. In the other 
isomer 3.106, H3 and C3 would be more deshielded because they would be 
next to the electronegative nitrogen atom. The concentration of the reaction (SM 
to solvent ratio) was varied (entries 2-6) in an attempt to decrease the amount 
of side products formed.  
It was observed that more dilute reactions (entries 5 and 6 Table XXX) took 
more time (5-8 minutes respectively) to achieve the set reaction temperature of 
150 ºC. For the standard concentration (0.18 M) the reaction took 1.5 minutes 
to reach that temperature. The desired product 3.105 was observed in all the 
reactions by TLC and UPLC, however all the more dilute reactions yielded a 
complex mixture of products (analysis by 1H NMR of the crude) regardless of 
the concentration, apart from the reaction with the increased concentration 
(entry 2) which led to an increase in the amount of side products formed. It 
seemed that the concentration did not play an important role in controlling 
product distribution. Due to the observation that the ratio between SM and 
product did not change between the first and second irradiation (TLC 
observation) there were concerns about the stability of the components of the 
reaction mixture while irradiation was taking place. To investigate their stability, 
silylated alkynenitrile 3.59 was irradiated in chlorobenzene for 30 minutes (15 + 
15 minutes, entry 7) and no degradation occured after each cycle. The next 
parameter to check was the lifetime of the catalyst. From previous experiments 
(section 3.4), it is known that CpCo(CO)2 efficiently catalyses the trimerisation 
of diethylacetylene dicarboxylate 2.112a. Accordingly, CpCo(CO)2 (20 mol %) 
was irradiated in chlorobenzene for 15 minutes before diethylacetylene 
dicarboxylate 2.112a (5 eq.) was added. After, the reaction mixture was 
subjected to irradiation for a further 15 minutes (entry 8). Monitoring by TLC 
revealed formation of the homotrimerised product 2.113a, indicating that the 
catalyst was still functional in the model system. However, when silylated 
alkynenitrile 3.59, phenylacetylene 3.104j and CpCo(CO)2 in chlorobenzene 
were irradiated for 15 minutes, followed by addition of  diethylacetylene 
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dicarboxylate 2.112a (5 eq.) and irradiation for a further 15 minutes (entry 9), no 
homotrimerised product 2.113a formed, suggesting that in this reaction system, 
after 15 minutes the catalyst is dead. It is possible the catalyst was also 
catalysing the trimerisation of phenylacetylene 3.104j in preference to 
diethylacetylene dicarboxylate 2.112a or the desired reaction of 3.59, therefore, 
the effect of the quantity of monoalkyne added to the reaction mixture was 
investigated. Three different quantities were chosen (0.5, 1 and 3 eq., entries 
10-12). Unreacted starting material 3.59 was observed in all reactions (by 
UPLC), however no conclusions can be drawn in relation to the effect of 
increasing the quantity of monoalkyne 3.104j. 
In summary, the desired [2+2+2] reaction is regioselective, but is disfavoured 
compared to unidentifiable side reactions. 
 
3.4.4 Dihydropyranopyridine derivatives 
 
 
Scheme 109 
Entry 
CpCo(CO)2 
a 
(mol %) 
Time 
(min) 
Monoalkyne 
2.112g (eq.) 
% yield 
b
 
RSM 3.107g 
1 20 15  10 Trace 43 
2 20 15  0.5 Trace 23 
3 20 15  1 Trace 42 
4 20 15  3 Trace 70 
5 20 30 3 Trace 56 
6
c
 20 15+15  3 --- --- 
7
 c
 20 10+15 3 --- --- 
8 20 10  3 26 56 
9 10 15  3 30 46 
10 10 30  3 12 55 
11 100 15  3 --- 76 
12 10 + 10 15 3 --- 62 
Table XXXI – [2+2+2] cyclotrimerisation of alkynenitrile 3.60 with 
diphenylacetylene 2.112g. a Reactions in PhCl at 150 ºC (300 W), C = 0.18 M. b 
Homotrimerised product 2.58 observed but not isolated in all reactions. c Irradiation for 
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15 minutes followed by addition of diethylacetylene dicarboxylate (5 eq.) and irradiation 
for another 15 minutes. 
 
Subsequently, the focus was turned towards the formation of the 6-membered 
ring dihydropyranopyridine derivatives. 
Alkynenitrile 3.60 was reacted with diphenylacetylene 2.112g (10 eq.) in PhCl 
with CpCo(CO)2 (20 mol %) as the catalyst at 150 ºC (300 W), affording cyclic 
adduct 3.107g in 43% yield, the remainder of the yield was the degradation 
products of the reaction mixture (Scheme 109, Table XXXI, entry 1). 
Since the reaction of alkynenitrile 3.60 with diphenylacetylene 2.112g gave a 
moderate yield of the desired product 3.107g, the conditions were further 
investigated in an attempt to optimise the reaction (Table XXXI). Decreasing the 
amount of monoalkyne from 10 to 3 equivalents (entries 2-4) increased the yield 
of the reaction to 70% , indicating that the homocyclisation of the monoalkyne 
(product 2.113g) competes with the formation of the desired product; even 
when 0.5 equivalents of monoalkyne was used there was still homotrimerised 
product  2.113g being formed. Extending the reaction time to 30 minutes (entry 
5) decreased the amount of product formed suggesting it may be unstable to 
the reaction conditions. 
To investigate the lifetime of the catalyst, two reactions were performed where 
starting material 3.60 was irradiated with diphenylacetylene 2.112g and the 
catalyst for 15 and 10 minutes. After this period, diethylacetylene dicarboxylate 
2.112a was added and each solution irradiated for a further 15 minutes (entries 
6 and 7). In both cases, the diethylacetylenedicarboxylate homotrimer 2.113a 
was obtained, which confirmed that the catalyst was still active, in contrast to 
reaction of 3.59 (Scheme 108). 
Decreasing the reaction time and the amount of the catalyst reduced the 
amount of product obtained and gave a higher percentage of RSM (entries 8-
10). On the other hand increasing the amount of catalyst to a stoichiometric 
amount (entry 11) does not significantly increase the amount of product formed 
(76%). 
In summary, CpCo(CO)2 is not chemoselective enough to react only with the 
alkynenitrile 3.60, because it competes for the homotrimerisation of 
diphenylacetylene 2.113g and perhaps for the oligomerisation of the SM. The 
best reaction conditions found for reaction of alkynenitrile 3.60 with 
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diphenylacetylene (Scheme 109) are diphenylacetylene (3 eq.), 20 mol % of 
catalyst and irradiation of the reaction mixture over 15 minutes at 150 ºC (300 
W) in chlorobenzene. 
 
 
Scheme 110 
 
Entry Monoalkyne Product:yield 
1 2.112g 
      3.107g: 70% 
2 2.112h 
 
                                  3.107h: 3.5% 
3 
a
 2.112a 
 
        3.107a: 12%         3.109a: 61% 
4 
b
 2.112a 
 
     3.107a 
b
                        3.109
b
 
5 2.112i 
 
     3.107i: 16%              3.109i: 21% 
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6 3.104j 
 
Degradation 
7 3.104k 
 
3.107k: 9% 
8 3.108n Degradation 
9 3.104l Did not react 
10 3.104m Degradation 
Table XXXII – [2+2+2] cyclotrimerisation of alkynenitrile 3.60 with different 
monoalkynes. The reactions were carried out with 3 eq. of monoalkyne, 20 mol % of 
CpCo(CO)2 in PhCl at 150 ºC (300 W) for 15 minutes, C = 0.18 M. 
a 5 minutes, b C = 
0.70 M, 10 minutes, products observed but not quantified. 
 
 
The reaction of a range of monoalkynes with alkynenitrile 3.60 were 
investigated (Scheme 110, Table XXXII) using the previously optimised reaction 
conditions (Scheme 109, Table XXXI). 
The reaction of alkynenitrile 3.60 with BTMSA 2.112h (entry 2) afforded 3.5% of 
the desired product 3.107h; the reaction was complete and TLC analysis 
suggested that the rest of the reaction mixture had degraded. The reaction with 
diethylacetylene dicarboxylate 2.112a (entry 3) was completed after 5 minutes 
affording predominantly by-product 3.109a (61%) along with the desired product 
3.107a (12%). Dilution of the reaction mixture to 0.70 M, by increasing the 
amount of chlorobenzene added (entry 4), should in theory decrease the 
probability of a second molecule of monoalkyne reacting with the alkyne branch, 
however this was not the case; the ratio of product 3.107a:by-product 3.109a 
observed by TLC was unchanged. Another alternative to increase the yield of 
the desired product from the cyclotrimerisation of alkynenitrile 3.60 with a 
monoalkyne diester, would be to increase the steric bulk of the ester to 
disfavour its homotrimerisation and the by-product formation. Di-tert-butyl but-2-
ynedioate 2.112i was reacted with alkyenitrile 3.60 (entry 6); the reaction was 
complete after 15 minutes, jugdged by tlc, (was slower than with diethyl 
acetylenedicarboxylate 2.112a) and afforded the desired product 3.62 in 16% 
yield. Unfortunately the by-product 3.109i was also isolated although in much 
lower quantity (21%). 
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 Figure 22 – 1H NMR of pyranopyridine 3.107k. 
 
TIPS acetylene afforded 9% of the desired product 3.107k (entry 7) as a single 
isomer (13C NMR). The 1H NMR aromatic coupling constant J3,4=7.8 Hz, 
characteristic of ortho coupling, indicates that it is structure 3.107k (Figure 22). 
The product was obtained regioselectively with the bulky TIPS group placed 
near the nitrogen atom which is consistent with most studies with alkynenitriles 
and non-symmetric diyenes (section 1.4.2.2).171,50 In contrast to the 
cyclotrimerisations of TIPS acetylene 3.104k and diphenylacetylene 2.112g, 
reaction with TIPS phenylacetylene 3.108n (entry 8, Table XXXII) gave only 
decomposition. The reactions with propargyl bromide 3.104l and propargyl 
amine 3.104m (entries 9 and 10) did not afford any product. In the former case 
the reaction mixture was black, but none of the starting material reacted, while 
in the latter case the reaction decomposed. Propargyl bromide is seldom used 
in cyclotrimerisation reactions to form benzene or pyridine derivatives. However, 
it has been used in a thermal Diels-Alder addition to form benzene172 and 
pyridine derivatives173.  
 
 
 
 
 
3.107k 
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3.4.5 Dihydroisobenzofuran and dihydrofuro[3,4-c]pyridine 
derivatives 
 
 
Scheme 111 
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Entry 
Unsaturated  
partner (3 eq.) 
Product : yield 
1 2.112g 
3.110g: 97% 
2 3.108n Degradation 
3 2.112h Degradation 
4 2.112a Degradation 
5 3.104k  
3.110k                        
(8% 1:1 mixture of isomers) 
6 3.95a 
 
3.111a : 31%                    3.112a : 34% 
7 3.95b 
 
3.111b : 30%                      3.112b : 29% 
8 3.95c Degradation 
9 3.95d 
 
3.111d : 20%                        3.112d : 20% 
10 3.95e 
 
3.111e : 27%                 3.112e : 28% 
11 3.95f  
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3.111f 
a
                               3.112f : 28% 
12 3.113a Degradation 
13 3.116a Degradation 
Table XXXIII – Reaction of dialkyne 3.63 with different partners. Reactions were 
catalysed by 20 mol % of CpCo(CO)2 in PhCl at 150 ºC (300 W) for 15 minutes. 
a 
observed but could not be isolated pure. 
 
The reaction of dialkyne 3.63 with diphenylacetylene 2.112g in the presence of 
CpCo(CO)2 (20 mol %) for 15 minutes afforded the desired cyclic adduct 3.110g 
in 97% yield (Scheme 111 Table XXXIII, entry 1). 
In order to incorporate more diversity into the final library of compounds, 
dialkyne 3.63 was reacted with a range of different monoalkynes and nitriles 
(Table XXXIII). Reacting dialkyne 3.63 with BTMSA 2.112h, diethylacetylene 
dicarboxylate 2.112a and TIPS phenylacetylene 3.108n resulted in 
decomposition of the reaction mixture (entries 2-5). Reaction of dialkyne 3.63 
with 4-fluorobenzonitrile 3.95a gave two separable isomers 3.111a (31%) and 
3.112a (34%), (entry 6). Similar results were obtained using benzonitrile 3.95b, 
2-(3-methoxyphenyl)acetonitrile 3.95e and 2-(3-
(trifluoromethyl)phenyl)acetonitrile 3.95f (entries 7, 10, 11). Reaction with 
indoline-3-carbonitrile 3.95d gave slightly lower yields of the desired products 
(entry 9), perhaps due to the low solubility of the indole in chlorobenzene. No 
regioselectivity was observed in any of the reactions of dialkyne 3.63 with the 
nitriles, that is because the electronics of both branches of the dialkyne are 
similar, so there is no electronic control of the nitrile’s orientation. 
Use of isocyanates and carbodiimides in the [2+2+2] cyclotrimerisation reaction 
would allow the synthesis of 2-pyridones and 2-iminopyridines (Section 1.4). 
Unfortunately, the only two cases studied here gave only decomposition of the 
reaction mixtures (entries 12 and 13). As potential future work, it will be 
important to adjust the reaction conditions for the synthesis of these two types 
of compounds and test different isocyanates and carbodiimides, in order to add 
greater diversity to the final library of compounds. 
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Scheme 112 
 
Entry Microwave
a
 
Conventional 
heating
b
 
Time 
(min) 
K2CO3 Observations 
1  --- 15 --- Degradation 
2  --- 5 --- SM + Degradation 
3  --- 10 --- SM + Degradation 
4  --- 15  Degradation 
5  --- 5+5+5  Degradation 
6
c
  --- 15  Degradation 
7 ---
b
  120  Degradation 
Table XXXIV – Attempted cyclotrimerisation of dialkyne 3.63 with TMSCN 3.95g. 
Reactions were carried out with 3 eq. of TMSCN and 20 mol % of CpCo(CO)2 in PhCl. 
a 150 ºC (300 W), b reflux, c 10 eq. TMSCN. 
 
As a further attempt to install a silyl group in the cyclic product, dialkyne 3.63 
was reacted with TMSCN 3.95g (Scheme 112, Table XXXIV). Applying the 
previously optimised conditions, reaction of dialkyne 3.63 with TMSCN was 
catalysed with CpCo(CO)2 in chlorobenzene at 150 ºC (300 W). After 15 
minutes the reaction mixture was degraded (entry 1). Shorter reaction times (5 
or 10 minutes) also gave only decomposition. It is noteworthy that there is still 
SM present in the reaction mixture at 10 minutes, which is completely 
decomposed after 15 minutes (entries 2 and 3). The degradation could be due 
to the release of HCN into the reaction mixture, therefore the reaction was 
carried out in the presence of K2CO3 for 15 minutes (entry 4) and also for pulses 
of 5 minutes until a total time of 15 minutes (entry 5). The same degradation 
pattern was obtained. Moreover, similar results were obtained using either 10 
eq. of TMSCN 3.95g under microwave conditions or carrying out the reaction 
using thermal heating (entries 6 and 7). There is no precedent for the use of 
TMSCN in [2+2+2] cyclotrimerisations. 
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3.4.6 Dihydrooxepinone, isobenzofuranone, and 
dihydrobenzoazepinone derivatives 
 
 
Scheme 113 
 
Reacting dialkyne ester 3.70 with diphenylacetylene 2.112g or 4-
fluorobenzonitrile 3.95a catalysed by CpCo(CO)2 at 150 ºC (300 W) under 
microwave irradiation (Scheme 113) led to decomposition of the reaction 
mixture; (very small quantities of the product were observed by UPLC). When 
diethylacetylene dicarboxylate 2.112a was used as the monoalkyne, the 
reaction afforded product 3.121 in 15% yield. 
 
 
Scheme 114 
 
No products were obtained from reactions of dialkyne ester 3.74 with 
diphenylacetylene 2.112g, diethylacetylene dicarboxylate 2.112a or 4-
fluorobenzonitrile 3.95a (Scheme 114). The reaction of dialkyne amide 3.90 with 
diphenylacetylene 2.112g was similarly unsuccessful (Scheme 114). 
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The building blocks derived from esters and amides seem to be more 
susceptible to degradation under the reaction conditions used. Future work 
should involve further exploration to find appropriate reaction conditions for 
[2+2+2] cyclotrimerisations of esters and amides. 
 
 
3.5 Conclusions 
 
The work developed showed the synthesis of heterocyclic molecules applying 
the concept of DOS and B/C/P strategy. 
 
 
Figure 23 – Build and couple steps with oxygen and nitrogen containing 
compounds synthesised. 
 
Oxygen and nitrogen containing compounds were used as building blocks for 
reaction with propargyl bromide 2.9, acrylonitrile 1.138 or with an acyl chloride  
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in the couple step affording several products to be used in the pair step (Figure 
23). 
In the pair step, a microwave assisted transition-metal catalysed [2+2+2] 
cyclotrimerisation of tethered alkynenitriles or dialkynes was performed. The 
best reaction conditions found here used CpCo(CO)2 as the catalyst at 150 ºC 
(300 W) in chlorobenzene. The transition-metal catalysed [2+2+2] 
cyclotrimerisations generally seem to progress with better yields with the 
oxygen containing compounds compared to nitrogen containing compounds, 
which require more work to optimise. 
The work developed above illustrated the importance of MAOS in organic 
synthesis. Using microwave radiation it was possible to test different reaction 
conditions and determine and generate compounds for biological evaluation. 
Unfortunately, for the pair step, it is not possible to draw a good correlation 
between successful reactions and the electronics of the alkynenitrile, dialkyne 
or monoalkyne. Similarly, no conclusion can be made about the size of the non-
aromatic ring formed, whether the formation of 5- or 6-membered rings is more 
favourable or not. Regardless of the alkyne used or ring size generated, 
employment of phenylacetylene led consistently to the highest yields. 
It was not possible to introduce a silyl group to allow for late stage derivatisation 
after pairing. The oxygen-containing building block 3.53 was successfully 
silylated, however did not undergo cyclotrimerisation. Reaction of silylated 
compound 3.59 with phenylacetylene 3.104j afforded a very small amount of 
product 3.105, which was generated regioselectively with the phenyl group 
adjacent to the nitrogen, rather than adjacent to the sterically demanding silyl 
group.  
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Chapter 4 Biological evaluation of bi- and tricyclic 
compounds 
 
4.1 General overview of cytochromes P450 
 
The cytochrome P450s (CYPs) belong to a superfamily of haemoproteins 
consisting of 57 different human CYPs genes and 58 pseudogenes. CYPs are 
expressed mainly in the liver where they play a major role in the 
oxidation/metabolism of xenobiotics, including 70% of drug molecules. CYPs 
are also involved in the synthesis of endogenous substrates such as steroids, 
fatty acids and vitamins (A and D), and less frequently mediate reduction 
reactions.174,175 
Recently, certain CYPs (such as CYP1A1, 1B1, 2J1, 2S1 and 2W1) have been 
found to be expressed in cancer tissues mainly in solid tumours (colon, breast, 
lung, ovarian, oesophagus), soft tissue sarcomas and metastatic disease.176 
CYP1B1 and 1A1 are most widely present in cancer cells and are the most 
studied CYPs; although their mRNA is also expressed in normal cells the 
protein appears not to be detected at significant levels. Recently CYP2W1 has 
been suggested to be an interesting anticancer target. CYP2W1 is the most 
specific form of CYPs hitherto found; it is expressed in colon tumours.175,177,178  
As CYPs are capable of metabolizing drugs, they potentially mediate a 
mechanism of drug resistance by hydroxylating lipophilic drugs leading to 
excretion from the cell. On the other hand, the expression of certain CYPs 
selectively in tumour tissues opens a window for a new and selective anticancer 
strategy, for example they can activate a prodrug in situ and thereby enhance 
cytotoxicity in tumour tissues.176,174 One example is AQ4N, a bioreductive 
cancer drug, which is metabolized by several CYPs under hypoxic conditions, to 
the amine, A4Q, which is 1000-fold more toxic than AQ4N.179 
Several other CYP-activated agents (such as resveratrol and phortress) and a 
CYP1B1 vaccine (Zyc300) are undergoing preclinical and clinical trials 
evaluations.174,176, 178 
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Figure 24 – Activation of duocarmycin bioprecursors derivatives 4.1a-d leading 
to DNA alkylation. 
 
Work at the ICT has identified the seco-duocarmycin as a pharmacophore 
which can be re-engineered to be selectively activated by CYP1A1 or 2W1. 
Duocarmycins are cytotoxic natural products whose mechanism of action 
involves the spirocyclisation of a chloromethylindoline embedded in the 
duocarmycin bioprecursor scaffold to produce a cyclopropane product that is 
necessary for DNA alkylation and apoptosis; the cyclopropane ring is attacked 
by an adenine residue in the minor groove of the DNA, forming an irreversible 
adduct leading to cell death (Figure 24). The de-hydroxylated duocarmycins 
exemplified by the chloromethylindoline ICT2700 lacks biological activity before 
no spirocyclisation can take place unless bioactivated by a CYP. For example, 
cells expressing CYP1A1 are very sensitive to treatment with ICT2700 whereas 
1A1-deficient cells are unaffected by treatment with this bioprecursor in vitro 
and in vivo.180,181 Closely related analogues, ICT2706 and 2705, are 
metabolised by CYP2W1 leading to rapid tumour cell death in expressing lines 
CYP2W1.29 
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4.2 Biological data 
 
 
Compound:number 
Ref. In 
graphs 
Compound:number 
Ref. In 
graphs 
 
RS-068 
 
RS-177 F1 
 
RS-190 
 
RS-177 F3 
 
RS-202 F1 
 
RS-179 F1 
 
RS-202 F3 
 
RS-179 F2 
 
RS-115  
 
RS-182 F1 
 
RS-146F12 
 
RS-182 F2 
 
RS-149 
 
RS-183 F2 
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RS-073 
 
RS-5MR 
 
RS-079 
 
RS-6MR 
 
RS-160 F1 
 
RS-6NBn 
 
RS-160 F2   
Table XXXV – Compounds subjected to biological evaluation. 
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Figure 25 – Relative gene expression of CYP1A1, 1A2 and 1B1 in a panel of 
human cancer cell lines. 
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A library of 21 compounds (Table XXXV) was investigated for their cytotoxic 
potential in RT112 (bladder) and MCF-7 (breast) cancer cell lines. These two 
cancer cell lines were chosen because RT112 has moderate-to-high levels of 
CYP1A1 but not 1A2 or 1B1 and MCF-7 expresses both 1A1 and 1B1 (Gene 
expressionFigure 25, data provided by Dr Mark Sutherland (ICT, 2013)).  
 
 
Figure 26 – Selective chemosensitivity of compounds shown in Table XXXV 
against RT112 bladder cancer cells. 
 
 
Figure 27 – Selective chemosensitivity of compounds shown in Table XXXV 
against MCF-7 breast cancer cells. 
 
20 compounds were screened against RT112 bladder cancer cells and MCF-7 
breast cancer cells (Figure 26 and Figure 27) at two doses 5 and 50 M. 
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Compound 3.91g (RS-068) was excluded due to problems of poor solubility. 
When screened at a dose of 50 M compounds 3.100 (RS-079) and 2.116a 
(RS-5MR) showed good inhibition of cell growth in the RT122 cell line and 
similarly compounds 3.110g (RS-149), 3.112a (RS-160F2), 3.112g (RS-183F2) 
showed inhibition in MCF-7 cell line. However, compounds 3.96 (RS-202F1), 
3.97 (RS-202F3), 3.98 (RS-073), 3.100 (RS-079), 3.111a (RS-160F1), 3.111b 
(RS-177F1), 3.111d (RS-179F1), 3.112d (RS-179F2) showed growth inhibition 
in both cell lines. When screening the compounds at a concentration of 5 M 
only compound 3.111d (RS-179F1) retained the capacity to inhibit cancer cell 
growth. Comparing the structure of compounds that inhibit cell growth it is hard 
to define a structure-activity relationship (SAR) pattern, which provides 
information that demonstrate why only 3.111d (RS-179F1) is active at the 
lowest dose.  
All the compounds were also investigated in HEK293-mock and 
HEK293/CYP2W1 transfected cell lines, however none of the compounds were 
shown to be cytotoxic at 50 µM. These results suggest that CYP2W1 is not able 
to activate compounds. 
 
 
Scheme 115 
 
Compound 3.111d (RS-179F1) is promising and more studies are needed to 
fully understand its mechanism of action. Nonetheless, given it is active in both 
RT112 and MCF-7 cells with an IC50 in the nano-molar range, it is possible that 
CYP1A1 is involved in bioactivating 3.111d (RS-179F1) in a similar way to the 
126 
  
oxidation of benzo[a]pyrene (B[a]P) 4.5 by CYP1A1 and 1B1 (Scheme 115).182 
These two CYP isoforms oxidise B[a]P 4.5 to form B[a]P-7-8-epoxide 4.6 which 
undergoes ring-opening by epoxide hydrolase to B[a]P-7,8-dihydrodiol 4.7. 
Further activation by CYP1A1 and 1B1 form a second epoxide (7,8-dihydroxy-
9,10-epoxy-7,8,9-10-tetrahydrobenzo[a]pyrene (B[a]PDE) 4.8), which is capable 
of crossing the nucleus membrane and react with DNA to form covalent adducts 
particularly at the exocyclic amines of 2’-deoxyguanosine (dGuo) 4.9  and 2’-
deoxyadenosine (dAdo) 4.10 (Scheme 115). The involvement of CYP1A1 in the 
bioactivation of 3.111d (RS-179F1) could be assessed by a number of 
experiments including incubating 3.111d (RS-179F1) (i) with alpha-
napthoflavone, a CYP1A1 inhibitor, in the chemosensitivity experiments and 
see if the cytotoxicity is diminished or abolished, and (ii) with CYP1A1 
recombinant protein and assess metabolites to see if epoxide products are 
generated. 
 
 
4.3 Conclusions 
 
From the screening of the 20 compounds it can be concluded that some 
compounds may be bioactivated by CYP1A1 and 1B1 with 3.111d (RS-179F1) 
identified as the most interesting analogue. Only one of the three compounds 
synthesised in Chapter 2 2.116a (RS-5MR) seem to have some activity when 
screened at 50 M against RT112 bladder cancer cell line, which is unsurprising 
given these lack the key aminol fragment in the quinocarcin scaffold. 
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Chapter 5 Future Directions 
 
 
The work generated in this thesis could be continued in several directions and 
some of the more immediate ones are outlined below as suggestions to future 
work packages:  
 
 
Chapter 2  Exploration of transition-metal catalysed [2+2+2] 
cyclotrimerisation of alkynes in the design and synthesis of tricyclic 
tetrahydroisoquinoline-based molecules  
 
 
Scheme 116 
 
(i) Derivatisation of the final tricyclic adduct to generate more enzymatically 
stable compounds, for example reduced derivatives such as 5.1-5-3 or amide-
linked compounds with improved aqueous solubility such as 5.4-5.6 (Scheme 
116). 
 
(ii)  Reduction of   the carbonyl groups from the lactams 2.116a, 2.117a and 
2.119a to the correspondent amino alcohols 5.7-5.9 and amines 5.10-5.12 
(Scheme 116). This will generate target compounds with an intact aminol with a 
simple chemical structure compared with ET-743 1.13. The de-hydroxy target 
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compounds 5.10-5.12 are likely to be inactive with a chemical structure that 
may be suitable for tumour-selective activation by extra-hepatic CYPs via 
regeneration of the aminol fragment in the resulting pharmacophore.  
 
 
 
Scheme 117 
 
 
(iii) Transition-metal catalysed [2+2+2] cyclotrimerisations will be performed with 
non-symmetric alkynes and nitriles therefore increasing the diversity of the 
tricyclic core library (Scheme 117) 
 
 
Chapter 3 Diversity-oriented synthesis for small library synthesis via 
transition-metal catalysed [2+2+2] cyclotrimerisations under microwave 
irradiation 
 
(i) Further investigation of the transition-metal mediated [2+2+2] 
cyclotrimerisation of the nitrogen containing compounds 3.86 and 3.89; i.e., 
attempt the pairing with more symmetric and non-symmetric monoalkynes, with 
nitriles and other unsaturated molecules. 
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Scheme 118 
 
(ii)  Reaction of alkynenitriles 3.53 and 3.60 with nitriles and non-metric alkynes 
(Scheme 118 a) 
(iii) Further interrogation of the reaction of dialkyne 3.63 with carbodiimides and 
isocyanates to afford iminopyridine 5.22 and pyridone 5.23 derivatives (Scheme 
118 b), and the cyclisation of ester dialkynes 3.70, 3.72 and 3.74 (Scheme 118 
c).  
With these approaches the diversity of the small library will be enriched and 
more compounds can be tested for biological activity. Compounds that show 
promising results in appropriate assays will be resynthesized and separation of 
enantiomers will be performed using a chiral stationary phase chromatography. 
 
Chapter 4 Biological evaluation of bi- and tricyclic compounds 
 
As mentioned in the introduction (section 1.3.1), the compounds synthesised in 
this thesis may have properties that are necessary for targeting the HIF-1 
pathway. In the first instance, the 20 compound library will be assessed for their 
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ability to inhibit HIF-1 expression; this will be carried out using conventional 
assays that measure the gene and protein expression of this transcription 
factor.23 If any of the compounds are able to inhibit HIF-1 expression, then more 
detailed studies will be carried out to understand where in the pathway the 
compounds are active. 
Additionally, the compounds may possess a capacity to inhibit cell migration as 
discussed in the introduction (section 1.3.1). As such, the 20 compound library 
will be further examined in functional assays of tumour cell migration by using 
standard radial migration and linear scratch assays.25 
Analogs of 3.111d (RS-179F1) are going to be synthesised with introduction of 
groups stable to metabolism, for example R groups will be introduced at 
different positions of the indole and the phenyl group at the initial alkyne will be 
changed. 
 
 
 
 
 
131 
  
Chapter 6 Experimental 
 
6.1 General methods 
Commercially available reagents were used as received without additional 
purification. All solvents used in reactions were purchased from Sigma-Aldrich. 
Petroleum ether refers to the fraction of petroleum spirit boiling in the range of 
60 to 80 °C. Where stated, mixtures of solvents are referred to as percentage 
volume to volume (v/v) ratios. 
Products described in Chapter 2 were purified by flash column chromatography 
using Merck 9385 silica gel 60 (40-63 μm). Products described in Chapter 3 
were purified using a CombiFlash companion system (Teledyne ISCO, Inc.) 
with pre-packed FLASH silica gel columns (Teledyne ISCO, Inc.). Analytical thin 
layer chromatography (TLC) was conducted on Merck silica gel 60 F254 
aluminium backed plates. Visualisation of the reaction components was 
accomplished by illumination under short wavelength (254 nm) ultraviolet light 
or using basic potassium permanganate, phosphomolybdic acid (PMA) or 
vanillin stain. 
All melting point (mp) values were determined on a Gallenkamp melting point 
apparatus and are stated uncorrected. Optical specific rotations were measured 
in Perkin Elmer 341 Polarimeter and are expressed in º10-1cm2g-1 and the 
concentration (c) in g/0.1 dm3. 
Proton Nuclear Magnetic Resonance (1H NMR) spectra were recorded using 
Bruker AMX400 (400 MHz), JEOL ECA-600 (600 MHz), Varian I-500 (500 Mz) 
or Varian I-400 (400 Mz) instruments. Carbon Nuclear Magnetic Resonance 
(13C NMR) sectra were performed in the same instruments operating at 101, 
150 MHz and 126 MHz. Chemical shifts for 1H and 13C NMR spectra are 
reported in parts per million (ppm) downfield from tetramethylsilane. Multiplets 
are reported as follow: br broad, s singlet, doublet, t triplet, q quartet, qn quintet, 
dd double doublet, m multiplet.  
IR spectra were recorded in a PerkinElmer Spectrum 100 FT-IR Spectrometer. 
Routine mass spectra were run on a Micromass Quattro Ultima spectrometer. 
The ionisation method (ESI or API), and mode [positive (+) or negative (-)] used 
are indicated for each compound. High resolution mass spectrometry was 
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performed at the National Mass Spectrometry Centre Swansea using MAT95 or 
MAT900 in the electrospray ionisation (ESI) mode.  
Microwave experiments were carried out in a CEM Discover microwave reactor. 
Cell lines: MCF-7 human breast carcinoma cell line (was purchased from 
ECACC, Salisbury, UK) and RT112 human bladder carcinoma cell line were 
cultured in RPMI 1640 cell culture medium supplemented with 1 mM sodium 
pyruvate, 2 mM L-glutamine and 10% fetal bovine serum (all compounds 
purchased from Sigma).  
 
6.2 Experimental procedures for Chapter 2 
 
 
N-Benzylprop-2-en-1-amine 2.5 
 
 
 
Using the procedure of Mukherjee and co-workers:75 Benzyl bromide 2.3 (5.0 
mL, 7.2 g, 42.0 mmol) was added via dropping funnel to a stirred suspension of 
N-allylamine 2.4 (25.3 mL, 19.2 g, 337 mmol) and K2CO3 (7.0 g, 50.4 mmol) at 
room temperature, under nitrogen atmosphere. After 24 h, the reaction mixture 
was filtered through a CeliteTM pad washing with DCM. After concentration 
under vacuum, the filtrate was purified by flash column chromatography 
(petroleum ether/ethyl acetate 10:1 to 2:1) affording N,N-allylbenzylamine 2.5 
(5.1 g, 82%) as a clear oil.  
Rf 0.40 (ethyl acetate/petroleum ether 1:1); H (400 MHz, CDCl3): 1.98 (brs, 1H, 
NH), 3.29 (dt, 2H, J 1.2 and 6.0 Hz, H1), 3.81 (s, 2H, CH2Ph), 5.13 (dq, 1H, J 
1.4 and 10.3 Hz, H3), 5.21 (dq, 1H, J 1.4 and 17.1 Hz, H3’), 5.94 (ddd, 1H, J 
6.0, 10.3 and 17.1 Hz, H2), 7.24-7.29 (m, 1H, HAr), 7.34 (m, 4H, HAr); C (100 
MHz, CDCl3): 51.6 (CH2), 53.1 (CH2), 116.2 (CH2, C3), 127.0 (CHAr), 128.2 
(CHAr), 128.4 (CHAr), 136.5 (CH, C2), 138.9 (CAr). NMR consistent with 
literature data.75 
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2-(Allyl(benzyl)amino)acetamide 2.2 
 
 
To a stirred suspension of K2CO3 (374 mg, 0.27 mmol) and N,N-
allylbenzylamine 2.5 (208 mg, 136 mmol) in anhydrous acetonitrile (3.6 mL) was 
added 2-bromoacetamide 2.6 (216 mg, 156 mmol) at room temperature under 
nitrogen atmosphere. The mixture was stirred for 24 h and after that time sat. 
aq. NaHCO3 solution (6 mL) was added. The mixture was extracted with DCM 
(3  30 mL) and the combined organic phases were dried over MgSO4. After 
concentration under vacuum, the mixture was purified by flash column 
chromatography (MeOH/DCM 2:98), yielding product 2.2 (281 mg, 98%) as a 
white solid.  
Rf 0.48 (MeOH/DCM 1:19); mp = 77-79 ºC; H (400 MHz, CDCl3): 3.09 (s, 2H, 
CH2CONH2), 3.13 (d, 2H, J 6.4 Hz, H1), 3.64 (s, 2H, CH2Ph), 5.20-5.26 (m, 2H, 
H3/H3’), 5.81-5.92 (m, 1H, H2), 6.99 (br s, 1H, NH), 7.08 (brs, 1H, NH), 7.24-
7.35 (m, 5H, HAr); C (100 MHz, CDCl3): 56.8 (CH2), 57.3 (CH2), 58.7 (CH2), 
118.6 (CH2), 127.2 (CHAr), 128.3 (CHAr), 128.7 (CHAr), 134.2 (CH), 137.7 
(CAr), 174.7 (C=O); max/cm
-1 (neat) 3384, 3187, 1651 (C=O), 1603; m/z (ESI+) 
205 ([M+H]+, 100%); HRMS calc. for C12H17N2O 205.1337, found 205.1335 
[M+H]+. 
 
 
4-Benzyl-6-(iodomethyl)piperazin-2-one 2.1 
 
 
A Schlenk tube was charged with 2-(allyl(benzyl)amino)acetamide 2.2 (104 mg, 
0.51 mmol), anhydrous triethylamine (150 µL, 109 mg, 1.08 mmol) and 
anhydrous pentane (2.0 mL) under argon. The stirred mixture was cooled to 0 
°C and trimethylsilyl trifluoromethanesulfonate (195 µL, 240 mg, 1.08 mmol) 
was added dropwise. After stirring for 3 h at room temperature, the layers were 
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allowed to separate and the upper layer was transferred by cannula to another 
Schlenk tube. The lower layer was washed twice with Et2O and the washings 
transferred to the second Schlenk tube. The combined layers were 
concentrated in vacuum, then cooled to 0 °C. A solution of iodine (284 mg, 1.12 
mmol) in anhydrous THF (1 mL) was added. The mixture was stirred for 2 h 
under argon and was then quenched with an aqueous saturated solution of 
NaHCO3 (5 mL) and Na2S2O3 (5 mL). The reaction mixture was extracted with 
ethyl acetate (3  10mL), and the combined organic layers were dried over 
MgSO4, concentrated under vacuum and purified by flash column 
chromatography (petroleum ether/ethyl acetate 4:1 to 1:4) affording 4-benzyl-6-
(iodomethyl)piperazin-2-one 2.1 (50 mg, 30%) as a pale yellow solid and 4-
benzyl-6-(iodomethyl)morpholin-2-one 2.10 (9 mg, 5%) as a yellow oil. 2-
(allyl(benzyl)amino)acetamide 2.2 (18 mg, 17%) was also recovered.  
Rf 0.5 (ethyl acetate); mp = 120 ºC (dec); H (400 MHz, CDCl3): 2.61 (dd, 1H, J 
5.1 and 12.0 Hz, CHH’I), 2.67 (dd, 1H, J 4.1 and 12.0 Hz, CHH’I), 3.01 (d, 1H, J 
16.5 Hz, H3), 3.11 (d, 1H, J 16.5 Hz, H3’), 3.12 (dd, 1H, J 6.3 and 10.0 Hz, H5), 
3.26 (dd, 1H, J 6.8 and 10.0 H5’), 3.47 (d, 1H, J 13.0 Hz, CHHPh), 3.54 (d, 1H, 
J 13.0 Hz, CHH’Ph), 3.51-3.54 (m, 1H, H6), 7.20-7.29 (m, 5H, HAr); C (100 
MHz, CDCl3): 8.5 (CH2I), 52.8 (CH, C6), 53.0 (CH2), 56.9 (CH2), 61.4 (CH2), 
127.7 (CHAr), 128.6 (CHAr) 129.0 (CHAr), 136.7 (CAr), 169.8 (C=O); max/cm
-1 
(neat) 2923, 1738 (C=O), 1627, 1380, 1244, 1197; m/z (ESI+) 331 ([M+H]+, 
100%); HRMS calc. for C12H15N2OI 331.0302, found 331.0308 [M+H]
+. 
 
 
4-Benzyl-6-(iodomethyl)morpholin-2-one 2.10 
 
 
Rf 0.6 (ethyl acetate /petroleum ether 3:7); H (400 MHz, CDCl3): 2.60 (dd, 1H, J 
7.0 and 12.5 Hz, CHHI), 2.91 (dd, 1H, J 3.2 and 12.5 Hz, CHH’I) 3.15 (d, 1H, J 
17.5 Hz, H3), 3.33 (d, 1H, J 17.5 Hz, H3’), 3.27 (dd, 1H, J 4.6 and 10.3 Hz, H5), 
3.33 (dd, 1H, J 7.9 and 10.3 H5’), 3.50 (d, 1H, J 12.8 Hz, CHHPh), 3.55 (d, 1H, 
J 12.8 Hz, CHH’Ph), 4.46 (m, 1H, H6), 7.19-7.31 (m, 5H, HAr); C (100 MHz, 
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CDCl3): 3.6 (CH2I), 52.5 (CH2), 55.0 (CH2), 61.3 (CH2), 77.8 (CH, C6), 129.0 
(CHAr), 128.7 (CHAr) 127.9 (CHAr), 134.2 (CAr), 166.8 (C=O); max/cm
-1 (neat) 
3190, 2850, 1698, 1650 (C=O), 1416, 1314; m/z (ESI+) 331 ([M+H]+, 100%); 
HRMS calc. for C12H15NO2I 332.0142, found 332.0142 [M+H]
+. 
 
 
Bis(2,4,6-trimethylpyridine)silver(I) hexafluorophosphate 2.15 
 
 
Using the procedure of Homsi and co-workers:85 2,4,6-trimethylpyridine 2.14 
was added dropwise to a stirred solution of silver nitrate (5.0 g, 29.6 mmol) and 
potassium hexafluorophosphate (5.5 g, 29.70 mmol) in H2O (50 mL) at 0 ºC. 
The reaction was allowed to warm to room temperature over 1 h, then it was 
filtered, and the solid washed with water, and dried in vacuo to yield silver 
bis(collidine) hexafluorophosphate 2.15 (14.4 g, 98%) as a white solid.  
mp = 213 ºC [lit.85 210 ºC]; H (400 MHz, CDCl3): 2.42 (s, 6H, CH3), 2.74 (s, 
12H, CH3), 7.12 (s, 4H, HAr). Data in agreement with literature.
85 
 
 
Bis(2,4,6-trimethylpyridine)iodine(I) hexafluorophosphate 2.16 
 
 
Using the procedure of Homsi and co-workers:85 a solution of iodine (1.0 g, 4.00 
mmol) in anhydrous DCM (24 mL) was added dropwise to a stirred solution of 
silver bis(2,4,6-trimethylpyridine) hexafluorophosphate 2.15 (2.1 g 4.21 mmol) in 
anhydrous DCM (6 mL) at 0 ºC under nitrogen. The mixture was stirred at rt for 
1 h and after that, a further 0.2 eq (0.4 g) of silver bis(2,4,6-trimethylpyridine) 
hexafluorophosphate 2.15 was added and the reaction mixture stirred for a 
further 1 h, until the iodine's colour disappeared. The reaction mixture was then 
filtered, washed with DCM and the filtrate concentrated in vacuo (maximum 
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bath temperature of 22 ºC) and bis(2,4,6-trimethylpyridine) iodine(I) 
hexafluorophosphate 2.16 (1.8 g, 85%) was obtained as a pale yellow solid. 
mp = 135  ºC [lit.85 132-133 ºC]; H (400 MHz, CDCl3): 2.40 (s, 3H, CH3), 2.44 
(s, 3H, CH3), 2.66 (s, 6H, CH3), 2.85 (s, 6H, CH3), 7.13 (s, 2H, HAr), 7.16 (s, 
2H, HAr). Data in agreement with literature.85 
 
 
Bis(2,4,6-trimethylpyridine)bromine(I) hexafluorophophate 2.17 
 
 
Using the procedure of Homsi and co-workers:85 bromine (200 L, 620 mg, 3.94 
mmol) in anhydrous DCM (24 mL) was added dropwise to a stirred solution of   
silver bis(2,4,6-trimethylpyridine) hexafluorophosphate 2.15 (2.0 g, 4.06 mmol) 
in anhydrous DCM (6 mL) at 0 ºC under nitrogen. The mixture was stirred at rt 
for 1 h and after that, a further 0.2 eq (0.4 g) of the of silver bis(2,4,6-
trimethylpyridine) hexafluorophosphate 2.15 was added and the reaction 
mixture stirred for a further 1 h, until the bromine's colour disappeared. The 
reaction mixture was filtered, washing with DCM and the filtrate concentrated in 
vacuo (maximum bath temperature of 22 ºC) to yield bis(2,4,6-trimethylpyridine) 
bromine hexafluorophosphate 2.17 (1.8 g, 95%) as a pale yellow solid.  
mp = 125 ºC [lit.85 127-128 ºC]; H (400 MHz, CDCl3): 2.40 (s, 6H, CH3), 2.70 (s, 
6H, CH3), 2.85 (s, 6H, CH3), 7.11 (s, 4H, HAr). Data in agreement with 
literature.85 
 
 
4-Benzyl-6-(bromomethyl)morpholin-2-one 2.25 
 
 
A solution of NBS (96 mg, 0.54 mmol) in dioxane (1.3 mL) was added dropwise 
to a stirred solution of 2-(allyl(benzyl)amino)acetamide 2.2 (100 mg, 0.49 mmol) 
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in a mixture of dioxane/water (680 µL, 2.25:1) at 0 ºC under nitrogen 
atmosphere. The mixture was stirred for 2 h at 0 ºC and then 24 h at rt. After 
that time, the solvents were removed under vacuum and the residue was 
dissolved in ethyl acetate (5 mL) and washed with brine (5 mL). The organic 
layer was separated, dried over MgSO4, concentrated under reduced pressure 
and purified by column chromatography (petroleum ether/ethyl acetate 7:3) to 
afford bromolactone 2.25 (28 mg, 21%) as a yellow oil and RSM 2.2 (39 mg, 
39%).  
Rf 0.8 (ethyl acetate); H (400 MHz, CDCl3): 2.63 (dd, 1H, J 6.9 and 12.6 Hz, 
CHH’Br), 2.85 (dd, 1H, J 3.4 and 12.6 Hz, CHH’Br), 3.16 (d, 1H, J 17.4 Hz, H3), 
3.32 (dd, 1H, J 1.0 and 17.4 Hz, H3’), 3.43 (dd, 1H, J 4.0 and 10.5 Hz, H5), 
3.47-3.52 (m, 1H, H5’), 3.50 (d, 1H, J 13.0 Hz, CHH’Ph), 3.55 (d, 1H, J 13.0 Hz, 
CHH’Ph), 4.60 (m, 1H, H6), 7.18-7.30 (m, 5H, HAr); C (100 MHz, CDCl3): 30.7 
(CH2Br), 51.2 (CH2), 55.8 (CH2), 61.4 (CH2), 77.6 (CH, C6), 128.0 (CHAr), 
128.7 (CHAr) 129.0 (CHAr), 135.8 (CAr), 166.8 (C=O); max/cm
-1 (neat) 2924, 
1739 (C=O), 1632, 1245; m/z (AP+) 284 ([M]+, 100% C12H15
79BrN2O), 286 ([M]
+, 
98% C12H15
81BrN2O); HRMS calc. for C12H15O2N1
79Br1 284.0281, found 
284.0287 [M+H]+. 
 
 
(S)-tert-butyl 4-formyl-2,2-dimethyloxazolidine-3-carboxylate 2.27 
 
 
Via reduction with DIBAL 
Using the procedure of Powell and co-workers:98 ester 2.26 (0.9 mL, 974 mg,  
3.76 mmol) was dissolved in stirring anhydrous toluene (7.8 mL) under nitrogen. 
After cooling to -78 ºC, DIBAL (6.6 mL of 1 M solution in THF, 6.57 mmol) was 
added dropwise at a rate to maintain the internal temperature below -60 ºC. The 
reaction was stirred for 3 h at -78 ºC and then quenched with cold methanol at a 
rate to maintain the internal temperature below -60 ºC. The reaction mixture 
was then allowed to warm to room temperature, and a 1.2 M sodium potassium 
tartrate solution (24 mL) was added and the mixture was stirred for 2 h until two 
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phases were observed. The reaction mixture was extracted with diethyl ether (3 
 8 mL) and the combined organic layers dried over Na2SO4, concentrated in 
vacuum and purified by flash column chromatography (ethyl acetate/petroleum 
ether 1:9 to 1:4) to yield aldehyde 2.27 (813 mg, 94%) as a clear oil.  
Rf 0.53 (petroleum ether/ethyl acetate 7:3); []
  
 
 = -94.5 (c 1.1, CHCl3), [lit.
99 
[]  
 
 = -93.3 (c 1.1, CHCl3)]; H (400 MHz, CDCl3): 1.36 (s, 5H, CH3), 1.44 (s, 
6H, CH3), 1.49 (s, 2H, CH3), 1.53 (s, 1H, CH3), 1.58 (s, 1H, CH3), 3.96-4.05 (m, 
2H), 4.13-4.28 (m, 1H), 9.48 (d, 0.61 H, J 1.9 Hz, CHO), 9.53 (brs 0.39 H, J 1.9 
Hz, CHO). Most peaks are doubled due to restricted rotation of NBOC group. 
Data in agreement with literature.99 
 
 
Via reduction with LiAlH4 followed by Swern oxidation 
Using the procedure of Dondoni and co-workers:99 Ester 2.26 (231 µL, 250 mg,  
0.96 mmol) in anhydrous THF (1.3 mL) was added dropwise to a stirred 
suspension of lithium aluminium hydride (55 mg, 1.44 mmol) in anhydrous THF 
(2.5 mL) at room temperature under argon. After 1.5 h, the reaction mixture was 
cooled to 0 ºC and a solution of NaOH (10%, 3 mL) was added dropwise and 
the resulting mixture stirred at rt for 1 h. The white precipitate was filtered 
through a pad of CeliteTM and washed with Et2O. The filtrate was washed with 
phosphate buffer (pH = 7.4), and the aqueous layer extracted with Et2O. The 
combined organic layers were dried over Na2SO4 and concentrated under 
vacuum, to yield alcohol 2.30 (276 mg, 100%) as yellow pale oil. 
 
(R)-Tert-butyl 4-(hydroxymethyl)-2,2-dimethyloxazolidine-3-carboxylate 
2.30 
 
 
Rf 0.29 (petroleum ether/ethyl acetate 7:3); []
  
 
 = +23.0 (c 5.0, CHCl3), [lit.
99 
[]  
 
 = +22.1 (c 1.5, CHCl3)]; H (400 MHz, CDCl3): 1.41(br s, 12 H, CH3), 1.47 
(s, 3H, CH3), 3.44 (brs, 1H, OH), 3.48 (dd, 1H, J 5.6 and 10.7 Hz), 3.68-3.71 (m, 
1H), 3.76-3.78 (m, 1H), 3.91-3.97 (m, 2H). Data in agreement with literature.99 
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Oxalyl chloride (640 µL of a 2 M solution in DCM, 1.28 mmol) was dissolved in 
stirred anhydrous THF (5.0 mL) under argon. The reaction was cooled to -78 °C 
and DMSO (181 µL, 199 mg, 2.55 mmol) was added dropwise and the reaction 
was stirred for 10 minutes.  A solution of alcohol 2.30 (184 mg, 0.80 mmol) in 
THF (5.0 mL) was then added dropwise and the reaction mixture stirred for 20 
minutes. DIPEA (890 µL, 660 mg, 5.11 mmol) was added dropwise and the 
reaction mixture was stirred for 1 h at -78 °C and a further 1 h at rt. After that 
time, the reaction was quenched with water (3 mL), extracted with ethyl acetate 
(3  3 mL) and the organic layer dried over Na2SO4, concentrated under 
reduced pressure and purified by flash column chromatography (ethyl 
acetate/petroleum ether 1:9) to yield aldehyde 2.27 (94 mg, 52%) as a pale 
yellow liquid. 
 
 
(R)-Tert-butyl 4-((benzyl(2-ethoxy-2-oxoethyl)amino)methyl)-2,2-
dimethyloxazolidine-3-carboxylate 2.29 
 
 
 
Using the procedure of Powel et al:98 Sodium cyanoborohydride (622 mg, 9.90 
mmol) was added to a stirred solution of aldehyde 2.27 (1.5 g, 6.34 mmol) and 
acetic acid (676 µL, 710 mg, 11.81 mmol) in methanol (20 mL) at 0 ºC under 
nitrogen. After 18 h the reaction was quenched with solid K2CO3 (large excess). 
The solvent was evaporated and the residue was dissolved in DCM and 
washed with a mixture of H
2
O/sat. NaHCO
3
/brine (5 mL 1:1:1). The aqueous 
layer was extracted with ethyl acetate (3  5 mL) and the combined organic 
layers dried over Na2SO4, concentrated in vacuum and purified by flash column 
chromatography (ethyl acetate/petroleum ether 1:4) affording amine 2.29 (1.4 g, 
55%) as a pale yellow oil. 
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Rf 0.65 (petroleum ether/ethyl acetate 7:3); []
  
 
 = -68.0 (c 2.5, CHCl3); H (400 
MHz, CDCl3): 1.22-1.27 (m, 3H), 1.43-1.47 (m, 12H), 1.54 (s, 3H), 2.58-2.64 (m, 
1H), 2.98 (d, 1 H, J 12.5 Hz), 3.27 (d, 1H, J 17.6 Hz, CHH’Ph), 3.33 (d, 1H, J 
17.6 Hz, CHH’Ph), 3.70-3.76 (m, 1H), 3.88-3.95 (m, 2H), 4.00 (d, 1H, J 10.0 
Hz), 4.05 (d, 1H, J 10.0 Hz), 4.11-4.18 (m, 1H), 7.24-7.52 (m 5H, HAr). NMR in 
agreement with literature.98 
 
 
(R)-4-Benzyl-6-(hydroxymethyl)piperazin-2-one 2.23  
 
 
 
Using the procedure of Powel et al:98 an aqueous solution of 6.0 M HCl (10.0 
mL) was added to a stirred solution of amine 2.29 (1.5 g, 3.57 mmol) in MeOH 
(18 mL) under nitrogen and the reaction mixture heated to reflux for 19 h. The 
reaction mixture was cooled to rt and neutralized with an aq. sat. solution of 
NaHCO3. The methanol was removed under vacuum and the residue was 
dissolved in DCM (90 mL) and washed with H2O/brine (1:1, 90 mL). The 
aqueous layer was extracted with DCM (3  90 mL) and the combined organic 
layers were dried over MgSO4 and concentrated in vacuum, to yield alcohol 
2.23 (635 mg, 81%) as a pale pink solid.  
Rf 0.37 (DCM/Methanol 9:1); mp: 77 – 83 ºC; []
  
 
 = -32.5 (c 4.0, CHCl3), [lit.
98 
[]  
 
 = -34.0 (c 11.4, CHCl3)]; H (400 MHz, CDCl3):
 2.37 (dd, 1H, J 5.7 and 11.7 
Hz, H5), 2.62 (dd, 1H, J 3.6 and 11.7 Hz, H5'), 2.99 (d, 1H, J 16.7 Hz, H3), 3.04 
(d, 1H, J 16.7 Hz, H3'), 3.39-3.55 (m, 5H, H6, CHH’OH, CHH’Ph), 4.33 (br s, 
1H, OH), 7.31-7.11 (m, 5H, HAr), 7.57 (s, 1H, NH); C (100 MHz, CDCl3): 51.1 
(CH2, C5), 52.7 (CH, C6), 56.6 (CH2, C3), 61.8 (CH2Ph), 65.2 (CH2OH), 127.7 
(CHAr), 128.6 (CHAr), 129.0 (CHAr), 136.4 (CAr), 170.3 (C=O); m/z (ESI+) 220 
[M+H]+, 100%. Data in agreement with literature.98 
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(R)-4-benzyl-6-(iodomethyl)piperazin-2-one 2.1 
 
 
Via reaction with methyl triphenoxy phosphonium iodide (P(PhOMe)3MeI)  
P(PhOMe)3MeI (204 mg, 0.452 mmol) was added to a solution of alcohol 2.23 
(50 mg, 0.23 mmol) in anhydrous THF (3.0 mL) at 0 ºC under nitrogen. After 2 
h, the reaction mixture was quenched with methanol (3 mL) and the solvents 
were evaporated under vacuum. The residue was dissolved in DCM (4 mL) and 
washed with an aq. sat. solution of Na2S2O3. The aqueous phase was then 
extracted with DCM (3  4 mL), dried over MgSO4 and concentrated under 
reduced pressure. Purification by flash column chromatography (ethyl 
acetate/petroleum ether 1:1) yielded iodolactam 2.1 (35 mg, 47%) as a yellow 
solid.  
mp = 120 ºC (dec); []  
 
 = +1.8 (c 3.8, CHCl3). The rest of the data is identical 
to the racemic compound previously obtained. 
 
 
Via reaction with phosphine polymer support 
A solution of iodine (75 mg, 0.30 mmol) in anhydrous toluene (2.0 mL) was 
added dropwise to a stirred slurry of alcohol 2.23 (50 mg, 0.23 mmol), imidazole 
(39 mg, 0.57 mmol) and triphenylphosphine polymer bound (166 mg of 3 
mmol/g loaded polymer) in anhydrous toluene (2.0 mL) at room temperature 
under nitrogen. The reaction mixture was heated at 50 ºC for 5 h, cooled to rt, 
and filtered through a pad of CeliteTM washing with DCM (5 mL). The filtrate was 
washed with an aq. sat. solution of NaHCO3 (5 mL), dried over MgSO4 and 
concentrated under vacuum to yield iodolactam 2.1 (61 mg, 86%). 
 
 
Via Finkelstein Reaction 
TsCl (52 mg, 0.27 mmol) was added to a stirred solution of alcohol 2.23 (50 mg, 
0.23 mmol) and NEt3 (63 µL, 46 mg, 0.45 mmol) in anhydrous DCM (1.5 mL) at 
room temperature under nitrogen. DMAP (cat.) was added and the reaction 
mixture stirred overnight. The solvents were evaporated under vacuum and the 
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residue purified by flash column chromatography (petroleum ether/ethyl acetate 
7:3) affording tosylate 2.31 (79 mg, 88%) as a yellow oil.  
Tosylate 2.31 (97 mg, 0.21 mmol) was then dissolved in stirred acetonitrile (4.0 
mL) and NaI (95 mg, 0.63 mmol) was added under N2, and the reaction mixture 
was heated at reflux for 24 h. After cooling to rt the precipitate was filtered off 
and the solution was concentrated under vacuum. The residue was dissolved 
with DCM (3 mL) and washed with an aq. sat. solution of Na2S2O3. The 
aqueous layer was extracted with DCM (3  3mL), the combined organic layers 
dried over MgSO4 and concentrated under reduced pressure to yield iodolactam 
2.1 (79 mg, 89%) as a thick yellow oil. 
 
 
 
 (R)-(4-Benzyl-6-oxopiperazin-2-yl)methyl 4-methylbenzenesulfonate 2.31 
 
 
 
Rf 0.20 (ethyl acetate); []
  
 
 = -38.1 (c 1.6, CHCl3) ; H (400 MHz, CDCl3): 2.30 
(s, 3H, CH3), 2.46 (dd, 1H, J 4.0 and 12.1 Hz, H3), 2.53 (dd, 1H, J 3.9 and 12.1 
Hz, H3’), 2.80 (d, 1H, J 16.7 Hz, H5), 3.03 (d, 1H, J 16.7 Hz, H5’), 3.35 (d, 1H, J 
13.0 Hz, CHH’Ph), 3.40 (d, 1H, J 13.0 Hz, CHH’Ph), 3.54 (m, 1H, H2), 3.89 (dd, 
1H, J 6.1 and 9.5 Hz, CHH’OTs), 4.03 (dd, 1H, J 7.1 and 9.5 Hz, CHH’OTs), 
7.09-7.11 (m, 2H, HAr), 7.17-7.26 (m, 5H, HAr), 7.66-7.68 (m, 2H, HAr); C (100 
MHz, CDCl3): 21.7 (CH3), 49.7 (CH2, C3), 50.3 (CH, C2), 56.7 (CH2, C5), 61.5 
(CH2Ph), 70.4 (CH2OTs), 127.8 (CAr), 128.0 (CHAr), 128.6 (CHAr), 128.9 
(CHAr), 130.1 (CHAr), 132.3 (CAr), 145.4 (CAr) ; max/cm
-1 (neat) 3628, 2965, 
1672 (C=O), 1627, 1360, 1173; m/z (ESI+) 375 ([M+H]+, 100%); HRMS calc. for 
C19H23N2O4S 375.1373, found 375.1376 [M+H]
+. 
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 (S)-4-Benzyl-6-methylpiperazin-2-one 2.34 
 
 
Preparation of organozinc intermediate: A Schlenk tube was charged with Zn 
dust (40 mg, 0.61 mmol) and purged with argon. Anhydrous THF (400 µL) and 
1,2-dibromoethane (2.5 µL, 5 mg, 0.03 mmol) were added and the stirred 
mixture was thrice heated to reflux with a hot-air gun and allowed to cool to rt. 
TMSCl (19 µL, 16 mg, 0.07 mmol) was added and the mixture stirred for 6 
minutes. To this activated zinc was added a solution of iodolactam 2.1 (100 mg, 
0.30 mmol) in anhydrous THF (100 µL). The mixture was stirred for 4.5 h. The 
excess of zinc was allowed to settle and the resulting solution employed in the 
next step of the reaction.  
Coupling reaction: CuCN (27 mg, 0.30 mmol) was added to a solution of LiCl 
(36 mg, 0.86 mmol, freshly dried under vacum at 50 ºC) in stirred anhydrous 
THF (200 µL). After the solution become yellow, it was cooled to -10 ºC and the 
solution of organozinc 2.32 previous formed was added dropwise via syringe. 
The solution was stirred for 12 minutes and then cooled to -78 °C. Propargyl 
bromide 2.9 (27 µL of an 80% solution in toluene, 0.24 mmol) was added and 
the reaction was stirred for 2 h at -20 ºC and then at rt overnight. The reaction 
was quenched with an aq. sat. solution of NH4Cl (3 mL),  extracted with ethyl 
acetate (3  3 mL), dried over MgSO4, concentrated under vacuum and purified 
by flash column chromatography (95:5 DCM/MeOH) to yield amine 2.2 (10 mg, 
17%) as white solid followed by lactam 2.34 (38 mg, 61%) as a white solid.  
Rf 0.46 (DCM/Methanol 9:1); mp = 120 ºC (dec); []
  
 
 = -10.9 (c 19.0, CHCl3) ; 
H (400 MHz, CDCl3): 1.08 (d, 3H, J 6.4 Hz, CH3), 2.04 (dd, 1H, J 8.4 and 11.6 
Hz, H5), 2.74 (dd, 1H, J 4.0 and 11.6 Hz, H5’), 2.88 (d, 1H, J 16.5 Hz, H3), 3.21 
(dd, 1H, J 1.1 and 16.5 Hz, H3’), 3.46 (d, 1H, J 13.1 Hz, CHH’Ph), 3.51 (d, 1H, J 
13.1 Hz, CHH’Ph), 3.54-3.61 (m, 1H, H6), 6.53 (brs, 1H, NH), 7.18-7.28 (m, 5H, 
HAr); C (100 MHz, CDCl3): 20.1 (CH3), 47.6 (CH, C6), 55.8 (CH2), 56.6 (CH2), 
61.7 (CH2), 127.5 (CHAr), 128.4 (CHAr) 129.0 (CHAr), 137.0 (CAr), 169.7 
(C=O); max/cm
-1 (neat) 3226, 2821, 1669 (C=O), 1454; m/z (ESI+) 205 ([M+H]+, 
100%); HRMS calc. for C12H17N2O 205.1335, found 205.1334 [M+H]
+.183 
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 (R)-4-Benzyl-6-(bromomethyl)piperazin-2-one 2.38 
 
 
NaH (6 mg of a 60% suspension in mineral oil, 0.02 mmol) was added to a 
stirred solution of tosylate 2.31 (50 mg, 0.13 mmol) in anhydrous DMF (0.5 mL) 
at rt, under nitrogen. After 30 minutes propargyl bromide 2.9 (31 µL of an 80% 
solution in toluene, 0.28 mmol) was added and the reaction was stirred for 19 h. 
The reaction mixture was quenched with an aq. sat. solution of NH4Cl (3 mL), 
extracted with ethyl acetate (3  3 mL) and the combined organic layers dried 
over MgSO4, concentrated under reduced pressure and purified by flash column 
chromatography (3% MeOH/DCM) to yield bromolactam 2.38 (10 mg, 26%), 
bromoalkyne 2.39 (3 mg, 7%) and bromoallene 2.40 (3 mg, 7%) as yellow oils. 
Rf 0.56 (DCM/MeOH 9:1); []
  
 
 = -5.1 (c 2.4, CHCl3); H (400 MHz, CDCl3): 2.58 
(dd, 1H, J 4.6 and 11.8 Hz, H5), 2.65 (dd, 1H, J 4.0 and 11.8 Hz, H5’), 3.04 (d, 
1H, J 16.7 Hz, H3), 3.16 (d, 1H, J 16.7 Hz, H3’), 3.32 (dd, 1H, J 10.1 and 6.7 
Hz, CHH’Br), 3.42 (dd,1H,  J  10.1 and 6.7 Hz, CHH’Br), 3.48 (d, 1H,  J  13.0 
Hz, CHH’Ph), 3.53 (d, 1H,  J 13.1 Hz, CHH’Ph), 3.58-3.64 (m, 1H, H6), 6.05 (s, 
1H, NH), 7.22-7.29 (m, 5H, HAr); C (100 MHz, CDCl3): 34.7 (CH2), 51.8 (CH, 
C6), 52.7 (CH2), 57.0 (CH2), 61.4 (CH2), 127.7 (CHAr), 128.6 (CHAr), 128.9 
(CHAr), 136.6 (CAr), 169.4 (C=O); max/cm
-1 (neat) 3299, 2920, 2776, 1668 
(C=O), 1623, 1476, 1462; m/z (ESI+) 283 ([M]+, 100% C12H15
79BrN2O), 285 
([M]+, 98% C12H15
81BrN2O) [M]
+; HRMS calc. for C12H16N2O
79Br 283.0441, found 
283.0436 [M+H]+. 
 
 (R)-4-Benzyl-6-(bromomethyl)-1-(prop-2-yn-1-yl)piperazin-2-one 2.39 
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Rf 0.82 (DCM/Methanol 9:1); []
  
 
 = -3.5 (c 1.4, CHCl3); H (400 MHz, CDCl3): 
2.22 (t, 1H, J 2.5 Hz, C≡CH), 2.47 (dd, 1H, J 2.4 and 12.2 Hz, H5), 2.89 (d, 1H, 
J 16.8 Hz, H3), 3.15-3.19 (m, 1H, H5’), 3.36 (dd, 1H, J 1.5 and 16.8 Hz, H3’), 
3.49 (d, 1H,  J  13.0 Hz, CHH’Ph), 3.50 (dd, 1H, J 1.4 and 6.8 Hz, CHH’Br),3.53 
(d, 1H, J 13.0 Hz, CHH’Ph), 3.67-3.76 (m, 2H, CHH’Br and H6), 3.88 (dd, 1H,  J 
2.5 and 17.8 Hz, NCHH’C≡C), 4.53 (dd, 1H, J 2.5 and 17.8 Hz, NCHH’C≡C), 
7.20-7.32 (m, 5H, HAr); C (100 MHz, CDCl3): 30.4 (CH2, CH2Br), 34.01 (CH2, 
NCH2), 50.9 (CH2, C5), 57.3 (CH, C6), 57.4 (CH2, C3), 61.5 (CH2, CH2Ph), 73.2 
(C, C≡C), 78.0 (CH, C≡CH), 127.8 (CHAr), 128.6 (CHAr), 129.1 (CHAr), 136.7 
(CAr), 167.3 (C=O); max/cm
-1 (neat) 3300, 3055, 2925, 2849, 2805, 1655 
(C=O), 1264; m/z (ESI+) 321 ([M]+, 100% C12H15
79BrN2O), 323 ([M]
+, 98% 
C12H15N2O
81Br); HRMS calc. for C15H18N2O
79Br 321.0597, found 321.0602 
[M+H]+. 
 
 
(6R)-4-Benzyl-6-(bromomethyl)-3-(propa-1,2-dien-1-yl)piperazin-2-one 2.40 
 
 
 
Rf 0.65 (DCM/Methanol 9:1); []
  
 
 = -34.0 (c 1.5, CHCl3); H (400 MHz, CDCl3): 
2.40 (dd,1H, J 5.1 and 12.3 Hz, H5),  2.97 (dd, 1H, J 4.0 and 12.3 Hz, H5’), 3.26 
(dd, 1H, J 8.0 and 10.0 Hz, CHH’Br) , 3.34 (dd, 1H, J  5.4 and  10.0  Hz, 
CHH’Br) , 3.46 (d, 1H, J 13.3 Hz, CHH’Ph), 3.50-3.57 (m, 1H, H6), 3.79 (d, 1H, 
J 7.0 Hz, H3) , 3.81 (d, 1H, J 13.3 Hz, CHH’Ph), 4.90- 4.80 (m, 2H, =CHH’), 
5.25 (dt, 1H, J 7.0 and  8.1 Hz, =CH) , 6.17 (br s, 1H, NH), 7.31-7.20 (m, 5H, 
HAr); C (100 MHz, CDCl3): 35.1 (CH2, CH2Br), 47.7 (CH2, C5), 52.8 (CH, C6), 
57.9 (CH2, CH2Ph), 64.5 (CH, C3), 76.9 (CH2, =CH2), 85.3 (CH, =CH), 127.7 
(CHAr), 128.6 (CHAr), 129.0 (CHAr), 137.5 (CAr), 169.8 (C=O), 210.5 (C, =C=); 
max/cm
-1 (neat) 3287, 2962, 2923, 2840, 1950, 1666 (C=O), 1619, 1455, 1061; 
m/z (ESI+) 321 ([M]+, 100% C12H17
79BrN2O), 323 ([M]
+, 98% C12H17
81BrN2O); 
HRMS calc. for C15H18N2O
79Br 321.0597, found 321.0594 [M+H]+. 
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(R)-4-Benzyl-6-(((tert-butyldimethylsilyl)oxy)methyl)piperazin-2-one 2.45 
 
 
 
TBDMSCl (82 mg, 0.55 mmol) was added to a stirred solution of alcohol 2.23 
(100 mg, 0.45 mmol) and imidazole (46 mg, 0.68 mmol) in anhydrous DCM (2.0 
mL) at room temperature under nitrogen, and the reaction mixture was stirred 
overnight. The reaction mixture was diluted with DCM (5 mL) and quenched 
with water (5 mL). The aqueous layer was extracted with ethyl acetate (3  5 
mL), and the combined organic layers were dried over MgSO4 and concentrated 
under reduced pressure to yield the protected alcohol 2.45 (130 mg, 85%) as a 
yellow oil.  
Rf 0.54 (ethyl acetate); []
  
 
 = -35.9 (c 2.5, CHCl3); H (400 MHz, CDCl3): 0.00 
(s, 3H, CH3), 0.01 (s, 3H, CH3), 0.83 (s, 9H, C(CH3)3), 2.27 (dd, 1H, J 6.5 and 
11.7, H5) , 2.68 (dd, 1H, J 3.6 and 11.7, H5’), 3.01 (brd, 1H, J 16.5 Hz, H3) , 
3.18 (dd, 1H, J 0.8 and 16.5 Hz, H3’) , 3.45 (dd, 1H, J 1.6 and 8.4 Hz, 
CHH’OTBDMS) , 3.48 (d, 1H, J 13.1 Hz, CHH’Ph) , 3.42-3.60 (m, 1H, H6), 3.55 
(d, 1H, J 13.1 Hz, CHH’Ph), 3.58 (dd, 1H, J 2.8 and 8.4 Hz, CHH’OTBDMS), 
6.26 (s, 1H, NH), 7.18-7.35 (m, 5H, HAr); C (100 MHz, CDCl3): -5.4 (CH3), -5.4 
(CH3), 18.2 (C), 25.8 (CH3), 50.3 (CH2), 53.3 (CH), 57.0 (CH2), 61.7 (CH2), 64.9 
(CH2), 127.6 (CHAr), 128.5 (CHAr), 129.0 (CHAr), 136.9 (CAr), 169.3 (C=O); 
max/cm
-1 (neat) 3299, 2954, 2931, 2850, 1651 (C=O), 1444, 1430, 1231; m/z 
(ESI) 335 [M+H]+, 100%. The sample decomposed before HRMS could be 
obtained. 
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 (R)-4-Benzyl-6-(((tert-butyldimethylsilyl)oxy)methyl)-1-(prop-2-yn-1-
yl)piperazin-2-one 2.46 
 
 
 
NaH (18 mg of a 60% suspension in mineral oil, 0.45 mmol) was added to a 
stirred solution of protected alcohol 2.45 (126 mg, 0.38 mmol) in anhydrous 
THF (2.0 mL) at rt under nitrogen. After 30 minutes propargyl bromide 2.9 (88 
µL of an 80% solution in toluene, 0.28 mmol) was added and the reaction 
mixture stirred for 21 h. The reaction mixture was quenched with an aq. sat. 
solution of NH4Cl (3 mL), extracted with ethyl acetate (3  3 mL) and the 
combined organic layers dried over MgSO4, concentrated under reduced 
pressure and purified by flash column chromatography (ethyl acetate/petroleum 
ether 1:1) to afford alkyne 2.46 (76 mg, 54%) as a yellow oil and recovered 
starting material 2.45 (37 mg, 30%).  
Rf 0.63 (ethyl acetate/petroleum ether 1:1); []
  
 
 = -6.0 (c 5.0, CHCl3); H (400 
MHz, CDCl3): -0.02 (s, 3H, CH3), 0.00 (s, 3H, CH3) , 0.81 (s, 9H, C(CH3)3), 2.17 
(t, 1H, J 2.5 Hz, C≡CH), 2.43 (dd, 1H, J 3.9 and 11.9 Hz, H5), 2.85 (brd, 1H, J 
16.6 Hz, H3), 2.98 (dm, 1H, J 2.2 and 11.9 Hz, H5’) , 3.30 (dd, 1H, J 1.4 and 
16.6 Hz, H3’), 3.44 (d, 1H, J 13.0 Hz, CHH’Ph), 3.50 (d, 1H, J 13.0 Hz, 
CHH’Ph), 3.53-3.58 (m, 1H,  H6), 3.75 (dd, 1H, J 3.8 and 8.6 Hz, 
CHH’OTBDMS), 3.78 (dd, 1H, J 6.5 and 8.5 Hz, CHH’OTBDMS), 3.85 (dd, 1H, 
J 2.5 and 17.5 Hz, NCHH’C≡C), 4.64 (dd, 1H,  J 2.5 and 17.5 Hz, NCHH’C≡C), 
7.17-7.29 (m, 5H, HAr); C (100 MHz, CDCl3): -5.5 (CH3), -5.4 (CH3), 18.2 (Ct-
Bu), 25.8 (CH3), 34.2 (CH2), 50.8 (CH2), 57.2 (CH, C6), 57.2 (CH2), 61.8 (CH2), 
62.2 (CH2), 72.0 (C, C≡C), 78.7 (CH, C≡CH), 127.5 (CHAr), 128.4 (CHAr), 
129.9 (CHAr), 136.9 (CAr), 167.4 (C=O); max/cm
-1 (neat) 3289, 2952, 2929, 
2260-2100, 1647 (C=O), 1462, 1427, 1253; m/z (ESI+) 373 ([M+H]+, 100%); 
HRMS calc. for C21H33O2N2Si 373.2306, found 373.2314 [M+H]
+. 
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 (R)-4-Benzyl-6-(hydroxymethyl)-1-(prop-2-yn-1-yl)piperazin-2-one 2.47 
 
 
 
 
TBAF (350 µL of a 1 M solution in THF, 0.34 mmol) was added to a stirred 
solution of alkyne 2.46 (77 mg, 0.21 mmol) in THF (1.0 mL) at 0 ºC under 
nitrogen. After 30 minutes, the reaction was quenched with an aq. sat. solution 
of NH4Cl (4 mL), extracted with ethyl acetate (3  4 mL) and the combined 
organic layers dried over MgSO4 and concentrated under reduced pressure 
affording alcohol 2.47 (47 mg, 89%) as a thick yellow oil.  
Rf 0.51 (DCM/MeOH 9:1); []
  
 
 = -12.2 (c 8.3, CHCl3); H (400 MHz, CDCl3): 
2.24 (t, 1H, J 2.6 Hz, C≡CH), 2.64 (ddd, 1H, J 1.5, 3.7 and 11.8 Hz, H5), 2.88 
(d, 1H, J 16.5 Hz, H3), 3.10 (dt, 1H, J 1.5 and 11.8 Hz, H5’), 3.43 (dd, 1H, J 1.5 
and 16.5 Hz, H3'), 3.49 (d, 1H, J 12.9 Hz, CHH’Ph), 3.53 (d, 1H, J 12.9 Hz, 
CHH'Ph), 3.63 (m, 1H, H6), 3.71 (dd, 1H, J 2.2 and 11.6 Hz, CHH’OH), 3.81 
(dd, 1H, J 2.5 and 17.7 Hz, NCHH’C≡C), 3.87 (ddd, 1H, J 1.5 and 4.2 and 11.6 
Hz, CHH’OH), 4.53 (s, 1H, OH), 4.76 (dd, 1H, J 2.6 and 17.7 Hz, NCHH'C≡C), 
7.16-7.35 (m, 5H, HAr); C (100 MHz, CDCl3): 33.2 (CH2, NCH2), 54.4 (CH, C6), 
54.4 (CH2, C5), 57.0 (CH2, C3), 61.9 (CH2, CH2Ph), 64.0 (CH2, CH2OH), 72.7 
(C≡C), 78.1 (C≡C), 128.1 (CHAr), 128.8 (CHAr), 129.1 (CHAr), 135.6 (CAr), 
166.7 (C=O); max/cm
-1 (neat) 3391, 3288, 2910, 2150, 1634 (C=O), 1455, 
1427, 1266; m/z (ESI+) 259 ([M+H]+, 100%); HRMS calc. for C15H19O2N2 
259.1441, found 259.1440 [M+H]+. 
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(R)-(4-Benzyl-6-oxo-1-(prop-2-yn-1-yl)piperazin-2-yl)methyl 
methanesulfonate 2.48 
 
 
 
 
MsCl (16 µL, 24 mg, 0.21 mmol) was added to a stirred solution of alcohol 2.47 
(41 mg, 0.16 mmol) and NEt3 (84 µL, 61 mg, 0.60 mmol) in anhydrous DCM 
(0.5 mL) at 0 ºC, under nitrogen and the reaction mixture was stirred overnight 
at rt. The reaction was quenched with an aq. sat. solution of NH4Cl (3 mL), 
extracted with ethyl acetate (3  3 mL) and the combined organic layers dried 
over MgSO4 and concentrated under vacuum, to yield mesylate 2.48 as a 
yellow oil. 
Rf 0.31 (ethyl acetate/petroleum ether 1:1); []
  
 
 = -8.9 (c 1.4, CHCl3); H (400 
MHz, CDCl3): 2.22 (t, 1H, J 2.6 Hz, C≡CH), 2.45 (dd, 1H, J 3.4 and 12.2 Hz, 
H3), 2.83 (s, 3H, CH3), 2.89 (d, 1H, J 16.8 Hz, H5), 2.98 (dt, 1H, J 2.0 and 12.2 
Hz, H3'), 3.41-3.45 (m, 1H, H5’), 3.44 (d, 1H, J 12.8 Hz, CHH’Ph), 3.54 (d, 1H, J 
12.8 Hz, CHH'Ph), 3.77-3.82 (m, 1H, H2), 3.91 (dd, 1H, J 2.6 and 17.6 Hz, 
NCHH’C≡C), 4.33 (ddd, 1H, J 0.6, 4.3 and 9.7 Hz, CHH’OMs), 4.41 (dd, 1H, J 
8.4 and 9.7 Hz, CHH’OMs), 4.53 (dd, 1H, J 2.6 and 17.6 Hz, NCHH’C≡C), 7.17-
7.31 (m, 5H, HAr); C (100 MHz, CDCl3): 34.6 (CH2, NCH2), 37.3 (CH3), 50.1 
(CH2, C3), 54.7 (CH, C2), 57.3 (CH2, C5), 61.4 (CH2, CH2Ph), 66.8 (CH2, 
CH2OMs), 73.1 (C, C≡C), 77.9 (CH, C≡CH), 127.8 (CHAr), 128.6 (CHAr), 129.2 
(CHAr), 136.5 (CAr), 167.1 (C=O); max/cm
-1 (neat) 3282, 2849, 2811, 1657 
(C=O), 1464, 1352, 1341, 1172; m/z (ESI+) 337 ([M+H]+, 50%), 158 (55%), 60 
(100%); HRMS calc. for C16H20O4N2S 337.1217, found 337.1219 [M+H]
+. 
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 (R)-(4-Benzyl-6-oxo-1-(propa-1,2-dien-1-yl)piperazin-2-yl)methyl 
methanesulfonate 2.49 
 
 
 
A Schlenk tube was purged with argon and charged with LAED (21 mg, 0.21 
mmol). DMSO (0.5 mL) was added and the stirred solution was cooled to 0 °C. 
A solution of mesylate 2.48 (35 mg, 0.10 mmol) in DMSO (0.5 mL) was added 
dropwise and the mixture was stirred at rt overnight. The reaction mixture was 
quenched with an aq. sat. solution of NH4Cl (3 mL), extracted with ethyl acetate 
(3  3 mL) and the combined organic layers dried over MgSO4, concentrated 
under reduced pressure and purified by flash column chromatography 
(petroleum ether/ethyl acetate 7:3 to 1:1) to afford allene 2.49 (3 mg, 9%) as a 
yellow oil and recovered starting material 2.48 (6 mg, 18%).  
Rf 0.60 (ethyl acetate/petroleum ether 1:1); []
  
 
 = -10.6 (c 0.75, CHCl3); H (400 
MHz, CDCl3): 2.43 (dd, 1H, J 2.1 and 12.2 Hz, H3), 2.78 (s, 3H, CH3), 2.90 (brd, 
1H, J 17.1 Hz, H5), 3.06 (dd, 1H, J 1.6 and 12.2 Hz, H3'), 3.48 (d, 2H, J 12.8 
Hz, CHH’Ph), 3.49 (dd, 1H, J 2.0 and 17.1 Hz, H5'), 3.55 (d, 1H, J 12.8 Hz, 
CHH'Ph), 3.67-3.77 (m, 1H, H2), 4.22 (ddd, 1H, J 1.2, 3.2 and 9.3 Hz, 
CHH’OMs), 4.42 (dd, 1H, J 9.3 Hz, CHH’OMs), 5.39 (dd, 1H, J 6.5 and 10.7 Hz, 
=CHH’), 5.50 (dd, 1H, J 6.5 and 10.7 Hz, =CHH'), 7.20-7.30 (m, 5H, HAr), 7.38 
(t, 1H, J 6.5 Hz, =CH); C (100 MHz, CDCl3): 37.1 (CH3), 49.2 (CH2, C3), 53.2 
(CH, C2), 57.3 (CH2, C5), 61.4 (CH2, CH2Ph), 65.4 (CH2, CH2OMs), 89.1 (CH2, 
=CHH), 97.1 (CH, =CH), 127.8 (CHAr), 128.6 (CHAr), 129.2 (CHAr), 136.5 
(CAr), 165.2 (C=O), 200.8 (C, =C=); max/cm
-1 (neat) 3253, 2924, 1659 (C=O), 
1455, 1360, 1347, 1174; m/z (ESI+) 337 ([M+H]+, 100%); HRMS calc. for 
C16H21O4N2S 337.1217, found 337.1217 [M+H]
+. 
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(S)-Ethyl 5-oxopyrrolidine-2-carboxylate 2.51 
 
 
 
 
Thionyl chloride (8.0 mL, 13.2 g, 0.11 mmol) was added dropwise to a stirred 
solution of L-glutamic acid 2.50 (8 g, 40.8 mmol) in ethanol (100 mL), at 0 ºC 
under nitrogen. The resulting mixture was stirring for two hours at 0 ºC then 
heated to reflux for an additional two hours. The reaction mixture was 
concentrated under vacuum and the residue purified by flash column 
chromatography (DCM/MeOH 1:0-19:1) to yield 2.51 (5.6 g, 90%) as a white 
solid. 
Rf 0.74 (1:9 MeOH/DCM); mp = 53 ºC, [lit.
184 49-51 ºC]; []  
 
 = +7.5 (c 5.0, 
ethanol), [lit.184 []  
 
 = +2.4 (c 1.0, ethanol)]; H (600 MHz, CDCl3): 1.32 (t, 3H, J 
7.1 Hz, CH3), 2.23-2.30 (m, 1H, H3), 2.36-2.42 (m, 2H, H3', H4), 2.44-2.51 (m, 
1H, H4'), 4.22-4.29 (m, 1H, H2), 4.25 (q, 1H, J 7.1 Hz, OCH2), 6.26 (s, 1H, NH). 
Data in agreement with literature.184 
 
 
(S)-5-(Hydroxymethyl)pyrrolidin-2-one 2.52  
 
 
 
 
Using the procedure of Ackermann and co-workers:185  NaBH4 (335 mg, 8.90 
mmol) was added to a stirred solution of ester 2.51 (1.4 g, 8.90 mmol) in 
ethanol (5 mL) of at 0 ºC, under nitrogen. After 2 h, the pH of the solution was 
adjusted to 4 by addition of conc. HCl. The reaction mixture was concentrated 
under vacuum and the residue suspended in DCM. The suspension was filtered 
through Celite® and the filtrate concentrated under reduced pressure. The 
residue was purified by flash column chromatography (MeOH/DCM 2:23) to 
yield alcohol 2.52 (860 mg, 86%) as a white solid.  
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Rf 0.46 (1:9 MeOH/DCM); mp = 84-87 ºC, [lit.
186 86-87 ºC]; []  
 
 = +29.2 (c 5.0, 
ethanol), [lit.187 []  
 
 = +31.5 (c 1.0, ethanol)]; H (600 MHz, CDCl3): 1.75-1.81 
(m, 1H, H4), 2.12-2.18 (m, 1H, H4'), 2.29-2.39 (m, 2H, H3, H3'), 3.44 (td, 1H, J 
6.8 and 11.5 Hz, CHH’OH), 3.66 (m, 1H, J 3.0, 5.7 and 11.5 Hz, CHH’OH), 
3.77-3.81 (m, 1H, H5), 4.36 (brt, 1H, J 5.9 Hz, OH), 7.40 (s, 1H, NH); C (150 
MHz, CDCl3): 22.7 (CH2, C4), 30.4 (CH2, C3), 56.6 (CH, C5), 66.0 (CH2, 
CH2OH), 179.5 (C=O); m/z (ES+) 116 ([M+H]
+, 100%). Data in agreement with 
literature.187  
 
 
(S)-5-(((Tert-butyldimethylsilyl)oxy)methyl)pyrrolidin-2-one 2.53 
 
 
 
TBDMSCl (1.8 g, 12.20 mmol) was added to a stirred solution of alcohol 2.52 
(1.3 g, 10.20 mmol) and imidazole (1.0 g, 15.30 mmol) in anhydrous acetonitrile 
(20 mL) at room temperature, under nitrogen. The reaction mixture was stirred 
overnight and then quenched with water (20 mL). The aqueous layer was 
extracted with ethyl acetate (3  30 mL) and the combined organic layers were 
dried over MgSO4 and concentrated under reduced pressure to yield the 
protected alcohol 2.53 (quantitative) as a pale yellow oil which required no 
further purification.  
Rf 0.28 (ethyl acetate); []
  
 
 = +41.6 (c 11.2, ethanol), [lit.188 []  
 
 = +44.7 (c 1.8, 
ethanol)]; H (600 MHz, CDCl3): 0.05 (s, 3H, CH3), 0.05 (s, 3H, CH3), 0.88 (s, 
9H, t-Bu), 1.70-176 (m, 1H, H4), 2.14-2.19 (m, 1H, H4'), 2.29-2.39 (m, 2H, 
H3/H3'), 3.43 (dd, 1H, J 3.9 and 10.1 Hz, CHH’OTBDMS), 3.62 (dd, 1H, J 7.8 
and 10.1 Hz, CHH’OTBDMS'), 3.72- 3.78 (m, 1H, H5), 5.87 (s, 1H, NH); C (150 
MHz, CDCl3): -5.3 (CH3), -5.3 (CH3), 18.3 (C), 22.8 (CH2, C4), 25.9 (CH3), 29.9 
(CH2, C3), 55.9 (CH, C5), 67.1 (CH2, CH2OTBDMS), 178.0 (C=O). Data in 
agreement with literature.188 
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(S)-5-(((Tert-butyldimethylsilyl)oxy)methyl)-1-(prop-2-yn-1-yl)pyrrolidin-2-
one 2.54  
 
 
 
NaH (329 mg of a 60% suspension in mineral oil, 13.70 mmol) was added 
portionwise to a stirred solution of protected alcohol 2.53 (2.6 g, 11.40 mmol) in 
anhydrous THF (13 mL) at room temperature, under nitrogen. After 30 minutes 
propargyl bromide 2.9 (2.7 mL of an 80% solution in toluene, 0.24 mmol) was 
added and the reaction mixture was stirred for 21 h. After that time the reaction 
was quenched with an aq. sat. solution of NH4Cl (15 mL), extracted with ethyl 
acetate (3  15 mL) and the combined organic layers dried over MgSO4, 
concentrated under reduced pressure and purified by flash column 
chromatography (ethyl acetate/petroleum ether 1:1) to afford alkyne 2.54 (2.4 g, 
80%) as a yellow oil.  
Rf 0.72 (ethyl acetate); []
  
 
 = +4.0 (c 1.5, CHCl3), [lit.
189 []  
 
 =+2.53 (c 1.8, 
CHCl3)] ; H (600 MHz, CDCl3): 0.05 (s, 3H, CH3), 0.06 (s, 3H, CH3), 0.88 (s, 
9H, t-Bu), 1.84-1.89 (m, 1H, H4), 2.08-2.15 (m, 1H, H4'), 2.19 (t, 1H, J 2.5 Hz, 
C≡CH), 2.33 (ddd, 1H, J 5.0, 10.2 and 17.5 Hz, H3), 2.43-2.49 (m, 1H, H3'), 
3.63 (dd, 1H, J 3.9 and 10.8 Hz, CHH’OTBDMS), 3.72 (ddd, 1H, J 1.0, 2.5 and 
17.6 Hz, NCHH’C≡C), 3.78 (dd, 1H, J 3.9 and 10.8 Hz, CHH’OTBDMS), 3.88 
(dq, 1H, J 3.9 and 7.9 Hz, H5), 4.60 (dd, 1H, J 2.6 and 17.6 Hz, NCHH’C≡C); C 
(150 MHz, CDCl3): -5.4 (CH3), -5.4 (CH3), 18.2 (C), 21.3 (CH2), 25.9 (CH3), 30.4 
(CH2), 30.6 (CH2), 58.4 (CH, C5), 63.8 (CH2), 72.0 (CH, C≡C), 78.3 (CH, 
C≡CH), 175.1 (C=O). Data in agreement with literature.189 
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(S)-5-(Hydroxymethyl)-1-(prop-2-yn-1-yl)pyrrolidin-2-one 2.55 
 
 
TBAF (15.2 mL of a 1 M solution in THF, 15.20 mmol) was added to a stirred 
solution of alkyne 2.54 (2.4 g, 9.10 mmol) in anhydrous THF (20 mL) at 0 ºC, 
under nitrogen. The reaction mixture was stirred for 30 min and then quenched 
with an aq. sat. solution of NH4Cl (20 mL), extracted with ethyl acetate (3  20 
mL) and the combined organic layers dried over MgSO4 and concentrated 
under reduced pressure affording alcohol 2.55 (3.6 g, quant.) as a yellowish 
solid.  
Rf 0.44 (1:9 MeOH/DCM); mp: 50-54 ºC; []
  
 
 = +15.0 (c 5.0, CHCl3); H (600 
MHz, CDCl3): 1.96-2.06 (m, 1H, H4), 2.09-2.21 (m, 1H, H4’), 2.26 (t, 1H, J = 2.5 
Hz, C≡CH), 2.31-2.40 (m, 1H, H3), 2.46-2.55 (m, 1H, H3’), 2.58 (brs, 1H, OH), 
3.65 (brd, 1H, J 11.8 Hz, CHH’OH), 3.80-3.89 (m, 1H, H5), 3.98 (brd, 1H, J = 
11.8 Hz, CHH’OH), 4.05 (dd, 1H, J = 17.6, 2.3 Hz, NCHH’C≡C), 4.31 (dd, 1H, J 
= 17.6, 2.4 Hz, NCHH’C≡C); C (150 MHz, CDCl3): 20.8 (CH2, C4), 30.3 (CH2, 
C3), 30.6 (CH2, NCH2), 59.3 (CH, C5), 62.7 (CH2, CH2OH), 72.0 (C, C≡C), 78.4 
(CH, C≡CH), 175.7 (C=O). max/cm
-1 (neat) 3346, 3275, 2931, 2874, 1650 
(C=O), 1450, 1418, 1430, 1247; m/z (ES+) 154 ([M+H]+,100%); HRMS calc. for 
C8H12O2N 154.0863, found 154.0861 [M+H]
+. 
 
 
 (S)-5-(Iodomethyl)-1-(prop-2-yn-1-yl)pyrrolidin-2-one 2.56  
 
 
MsCl (92 L, 136 mg, 1.19 mmol) was added to a stirred solution of alcohol 
2.55 (141 mg, 0.92 mmol) and NEt3 (486 L, 353 mg, 3.48 mmol) in anhydrous 
DCM (5.0 mL) at rt under argon and the reaction mixture stirred for 18 h. The 
reaction was quenched with water (5 mL) and the layers separated. The 
155 
  
aqueous phase was extracted with ethyl acetate (3  5 mL), dried over MgSO4 
and concentrated under vacuum to give the corresponding mesylate (212 mg, 
0.92 mmol) that was used without further purification. The mesylate was 
dissolved in stirred anhydrous MeCN (2.0 mL), sodium iodide (413 mg, 2.78 
mmol) was added and the reaction mixture was heated to reflux overnight. After 
evaporation of the solvent, the residue was purified by flash column 
chromatography (ethyl acetate/petroleum ether 1:1 to 4:2) affording iodide 2.56 
(199 mg, 83%) as a clear oil. 
 Rf 0.74 (1:9 MeOH/DCM); []
  
 
 = -29.4 (c 8.6, CHCl3); H (400 MHz, CDCl3): 
1.74-1.88 (m, 1H, H4), 2.16- 2.31 (m, 2H, H4'), 2.24 (t, 1H, J 2.4 Hz, C≡CH), 
2.38 (ddd, 1H, J 6.2, 10.4, 17.0 Hz, H3), 2.55 (ddd, 1H, J 6.0, 10.4, 17.0 Hz, 
H3'), 3.38 (dd, 1H, J 5.9 and 10.8 Hz, CHH’I), 3.45 (dd, 1H, J 2.5 and 10.8 Hz, 
CHH’I), 3.64 (td, 1H, J 2.3 and 17.9 Hz, NCHH’C≡C), 3.78-3.83 (m, 1H, H5), 
4.60 (dd, 1H, J 2.4 and 17.9 Hz, NCHH'C≡C); C (100 MHz, CDCl3): 10.8 (CH2, 
CH2I), 24.7 (CH2, C4), 29.8 (CH2, C3), 30.0 (CH2, NCH2), 56.3 (C5), 72.9 (C, 
C≡C), 77.2 (CH, C≡CH), 174.4 (C=O); max/cm
-1 (neat) 3287, 3233, 2952, 2116, 
1677 (C=O), 1409, 1247. NMR in agreement with literature – data for the 
racemic compound.190 
 
 
5-Methylene-1-(prop-2-yn-1-yl)pyrrolidin-2-one 2.57 and 5-methylene-1-
(propa-1,2-dien-1-yl)pyrrolidin-2-one 2.58 
 
 
A Schlenk tube was charged with LAED (35 mg, 0.38 mmol) and purged with 
argon. DMSO (0.5 mL) was added and the stirred solution was cooled to 0 °C. 
A solution of iodide 2.56 (50 mg, 0.19 mmol) in DMSO (0.5 mL) was added 
dropwise and the mixture was stirred at rt overnight. The reaction mixture was 
quenched with an aq. sat. solution of NH4Cl (3 mL), extracted with ethyl acetate 
(3  3 mL) and the combined organic layers were dried over MgSO4 and 
concentrated under reduced pressure. Purification of the residue by flash 
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column chromatography (petroleum ether/ethyl acetate 9:1) afforded allene 2.58 
(5 mg, 18%) and alkyne 2.57 (18 mg, 72%) as yellow oils. 
 
5-Methylene-1-(propa-1,2-dien-1-yl)pyrrolidin-2-one 2.58 
Rf 0.74 (ethyl acetate/petroleum ether 1:1); H (400 MHz, CDCl3): 2.50- 2.54 (m, 
2H, H3), 2.78-2.66 (m, 2H, H4), 4.31 (d, 1H, J 1.7 Hz, =CHH’), 4.93 (d, 1H, J 
1.7 Hz, =CHH’), 5.41 (d, 2H, J 6.7 Hz, =CH2), 6.93 (t, 1H, J 6.7 Hz, =CH);
 C 
(100 MHz, CDCl3): 24.3 (CH2, C4), 26.5 (CH2, C3), 28.6 (CH2, =CH2), 85.8 
(CH2, =CHH), 88.7 (CH, =CH), 204.1 (C, =C=); max/cm
-1 (neat) 3299, 2923, 
2846, 1681 (C=O), 1365; m/z (ES+) 136 ([M+H]+, 100%); HRMS calc. for 
C8H10ON 136.0757, found 136.0753 [M+H]
+. 
 
5-Methylene-1-(prop-2-yn-1-yl)pyrrolidin-2-one 2.57 
Rf 0.58 (ethyl acetate/petroleum ether 1:1); H (400 MHz, CDCl3): 2.18 (t, 1H, J 
2.5 Hz, C≡CH), 2.49-2.55 (m, 2H, H3,H3’), 2.69-2.76 (m, 2H, H4,H4’), 4.26-4.28 
(m, 3H, =CHH’/NCHH’C≡C), 4.42 (br q, 1H, J 2.0 Hz, =CHH’); C (100 MHz, 
CDCl3): 23.6 (CH2, C4), 29.0 (CH2), 29.1 (CH2), 71.4 (C, C≡C), (CH, C≡CH) 
85.6 (CH2, =CH2), 145.2 (CH, C5), 175.0 (C=O); max/cm
-1 (neat) 3357, 3285, 
2983, 2932, 1664 (C=O), 1437, 1405; m/z (ES+) 136 ([M+H]+, 100%); HRMS 
calc. for C8H10ON 136.0757, found 136.0756 [M+H]
+. 
 
 
(S)-(5-Oxopyrrolidin-2-yl)methyl 4-methylbenzenesulfonate 2.59  
 
 
TsCl (1.5 g, 7.92 mmol) was added to a stirred solution of alcohol 2.52 (766 mg, 
6.65 mmol) and NEt3 (1.8 mL, 1.3 g, 13.20 mmol) in anhydrous DCM (20 mL) at 
rt under nitrogen.  DMAP (81 mg, 0.66 mmol) was added and the reaction 
mixture was stirred overnight. The solvent was evaporated under vacuum and 
the residue purified by flash column chromatography (petroleum ether/ethyl 
acetate 2:4) to yield tosylate 2.59 (1.8 g, 98%) as an off-white solid.  
Rf 0.65 (MeOH/DCM 1:19); mp = 126 ºC [lit.
191 124-127 ºC]; []  
 
 = +27.4 (c 3.6, 
CHCl3), [lit.
191 []  
 
 = +20.3 (c 1.0, CHCl3)]; H (400 MHz, CDCl3): 1.68-1.80 (m, 
157 
  
1H, H3), 2.13-2.21 (m, 1H, H3'), 2.36-2.22 (m, 2H, H4/H4'), 2.40 (s, 3H, CH3), 
3.80-3.91 (m, 2H, H2/CHH’OTs), 3.92-4.04 (m, 1H, CHH’OTs), 6.95 (s, 1H, 
NH), 7.32 (d, 2H, J 8.2 Hz, HAr), 7.74 (d, 2H, J 8.2 Hz, HAr); C (100 MHz, 
CDCl3): 21.7 (CH3), 22.8 (CH2, C3), 29.4 (CH2, C4), 52.6 (CH, C2), 72.0 (CH2, 
CH2OTs), 127.9 (CHAr), 130.1 (CHAr), 132.2 (CAr), 145.4 (CAr), 178.3 (C=O); 
m/z (ES+) 270 ([M+H]+, 100%). Consistent with literature data.191  
 
 
 (S)-5-(Iodomethyl)pyrrolidin-2-one 2.60  
 
 
NaI (3.5 g, 23.1 mmol) was added to a stirred solution of tosylate 2.59 (1.8 g, 
6.62 mmol) in anhydrous acetonitrile (36 mL) under N2 and the reaction mixture 
was heated at reflux for 5 h. After cooling to rt, the precipitate formed was 
filtered off and the filtrate was concentrated under vacuum. The residue was 
dissolved in DCM, washed with an aq. sat. solution of Na2S2O3 and the organic 
layer dried over MgSO4. After concentration under reduced pressure, 
iodolactam 2.60 was obtained quantitatively as a yellowish solid.  
Rf 0.28 (MeOH/DCM 1:19), mp = 78-81 ºC [lit.
115 79-81 ºC]; []  
 
 = -10.0 (c 6.6, 
CHCl3), [lit.
115 []  
 
 = -11.6 (c 1.1, CHCl3)]; H (400 MHz, CDCl3): 1.71-1.83 (m, 
1H, H4), 2.23-2.28 (m, 1H, H4'), 2.35-2.29 (m, 1H, H3), 2.35-2.49 (m, 1H, H3'), 
3.16 (dd, 1H, J 4.4 and 8.5 Hz, CHH’I), 3.19 (dd, 1H, J 4.4 and 8.5 Hz, CHH’I), 
3.79 (dq, 1H, J 5.9 Hz, H5), 6.97 (s, 1H, NH); C (100 MHz, CDCl3): 9.6 (CH2, 
CH2I), 25.4 (CH2, C4), 28.4 (CH2, C3), 53.2 (CH, C5), 176.4 (C=O). Data in 
agreement with literature.115 
 
 
(S)-5-Allylpyrrolidin-2-one 2.63 
 
 
Using the procedure of Kamimura and co-workers:115 Vinylmagnesium bromide 
2.62 (7.6 mL of a 1 M solution in THF, 7.60 mmol) was added to a stirred 
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solution of iodolactam 2.60 (300 mg, 1.33 mmol) and CuI (660 mg, 3.47 mmol) 
in anhydrous THF (10 mL) at -30 ºC, under argon. The reaction mixture was 
stirred for 2 h at -30 ºC, then was allowed to warm to 4 ºC and stirred overnight 
at 4 ºC. The reaction was quenched with an aq. sat. solution of NH4Cl (10 mL), 
the layers separated and the aqueous phase was extracted with DCM (3  10 
mL). The combined organic phases were dried over MgSO4, concentrated 
under vacuum and purified by flash column chromatography (petroleum 
ether/ethyl acetate 9:1 to 0:1) to yield alkene 2.63 (124 mg, 74%) as a brown 
oil.  
Rf 0.28 (ethyl acetate); []
  
 
 = +3.6 (c 2.2, CHCl3), [lit.
192 []  
 
 = +2.5 (c 1.2, 
CHCl3)]; H (400 MHz, CDCl3): 1.68-1.80 (m, 1H, H4), 2.15-2.28 (m, 3H, 
H4'/CCHH’), 2.29-2.34 (m, 2H, H3/H3'), 3.69 (dq, 1H, J 6.6 Hz, H5), 5.06-5.17 
(m, 2H, =CHH’), 5.68-5.81 (m, 1H, =CH), 6.62 (br s, 1H, NH); C (100 MHz, 
CDCl3): 26.6 (CH2, C4), 30.3 (CH2, C3), 41.0 (CH2, CCH2), 53.8 (CH, C5), 118.4 
(CH2, =CH2), 133.7 (CH, =CH), 178.3 (C=O). Data in agreement with 
literature.115  
 
 
 (5S)-5-(2,3-Dibromopropyl)pyrrolidin-2-one 2.64a/b 
 
 
Br2 (205 L, 639 mg , 3.98 mmol) was added dropwise to a stirred solution of 
alkene 2.63 (250 mg, 2.00 mmol) in anhydrous DCM (5.0 mL) at 0 ºC under 
argon and the reaction mixture stirred for 30 minutes. The reaction mixture was 
diluted with ethyl acetate and quenched with an aq. sat. solution of Na2S2O3. 
The layers were separated, the aqueous layer was extracted with ethyl acetate 
(3  5 mL), and the combined organic layers were dried over MgSO4, 
concentrated under vacuum yielding dibromoalkane 2.64a/b (570 mg, 67%) as 
a white solid comprising a mixture of two isomers. The isomers were separated 
by flash column chromatography (petroleum ether/ethyl acetate 1:1 to 0:1) to 
provide analytical samples as colourless oils.  
 
 
159 
  
Less polar isomer: 2.64a 
Rf 0.31 (ethyl acetate); []
  
 
 = +53.8 (c 6.0, CHCl3); H (400 MHz, CDCl3): 1.75-
1.86 (m, 1H, CHH’Br), 1.881.95 (m, 1H, H4), 2.24-2.46 (m, 4H, 
CHH'Br/H3'/H3/H4'), 3.61 (dd, 1H, J 10.0 and 10.3 Hz, CHH’), 3.90 (dd, 1H, J 
4.1 and 10.3 Hz, CHH'), 3.95-4.03 (m, 1H, CHBr), 4.18-4.28 (m, 1H, H5), 7.16 
(s, 1H, NH); C (100 MHz, CDCl3): 27.3 (CH2, CH2Br), 29.9 (CH2, C3), 36.3 
(CH2, CHH), 43.3 (CH2, C4), 49.1 (CH, C5), 52.5 (CH, CHBr), 178.67 (C=O). 
max/cm
-1 (neat) 3167, 3079, 2964, 2888, 1680 (C=O), 1433, 1392, 1355, 1316, 
1298, 1266; m/z (ES+) 284 ([M+H]+, 51% C7H12
79Br2NO), 286 ([M+H]
+, 100% 
C7H12
79Br81BrNO), 288 ([M+H]+, 49% C7H12
81Br2NO); HRMS calc. for 
C7H12ON
79Br2 283.9280, found 283.9283 [M+H]
+. 
 
More polar isomer: 2.64b 
Rf 0.18 (ethyl acetate); []
  
 
 = -29.2 (c 6.5, CHCl3); H (400 MHz, CDCl3): 1.66-
1.80 (m, 1H, CHH’Br), 1.96-2.11 (m, 1H, H4), 2.27-2.48 (m, 4H, 
H4/H3/H3'/CHH'Br), 3.61 (dd, 1H, J 10.3 Hz, CHH’), 3.88 (dd, 1H, J 4.1 and 
10.3 Hz, CHH'), 3.88-3.95 (m, 1H,CHBr), 4.11 (tt, 1H, J 4.1 and 10.3 Hz, H5), 
6.55 (s, 1H, NH); C (100 MHz, CDCl3): 27.0 (CH2, CH2Br), 29.8 (CH2, C3), 36.1 
(CH2, CHH), 42.9 (CH2, C4), 48.2 (CH, C5), 53.1 (CH, CHBr), 177.9 (C=O); 
max/cm
-1 (neat) 3284, 3188, 3094, 2940, 1647 (C=O), 1272, 1150; m/z (ES+) 
284 ([M+H]+, 51% C7H12
79Br2NO), 286 ([M+H]
+, 100% C7H12
79Br81BrNO), 288 
([M+H]+, 49% C7H12
81Br2NO); HRMS calc. for C7H12ON
79Br2 283.9280, found 
283.9285 [M+H]+. 
 
 
(S)-5-(Prop-2-yn-1-yl)pyrrolidin-2-one 2.61 
 
 
KOtBu (132 mg, 0.59 mmol) was added in small portions to a stirred solution of 
dibromoalkane 2.64a/b (71 mg, 0.14 mmol) in anhydrous THF (2.0 mL) at rt 
under argon. After 24 h, the solvent was removed under vacuum and the 
residue was purified by flash column chromatography (petroleum ether/ethyl 
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acetate 1:1 to 0:1) affording the desired alkyne 2.61 (8 mg, 25%), allene 2.65 (2 
mg, 8%) and alkyne 2.66 (3 mg, 10%) as yellow oils. 
Rf 0.23 (Ethyl acetate 2 elutions); mp = 104-106 ºC, [lit.
128 (racemate) 109-111 
ºC]; []  
 
 = +66.4 (c 1.9, CHCl3); H (400 MHz, CDCl3): 1.77-1.94 (m, 1H, H4), 
2.04 (t, 1H, J 2.6 Hz, C≡CH), 2.26-2.48 (m, 5H, H4'/H3/H3'/CHH'), 3.77-3.88 
(dq, 1H, J 6.2 Hz, H5), 6.05 (s, 1H, NH); C (100 MHz, CDCl3): 26.3 (CH2, C4), 
26.3 (CH2), 29.9 (CH2), 51.0 (CH, C5), 70.9 (CH, C≡CH), 79.9 (C, C≡C), 177.8 
(C=O). Data in agreement with literature (racemic compound).128 
 
 (S)-5-(Propa-1,2-dien-1-yl)pyrrolidin-2-one 2.65 
 
 
Rf 0.32 (Ethyl acetate 2 elutions); []
  
 
 = +52.0 (c 0.3, CHCl3); H (400 MHz, 
CDCl3): 1.90-1.99 (m, 1H, H4), 2.26-2.50 (m, 3H, H4'/H3/H3'), 4.19-4.21 (m, 1H, 
H5), 4.88 (dd, 1H, J 2.1 and 6.5 Hz, =CHH’), 4.88 (dd, 1H, J 2.1 and 6.5 Hz, 
=CHH’), 5.16 (ddd, 1H, J 6.5 Hz, =CH), 5.63 (s, 1H, NH); C (100 MHz, CDCl3): 
28.4 (CH2), 29.7 (CH2), 52.8 (CH, C5), 78.3 (CH2, =CH2), 92.8 (CH, =CH), 
178.0 (C=O), 207.4 (=C=). Data in agreement with literature (racemic 
compound).193 
 
 
 (S)-5-(Prop-1-yn-1-yl)pyrrolidin-2-one 2.66 
 
 
Rf 0.37 (Ethyl acetate 2 elutions); []
  
 
 = +7.5 (c 0.8, CHCl3) ; H (400 MHz, 
CDCl3): 1.82 (d, 3H, J 2.2 Hz, CH3), 2.07-2.18 (m, 1H, H4), 2.22-2.34 (m, 1H, 
H3), 2.35-2.51 (m, 1H, H3'/H4'), 4.33 (ddd, 1H, J 2.2, 5.4 and 7.4 Hz, H5), 5.76 
(s, 1H, NH); C (100 MHz, CDCl3): 3.5 (CH3), 29.3 (CH2), 29.5 (CH2), 44.9 (CH, 
C5), 78.2 (C≡C), 80.3 (C≡C), 177.4 (C=O). Data in agreement with literature 
(racemic compound).194  
 
 
161 
  
(S)-5-(2-Bromoallyl)pyrrolidin-2-one 2.67 
KtBuO (113 mg, 1.01 mmol) was added to a stirred solution of dibromoalkanes 
2.64a/b (115 mg, 0.40 mmol) in anhydrous THF (4.0 mL) at rt, under argon. 
After 2.5 h, the solvent was removed under vacuum and the residue was 
purified by flash column chromatography (petroleum ether/ethyl acetate 1:1 to 
0:1) to yield alkyne 2.61 (27 mg, 40%), bromoalkene 2.67 (18 mg, 22%) and 
bromoalkene 2.68 (12 mg, 14%) yellow oils. 
 
 
 
Rf 0.30 (Ethyl acetate 2 elutions); []
  
 
 = +49.3 (c 7.1, CHCl3); H (400 MHz, 
CDCl3): 1.67-1.81 (m, 1H, H4), 2.28-2.39 (m, 3H, H4'/H3/H3'), 2.57 (dd, 2H, J 
0.8 and 7.0 Hz, CHH’), 3.93-4.03 (m, 1H, H5), 5.53 (d, 1H, J 1.8 Hz, =CHH’), 
5.67-5.68 (m, 1H, =CHH'), 6.24 (s, 1H, NH); C (100 MHz, CDCl3): 26.4 (CH2, 
C4), 29.9 (CH2, C3), 48.3 (CH2), 52.3 (CH, C5), 119.9 (CH2, =CH2), 129.4 (C, 
=CBr), 177.8 (C=O); max/cm
-1 (neat) 3279, 2953, 2865, 1632 (C=O), 1441, 
1399, 1266; m/z (ESI) 206 ([M+H]+, 100% C7H11
81BrNO), 204 ([M+H]+, 98% 
C7H11
81BrNO); HRMS calc. for C7H11ONBr 204.0019, found 204.0020 [M+H]
+. 
 
 
 (S,Z)-5-(3-Bromoallyl)pyrrolidin-2-one 2.68 
 
 
Rf 0.23 (Ethyl acetate 2 elutions); []
  
 
 = +57.2 (c 5.4, CHCl3); H (400 MHz, 
CDCl3): 1.67-1.79 (m, 1H, H4), 2.18-2.28 (m, 5H, H4'/H3/H3'/CHH’), 3.70 (dq, 
1H, J 6.5 Hz, H5), 6.07-6.20 (m, 2H, CH=CH), 6.74 (s, 1H, NH); C (100 MHz, 
CDCl3): 26.3 (CH2, C4), 30.0 (CH2, C3), 39.8 (CH2), 53.2 (CH, C5), 107.8 (CH, 
=CH), 132.8 (CH, =CH), 178.2 (C=O); max/cm
-1 (neat) 3170, 2920, 2876, 1669 
(C=O), 1400, 1375, 1234; m/z (ES+) 206 (100% C12H15BrN2O, 
79Br), 204 (98% 
C12H15BrN2O, 
81Br) [M]+. The sample decomposed before HRMS could be 
obtained. 
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2-Iodoxybenzoic acid 
 
 
Using the procedure of Frigerio and co-workers:195 2-iodobenzoic acid (15 g, 
60.48 mmol) was added to a stirred suspension of OxoneTM (55 g, 181.4 mmol) 
in water (170 mL) and stirred for 10 min. The mixture was then warmed to 70 ºC 
over 20 min and stirred for 3 h. A further 3 equivalents of OxoneTM (55 g, 181.4 
mmol) were added and the reaction stirred for further 3 h. The reaction mixture 
was cooled to 0 ºC and slowly stirred for 1.5 h, to precipitate the product. The 
resulting white solid was filtered, washed with water (5  10 mL) and acetone (2 
 10 mL) and dried under vacuum at rt for 16 h to yield IBX (13.3 g, 79%) as a 
white solid. 
H (400 MHz, DMSO): 7.85 (dt, 1H, J 0.9 and 7,6 Hz, HAr), 7.98-8.05 (m, 2H, 
HAr), 8.15 (d, 1H, J 6.6 Hz, HAr). NMR in agreement with literature.195 
 
 
(S)-Tert-butyl 2-(((tert-butyldimethylsilyl)oxy)methyl)-5-oxopyrrolidine-1-
carboxylate 2.75 
 
 
DMAP (234 mg, 1.92 mmol) was added to a stirred solution of amide 2.53 (4.4 
g, 19.27 mmol), triethylamine (8.1 mL, 5.9 g, 57.80 mmol) and Boc2O (6.3 g, 
28.90 mmol) in DCM (88 mL) at 0 ºC under nitrogen. The reaction was stirred 
overnight and then quenched with water (50 mL) and the layers separated. The 
aqueous layer was extracted with ethyl acetate (3  50 mL) and the combined 
organic layers were dried over MgSO4 and concentrated under reduced 
pressure to yield the product 2.75 (4.7 g, 70%) as a yellow oil. 
Rf  0.4 (petroleum ether/ethyl acetate 4:1);   ]
  
 
 = -57.7 (c 7.2, CHCl3), [lit.
196 
  ]   
 
 = -61.0 (c 1.1, CHCl3)]; H (400 MHz, CDCl3): 0.02 (s, 3H, CH3), 0.03 (s, 
3H, CH3), 0.86 (s, 9H, CH3),  1.51 (s, 9H, CH3), 1.97-2.17 (m, 2H, H3/H3’), 2.35 
(ddd, 1H, J 2.3, 9.7 and 17.5 Hz, H4), 2.64-2.73 (m, 1H, H4’), 3.67 (dd, 1H, J 
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2.3 and 10.4 Hz, CHH’OTBDMS), 3.90 (dd, 1H, J 4.0, 10.4 Hz, CHH’OTBDMS), 
4.13-4.17 (m, 1H, H2); C (100 MHz, CDCl3): -5.6 (CH3), -5.5 (CH3), 18.2 (C), 
21.1 (CH2, C3), 25.8 (CH3), 28.1 (CH3), 32.3 (CH2, C4), 58.9 (CH, C2), 64.3 
(CH2, CH2OTBS), 82.7 (C), 150.1 (C=O), 174.9 (C=O). NMR in agreement with 
literature.196 
 
 
 
(S)-Tert-butyl 2-(hydroxymethyl)-5-oxopyrrolidine-1-carboxylate 2.76 
 
 
 
 
Acetic acid (1.4 mL, 1.5 g, 24.90 mmol) was added to a stirred solution of Boc 
protected amide 2.75 (3.7 g, 11.35 mmol) in THF (74 mL) at room temperature 
under nitrogen. TBAF (13.6 mL of a 1 M solution in THF, 13.62 mmol) was 
added dropwise and the reaction stirred overnight. The reaction was then 
quenched with water (80 mL), the layers separated and the aqueous layer was 
extracted with ethyl acetate (3  80 mL). The combined organic layers were 
dried over MgSO4, concentrated under reduced pressure and purified by flash 
column chromatography (petroleum ether/ethyl acetate 1:1) to yield product 
2.76 (2.2 g, 88%) as a white solid. 
Rf 0.35 (ethyl acetate/petroleum ether 4:1); mp = 98-101 ºC [lit.
197 98-99 ºC]; 
  ]   
 
 = -70.6 (c 5.2, CHCl3), [lit.
197   ]   
 
 = -63.0 (c 0.6, CHCl3)]; H (400 MHz, 
CDCl3): 1.50 (s, 9H, CH3), 1.93-2.02 (m, 1H, H3), 2.10-2.17 (m, 1H, H3’), 2.39 
(ddd, 1H, J 3.0, 9.9 and 17.7 Hz, H4), 2.63-2.72 (m, 1H, H4’), 2.78 (brs, 1H, 
OH), 3.71 (dd, 1H, J 3.8 and 11.4 Hz, CHH’OH), 3.83 (dd, 1H, J 4.0, 11.4 Hz, 
CHH’OH), 4.18-4.23 (m, 1H, H2); C (100 MHz, CDCl3): 20.9 (CH2, C3), 28.0 
(CH3), 32.0 (CH2, C4), 59.4 (CH, C2), 64.4 (CH2, CH2OH), 83.3 (C), 150.7 
(C=O), 175.0 (C=O). Data in agreement with literature.120 
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 (S)-tert-Butyl ((5-oxopyrrolidin-2-yl)methyl) carbonate 2.77 
 
 
TBAF (306 L of a 1 M solution in THF, 0.34 mmol) was added to a stirred 
solution of diprotected compound 2.75 (112 mg, 0.34 mmol) in THF (1.0 mL) at 
room temperature under nitrogen. After 30 minutes the reaction was diluted with 
ethyl acetate (3 mL) and water was added (5 mL). The layers were separated 
and the aqueous layer was extracted with ethyl acetate (3  5 mL). The 
combined organic layers were dried over MgSO4, concentrated under reduced 
pressure and purified by flash column chromatography (petroleum ether/ethyl 
acetate 1:1 to 0:1) to yield alcohol 2.77 (26 mg, 35%) as a clear oil and amide 
2.76 in (15 mg, 21%) as white solid. 
Rf 0.25 (ethyl acetate);   ]
  
 
 = +40.2 (c 7.8, CHCl3), [lit.
198   ]   
 
 = -63.0 (c 0.6, 
CHCl3)]; H (400 MHz, CDCl3): 1.48 (s, 9H, CH3), 1.79-1.86 (m, 1H, H3), 2.21-
2.30 (m, 1H, H3’), 2.32-2.41 (m, 2H, H4/H4’), 3.87-3.94 (m, 2H, H2/CHH’OBoc), 
4.10-4.17 (m, 1H, CHH’OBoc), 5.99 (s, 1H, NH); C (100 MHz, CDCl3): 23.1 
(CH2, C3), 27.7 (CH3), 29.3 (CH2, C4), 52.7 (CH, C2), 69.4 (CH2, CH2OBoc), 
82.9 (C), 153.2 (C=O), 177.7 (C=O). Data in agreement with literature.120 
 
 
(S)-tert-Butyl 2-formyl-5-oxopyrrolidine-1-carboxylate 2.78 
 
 
TEMPO (150 mg, 0.96 mmol) was added to a stirred solution of alcohol 2.76 
(2.1 g, 9.58 mmol) and BAIB (3.4 g, 10.54 mmol) in DCM (20 mL) at room 
temperature under nitrogen. The reaction mixture was stirred for 24 h and then 
diluted with DCM (10 mL) and quenched with an aq. sat. solution of Na2S2O3. 
The aqueous layer was extracted with DCM (3  30 mL) and the combined 
organic layers washed with a saturated aqueous NaHCO3 solution (80 mL), 
dried over MgSO4, concentrated under reduced pressure and purified by flash 
column chromatography (petroleum ether/ethyl acetate 4:1) affording aldehyde 
2.78 (1.7 g, 84%) as a thick colourless oil. 
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Rf 0.47 (ethyl acetate/petroleum ether 4:1);   ]
  
 
 = -68.8 (c 5.4, CHCl3); H (400 
MHz, CDCl3): 1.48 (s, 9H, CH3), 1.98-2.06 (m, 1H, H3), 2.18-2.28 (m, 1H, H3’), 
2.48-2.53 (m, 2H, H4/H4’), 4.56 (ddd, 1H, J 2.0, 4.8 and 9.4 Hz, H2), 9.57 (d, 
1H, J 2.0 Hz, CHO); C (100 MHz, CDCl3): 18.3 (CH2, C3), 27.9 (CH3), 31.2 
(CH2, C4), 64.2 (CH, C2), 84.2 (C), 149.4 (C=O), 173.1 (C=O), 197.0 (CHO). 
Data in agreement with literature.199 
 
 
(S)-tert-butyl 2-((R)-1-hydroxyprop-2-yn-1-yl)-5-oxopyrrolidine-1-
carboxylate and (S)-tert-butyl 2-((S)-1-hydroxyprop-2-yn-1-yl)-5-
oxopyrrolidine-1-carboxylate 2.80a/b 
 
 
Ethynyl magnesium bromide 2.79 (1.8 mL of a 0.5 M solution in THF, 8.89 
mmol) was added to a stirred solution of aldehyde 2.78 (94 mg, 0.44 mmol) in 
THF (2.0 mL) at 0 ºC under nitrogen. After 1 h the reaction mixture was 
quenched with an aq. sat. solution of NH4Cl (5 mL). The layers were separated 
and the aqueous layer was extracted with ethyl acetate (3  5 mL) and the 
combined organic layers dried over MgSO4, concentrated under reduced 
pressure and purified by flash column chromatography (ethyl acetate/petroleum 
ether 1:1) affording alcohols 2.80a and 2.80b as two separable isomers (17 mg, 
16%  and 28 mg, 26%) as colourless oils. 
 
Less polar isomer: 280a 
Rf 0.53 (ethyl acetate/petroleum ether 1:1); []
  
 
 = +63.8 (c 2.4, CHCl3); H (400 
MHz, CDCl3): 1.55 (s, 9H, CH3), 2.12-2.23 (m, 2H, H3/H3’), 2.36-2.44 (m, 1H, 
H4), 2.51 (d, 1H, J 2.2 Hz, C≡CH), 2.77 (dt, 1H, J 10.0 and 17.8 Hz, H4’), 3.16 
(d, 1H, J 6.0 Hz, OH), 4.28-4.32 (m, 1H, H2), 4.77-4.80 (m, 1H, CHOH); C (100 
MHz, CDCl3): 19.5 (CH2, C3), 28.0 (CH3), 32.1 (CH2, C4), 62.0 (CH, C2), 64.6 
(CH, CHOH), 75.0 (C, C≡C), 81.3 (CH, C≡CH), 83.9 (C), 151.2 (C=O), 174.6 
(C=O); max/cm
-1 (neat) 3449, 3259, 2977, 2920, 2112, 1763 (C=O), 1370, 
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1291, 1252, 1151; m/z (ES+) 501 (100%), 262 ([M+Na]+, 50%), 140 ([(M-
Boc)+H]+, 50%); HRMS calc. for C12H18O4N 240.1230, found 240.1227 [M+H]
+. 
 
More polar isomer: 280b 
Rf 0.41 (ethyl acetate/petroleum ether 1:1); []
  
 
 = -97.0 (c 2.0, CHCl3); H (400 
MHz, CDCl3): 1.54 (s, 9H, CH3), 2.11-2.20 (m, 1H, H3), 2.22-2.30 (m, 1H, H3’), 
2.41-2.49 (m, 2H, H4), 2.47 (d, 1H, J 2.2 Hz, C≡CH), 2.56 (d, 1H, J 4.1 Hz, OH), 
2.80 (dt, 1H, J 10.2 and 18.0 Hz, H4’), 4.32 (ddd, 1H, J 1.9, 5.5 and 8.7 Hz, H2), 
4.79 (brs, 1H, CHOH); C (100 MHz, CDCl3): 18.9 (CH2, C3), 28.0 (CH3), 31.8 
(CH2, C4), 60.7 (CH, C2), 63.4 (CH, CHOH), 75.3 (C, C≡C), 81.5 (CH, C≡CH), 
83.8 (C), 150.7 (C=O), 174.2 (C=O); max/cm
-1 (neat) 3447, 3253, 2978, 2918, 
2110, 1761 (C=O), 1370, 1293, 1254, 1153; m/z (ES+) 501 (100%), 262 
([M+Na]+, 20%), 140 ([(M-Boc)+H]+, 10%); HRMS calc. for C12H17O4NNa 
262.1050, found 262.1050 [M+Na]+. 
 
 
5-Ethoxypyrrolidin-2-one 2.90 
 
 
NaBH4 (2.9 g, 75.7 mmol) was added over 2 h to a stirred solution of 
succinimide 2.88 (5.0 g, 50.5 mmol) in ethanol (225 mL) at 0 ºC. Every 15 min 
for 5 h, 4 drops of HCl (2 M in ethanol) was added over 5 h. After 5 h, the pH 
was adjusted to 4 and the slurry was stirred for 2 h. The reaction mixture was 
neutralised with KOH (3% in ethanol). Evaporation of the solvents under 
vacuum afforded a white solid which was triturated with diethyl ether. The 
resulting suspension was filtered and the filtrate concentrated under vacuum 
and purified by flash column chromatography on deactivated (10% w/W H20) 
alumina (Et2O), affording ethoxy lactam 2.90 (2.5 g, 41%) as a white solid and 
4-hydroxybutanamide 2.89 (624 mg, 12%) as white solid.  
Rf 0.46 (MeOH/DCM 1:9); mp = 56-60 ºC [lit.
127 56-58 ºC]; H (400 MHz, CDCl3): 
1.22 (t, 3H, J 7.0 Hz, CH3), 1.96-2.14 (m, 1H, H4), 2.15-2.39 (m, 2H, H3/H4'), 
2.49-2.58 (m, 1H, H3), 3.38-3.47 (m, 1H, OCHH’), 3.54-3.61 (m, 1H, OCHH'), 
4.98 (d, 1H, J 6.0 Hz, H5), 7.86 (br s, 1H, NH); C (100 MHz, CDCl3): 15.2 
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(CH3), 28.3 (CH2), 28.4 (CH2), 62.8 (CH2, OCH2), 85.8 (CH, C5), 179.5 (C=O). 
Data in agreement with literature.127  
 
4-Hydroxybutanamide 2.89 
 
 
Rf 0.13 (MeOH/DCM 1:9). mp = 51-54 ºC [lit.
200 52-53 ºC]; H (400 MHz, DMSO-
d6): 1.06 (p, 2H, J 6.9 Hz, H3), 1.52 (q, 2H, J 6.9 Hz, H2), 2.82 (t, 2H, J 6.9 Hz, 
H4), 6.13 (s, 1H, NH), 6.68 (s, 1H, NH); C (100 MHz, DMSO-d6): 28.4 (CH2, 
C3), 31.8 (CH2, C2), 60.3 (CH2, C4), 174.36 (C=O). NMR in agreement with 
literature.200 
 
 
5-(Prop-2-yn-1-yl)pyrrolidin-2-one 2.61 
 
 
From succinimide 
Allenyltin 2.91 (360 L of a 80% solution in toluene, 0.97 mmol) was added to a 
stirred solution of ethoxy lactam 2.90 (50 mg, 0.39 mmol) in anhydrous DCM (1 
mL) at -30 ºC under argon. BF3
.OEt2 (96 L, 110 mg, 0.77 mmol) was then 
added dropwise and the reaction was stirred for 7 h at -30 ºC. The reaction 
mixture was quenched with an aq. sat. solution of NaHCO3 (2 mL) and stirred 
vigorously for 2 minutes. The layers were separated, the aqueous phase was 
extracted with DCM (3  3 mL) and the combined organic layers were dried 
over MgSO4, concentrated under vacuum, and purified by flash column 
chromatography (ethyl acetate/petroleum ether 1:1 to 1:0) to afford allene 2.65 
(0.9 mg, 2%) as a colourless oil, a mixture of alkyne 2.61 and allene 2.65 (9:1, 
13.8 mg) and alkyne 2.61 (22.2 mg, 47%) as a yellow powder. The overall yield 
of alkyne 2.61 was 73% (35 mg). Data for the compounds was in accordance 
with those previously described. 
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1,5-Di(prop-2-yn-1-yl)pyrrolidin-2-one 1.132 
 
 
NaH (12 mg of a 60% suspension in mineral oil, 0.51 mmol) was added to a 
stirred solution of alkyne 2.61 (48 mg, 0.390 mmol) in anhydrous DMF (1.0 mL) 
at 0 ºC under nitrogen. After 30 minutes, propargyl bromide 2.9 (91 L of a 80% 
solution in toluene, 0.82 mmol) was added and the reaction mixture was 
warmed to rt and stirred for 45 min. The reaction mixture was quenched with 
water (3 mL) and extracted with ethyl acetate (3  3 mL) and the combined 
organic layers dried over MgSO4, concentrated under vacuum and purified by 
flash column chromatography (ethyl acetate/petroleum ether 7:3) to afford 
dialkyne 1.132 (52 mg, 83%) as a yellowish oil.  
Rf: 0.46 (petroleum ether/ethyl acetate 1:1); H (400 MHz, CDCl3): 1.88-2.00 (m, 
1H, H4), 1.97 (t, 1H, J 2.6 Hz, C≡CH), 2.20 (t, 1H, J 2.3 Hz, C≡CH), 2.16-2.26 
(m, 2H, H4'), 2.27-2.38 (m, 1H, H3), 2.44-2.53 (m, 3H, H3’/CCHH’), 3.67 (dd, 
1H, J 2.3 and 17.8 Hz, NCHH’), 3.92 (dq, 1H, J 5.0 and 9.8 Hz, H5), 4.55 (dd, 
1H, J 2.3 and 17.8 Hz, NCHH'); C (100 MHz, CDCl3): 23.1 (CH2), 23.3 (CH2), 
29.9 (CH2), 30.0 (CH2), 55.3 (CH, C5), 71.3 (C, C≡C), 72.4 (C, C≡C), 77.5 (CH, 
C≡CH), 78.9 (CH, C≡CH), 174.6 (C=O); max/cm
-1 (neat) 3284, 2960, 2919, 
2118, 1676 (C=O), 1416, 1250, 1180; m/z (ES+) 162 ([M+H]+, 100%); HRMS 
calc. for C10H12ON 162.0913, found 162.0917 [M+H]
+. 
 
 
Tributyl(propa-1,2-dien-1-yl)stannane 2.91 
 
 
Tributyltin chloride (5.4 mL, 6.5 g, 20.00 mmol) was added to a stirred solution 
of magnesium (631 mg, 26.00 mmol) and lead bromide (366 mg, 1.00 mmol) in 
THF (20 mL) at room temperature under argon. Propargyl bromide 2.9 (2.8 mL 
of an 80% solution in toluene, 26.00 mmol) was added dropwise and the 
reaction was slightly heated with a heat gun, then stirred for 2.5 h at room 
temperature. The reaction mixture was quenched with an aq. sat. solution of 
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NH4Cl (20 mL) and the layers were separated. The aqueous layer was 
extracted with ethyl acetate (3 x 40 mL) and the combined organic layers 
washed with brine (40 mL), dried over Na2SO4, concentrated under vacuum and 
purified by flash column chromatography on deactivated (10% w/w H2O) 
alumina (hexane) affording allenyl tin 2.91 (21.2 g, 81%) as a colourless liquid.  
Rf 0.5 (hexane); H (400 MHz, CDCl3): 0.90 (t, 9H, J 7.3 Hz, CH3), 0.95-0.99 (m, 
6H, CH2), 1.27-1.36 (m, 6H, CH2), 1.43-1.57 (m, 6H, CH2), 4.14 (d, 2H, J 7.1 
Hz, CH2), 4.97 (t, 1H, J 7.1 Hz, CH); C (100 MHz, CDCl3): 10.3 (CH2), 13.7 
(CH3), 27.2 (CH2), 28.9 (CH2), 63.1 (CH2), 73.9 (CH), 209.8 (C). NMR in 
agreement with literature.130 
 
 
6-Ethoxypiperidin-2-one 2.105 
 
 
Sodium borohydride (3.55 g, 94.30 mmol) was added portionwise to a stirred 
solution of piperidine-2,6-dione 2.104 (4.76 g, 42.10 mmol) in ethanol (250 mL) 
at 0 °C. Every 15 min for 5 h, 4 drops of HCl (2 M in ethanol) were added. After 
5 h, the reaction mixture was acidified (pH 3) by the addition of HCl (2 M in 
ethanol) and stirred for an additional 2 h at 0 °C. The reaction was neutralized 
with KOH (3% in ethanol) and the resulting milky solution concentrated under 
vacuum. The resultant white solid was extracted with DCM (3 x 100 mL), the 
organic layer filtered, and the filtrate was concentrated under vacuum and 
purified by flash column chromatography (5% MeOH/DCM) to yield 6-
ethoxypiperidin-2-one 2.105 (3.0 g, 50%) as a white solid. 
Rf 0.37 (5% MeOH/DCM); mp = 112-115 ºC [lit.
201 122- 123 ºC];  H (400 MHz, 
CDCl3): 1.21 (t, 3H, J 7.0 Hz, CH3), 1.65-1.76 (m, 1H, H4), 1.77-1.82 (m, 1H, 
H5), 1.88-1.96 (m, 1H, H5’), 2.02-2.07 (m, 1H, H4’), 2.26-2.37 (m, 1H, H3), 
2.38-2.46 (m, 1H, H3’), 3.42 (dq, 1H, J 8.9 and 7.0 Hz, OCHH’), 3.62 (dq, 1H, J 
8.9 and 7.0 Hz, OCHH’), 4.66 (app q, 1H, J 3.5 Hz, H6), 6.93 (s, 1H, NH); C 
(100 MHz, CDCl3): 15.3 (CH3), 16.2 (CH2, C4), 27.9 (CH2, C5), 31.7 (CH2, C3), 
62.7 (OCH2), 81.8 (CH, C6), 172.8 (C=O). Data in agreement with literature.
201
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6-(Prop-2-yn-1-yl)piperidin-2-one 2.106 
 
 
To a stirred solution of 6-ethoxylactam 2.105 (500 mg, 3.49 mmol) in DCM (5.0 
mL) at -40 °C under argon was added allenyl tin 2.91 (2.6 mL, 2.87 g, 8.73 
mmol). BF3.OEt2 (862 L, 991 mg, 6.98 mmol) was then added dropwise and 
the reaction was stirred at -40 ºC for 7 h. The reaction mixture was then 
quenched with an aq. sat. solution of NaHCO3 (30 mL), extracted with ethyl 
acetate (3  30 mL), dried over MgSO4, concentrated under reduced pressure 
and purified by flash column chromatography (petroleum ether/ethyl acetate 7:3 
to 0:1) affording alkyne 2.106 contaminated with the correspondening allene. 
The mixture was crystallised from ethyl acetate to yield alkyne 2.106 (275 mg, 
55%) as a pale yellow solid. 
Rf 0.37 (5% MeOH/DCM); mp = 87-89 ºC [lit.
128 98-100 ºC]; H (400 MHz, 
CDCl3): 1.41-1.50 (m 1H, H5), 1.65-1.76 (m, 1H, H4), 1.86-1.94 (m, 1H, H4’), 
1.94-2.01 (m, 1H, H5’), 2.08 (t, 1H, J 2.6 Hz, C≡CH), 2.24-2.33 (m, 2H, 
H3/CHH’), 2.36-2.43 (m, 2H, H3’/CHH’), 3.54 (tt, 1H, J 4.8 and J 9.2 Hz, H6), 
6.20 (brs, 1H, NH); C (100 MHz, CDCl3): 19.5 (CH2, C4), 26.7 (CH2, CHH), 
28.1 (CH2, C5), 31.3 (CH2, C3), 51.8 (CH, C6), 71.6 (C, C≡C), 79.6 (CH, 
C≡CH), 172.1 (C=O). Data in agreement with literature.128 
 
 
1,6-Di(prop-2-yn-1-yl)piperidin-2-one 1.133 
 
 
NaH (191 mg of a 60% suspension in mineral oil, 4.78 mmol) was added to a 
stirred solution of alkyne 2.106 (437 mg, 3.19 mmol) in DMF (8 mL) at 0 °C 
under argon and the reaction mixture stirred for 30 minutes. Propargyl bromide 
2.9 (745 L of an 80% solution in toluene, 6.69 mmol) was added dropwise and 
the reaction mixture was stirred for an additional 30 minutes at 0 ºC. The 
reaction was quenched with aq. sat. solution of NH4Cl (10 mL), extracted with 
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ethyl acetate (3  10 mL), dried over MgSO4, concentrated under vacuum and 
purified by flash chromatography (petroleum ether /ethyl acetate 1:1) to afford 
dialkyne 1.133 (293 mg, 90%) as a pale white solid. 
Rf 0.30 (ethyl acetate/petroleum ether 1:1); mp = 66-68 ºC; H (400 MHz, 
CDCl3): 1.69-1.79 (m, 1H, H4), 1.84-1.96 (m, 2H, H5/H4’), 2.03-2.10 (m, 1H, 
H5’), 2.04 (t, 1H, J 2.7 Hz, C≡CH), 2.22 (t, 1H, J 2.5 Hz, C≡CH), 2.41 (app t, 
2H, J 6.6 Hz, H3/H3’), 2.52 (ddd, 1H, J 2.9, 8.5 and 16.9 Hz, CCHH’), 2.63 (dt, 
1H, J 2.9 and 16.9 Hz, CCHH’), 3.82-3.87 (m, 1H, H6), 3.84 (dd, J 2.5 and 17.6 
Hz, NCHH’), 4.77 (dd, J 2.5 and 17.6 Hz, NCHH’); C (100 MHz, CDCl3): 17.5 
(CH2, C4), 23.1 (CH2, CHH), 27.0 (CH2, C5), 32.2 (CH2, C3), 33.6 (CH2, 
NCHH), 54.7 (CH, C6), 71.4 (C, C≡C), 72.1 (C, C≡C), 78.7 (CH, C≡CH), 79.9 
(CH, C≡CH), 170.1 (C=O); max/cm
-1 (neat) 3280, 2965, 2923, 2116, 1672 
(C=O), 1418, 1251, 1181; m/z (AP+) 176 ([M+H]+, 100%); HMRS calc. for 
C11H14ON 176.1070, found 176.1072 [M+H]
+. 
 
 
4-Benzylpiperazine-2,6-dione 2.108 
 
 
 
To a stirred solution of 2,2'-(benzylazanediyl)diacetic acid 2.107 (2.5 g, 11.2 
mmol) in DMF (35 mL) under argon was added ammonium formate (2.1 g, 33.6 
mmol). The reaction was heated under reflux for 22 h, then diluted with ethyl 
acetate (50 mL) and washed with saturated aqueous NaHCO3 solution (50 mL). 
The organic phase was washed with brine (3  50 mL), dried over MgSO4 and 
concentrated under reduced pressure to afford the 4-benzylpiperazine-2,6-
dione 2.118 (3.0 g, 65%) as a white solid.  
Rf 0.32 (ethyl acetate/petroleum ether 3:7);  mp = 103-105 ºC [lit.
202 105-106 
ºC]; H (400 MHz, CDCl3): 3.36 (s, 4H, H3/H5), 3.66 (s, 2H, CH2), 7.27-7.37 (m, 
5H, HAr), 9.11 (s, 1H, NH); C (100 MHz, CDCl3): 55.2 (CH2, C3), 55.2 (CH2, 
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C5) 60.5 (CH2, CH2Ph), 128.1 (CHAr), 128.7 (CHAr), 129.1 (CHAr), 135.4 
(CAr), 170.7 (C=O). Data in agreement with literature.202 
 
 
4-Benzyl-6-hydroxypiperazin-2-one 2.109 
 
 
 
 
Sodium borohydride (1.2 g, 32.70 mmol) was added portionwise over 2 h to a 
stirred solution of 4-benzylpiperazine-2,6-dione 2.108 (3.0 g, 14.6 mmol) in 
ethanol (87 mL) at 0 °C. Every 15 minutes for 5 h, 2 drops of HCl (2 M in 
ethanol) were added, keeping the temperature at 0 °C. The reaction was 
acidified (pH ~3) by addition of HCl (2 M in ethanol) and stirred for an additional 
2 h at 0 °C. The reaction was neutralized with KOH (3% in ethanol) and the 
resulting milky solution concentrated under vacuum. The resultant white solid 
was extracted with DCM (3  100 mL), the organic layer filtered then the filtrate 
was concentrated under vacuum and purified by flash column chromatography 
(5% MeOH/DCM) to yield alcohol 2.109 (1.9 g, 62%) as a white solid. 
Rf 0.33 (1:19 MeOH/DCM); mp = 114-116 ºC; H (400 MHz, CDCl3): 2.49 (dd, 
1H, J 2.2 and 11.7 Hz, H5), 2.77 (brd, 1H, J 11.7 Hz, H5’), 2.86 (d, 1H, J 16.7 
Hz, H3), 3.30 (d, 1H, J 16.7 Hz, H3’), 3.50 (d, 1H, J 12.9 Hz, CHH’Ph), 3.55 (d, 
1H, J 12.9 Hz, CHH’Ph), 4.02 (d, 1H, J 9.8 Hz, OH), 4.78 (brs, 1H, H6), 7.19-
7.28 (m, 5H, HAr); C (100 MHz, CDCl3): 55.5 (CH2, C5), 57.0 (CH2, C3), 61.4 
(CH2, CH2Ph), 74.2 (CH, C6), 127.8 (CHAr), 128.6 (CHAr), 129.1 (CHAr), 136.1 
(CAr), 169.7 (C=O); max/cm
-1 (neat) 3190, 3000, 2841, 2818, 1665 (C=O), 
1452, 1319, 1087; m/z (AP+) 207 ([M+H]+, 100%); HMRS calc. for C11H15O2N2 
207.1128, found 207.1128 [M+H]+. 
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4-Benzyl-6-ethoxypiperazin-2-one 2.110 
 
 
PTSA (341 mg, 1.79 mmol) was added to a stirred solution of alcohol 2.109 (1.9 
g, 8.96 mmol) in ethanol (30 mL) and the reaction mixture heated at 60 °C for 4 
h. The reaction was quenched with an aq. sat. solution of NaHCO3 (30 mL). The 
reaction mixture was extracted with DCM (3  30 mL) and the combined organic 
layers dried over MgSO4 and concentrated under vacuum to yield compound 
2.110 (quantitative) as a white solid which was used in the next step without 
further purification. 
Rf 0.35 (EA); mp = 89-90 ºC; H (400 MHz, CDCl3): 1.21 (t, 3H, J 7.0 Hz, CH3), 
2.67 (dd, 1H, J 3.8 and 12.2 Hz, H5), 2.73 (dd, 1H, J 4.2 and 12.2 Hz, H5’), 3.07 
(d, 1H, J 16.6 Hz, H3), 3.26 (d, 1H, J 16.6 Hz, H3’), 3.43 (dq, 1H, J 7.0 and 9.0 
Hz, OCHH’), 3.56-3.68 (m, 1H, OCHH’), 3.57 (d, 1H, J 13.1 Hz, CHH’Ph), 3.66 
(d, 1H, J 13.1 Hz, CHH’Ph), 4.68-4.70 (m, 1H, H6), 6.71 (brs, 1H, NH), 7.28-
7.35 (m, 5H, HAr); C (100 MHz, CDCl3): 15.3 (CH3), 53.2 (CH2, C5), 56.7 (CH2, 
C3), 61.4 (CH2, CH2Ph), 63.1 (CH2, OCH2), 80.9 (CH, C6), 127.6 (CHAr), 128.5 
(CHAr), 129.1 (CHAr), 136.4 (CAr), 169.7 (C=O); max/cm
-1 (neat) 3198, 3065, 
2972, 2899, 1675 (C=O), 1496, 1420, 1336, 1311, 1282, 1081; m/z (AP+) 235 
([M+H]+, 100%); HMRS calc. for C13H19O2N2 235.1441, found 235.1439 [M+H]
+. 
 
 
4-Benzyl-6-(prop-2-yn-1-yl)piperazin-2-one 2.8 
 
 
Allenyl tin 2.91 (190 L, 168 mg, 0.51 mmol) was added to a stirred solution of 
ethoxy lactam 2.110 (48 mg, 0.20 mmol) in DCM (1.0 mL) at -40 ºC under argon. 
BF3
.OEt2 (50 L, 58 mg, 0.41 mmol) was added dropwise and the reaction 
mixture heated under reflux for 6 h. The reaction was then quenched with an 
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aq. sat. solution of NaHCO3 solution (5 mL), extracted with ethyl acetate (3  5 
mL), dried over MgSO4, concentrated under reduced pressure and purified by 
flash column chromatography (petroleum ether/ethyl acetate 7:3 to 0:1) 
affording alkyne 2.8 contaminated with the corresponding allene which was 
recrystallised from ethyl acetate to yield alkyne 2.8 (25 mg, 54%) as a white 
solid. 
Rf 0.47 (EA); mp = 169-171 ºC; H (400 MHz, CDCl3): 2.07 (t, 1H, J 2.6 Hz, 
C≡CH), 2.42-2.48 (m, 3H, H5, CHH’), 2.79 (dd, 1H, J 4.2 and 11.8 Hz, H5’), 
3.14 (d, 1H, J 16.7 Hz, H3), 3.21 (d, 1H, J 16.7 Hz, H3’), 3.60 (s, 2H, CH2Ph), 
3.61-3.67 (m, 1H, H6), 6.11 (brs, 1H, NH), 7.27-7.35 (m, 5H, HAr); C (100 MHz, 
CDCl3): 24.7 (CH2), 50.6 (CH, C6), 53.1 (CH2, C5), 56.9 (CH2, C3), 61.5 (CH2, 
CH2Ph), 71.5 (C, C≡C), 79.6 (CH, C≡CH), 127.6 (CHAr), 128.5 (CHAr), 128.9 
(CHAr), 136.8 (CAr), 169.2 (C=O); max/cm
-1 (neat) 3227, 3064, 2925, 2803, 
2762, 2000, 1658 (C=O), 1421, 1345; m/z (AP+) 229 ([M+H]+, 100%); HMRS 
calc. for C14H17N2O 229.1335, found 229.1337 [M+H]
+. 
 
 
4-Benzyl-1,6-di(prop-2-yn-1-yl)piperazin-2-one 1.128 
 
 
NaH (24 mg of a 60% suspension in mineral oil, 0.61 mmol) was added to a 
stirred solution of alkyne 2.8 (100 mg, 0.44 mmol) in DMF (1.0 mL) at 0 °C 
under argon. After 30 minutes propargyl bromide 2.9 (102 L of an 80% solution 
in toluene, 0.92 mmol) was added dropwise and the reaction mixture was stirred 
for an additional 30 minutes at 0 ºC. The reaction was quenched with an aq. 
sat. solution of NH4Cl (5 mL), extracted with ethyl acetate (3  5 mL) and the 
combined organic layers dried over MgSO4, concentrated under vacuum and 
purified by flash column chromatography (petroleum ether /ethyl acetate 1:1) to 
afford dialkyne 1.128 (110 mg, 93%) as a pale yellow oil. 
Rf 0.36 (petroleum ether/ethyl acetate 7:3); H (400 MHz, CDCl3): 1.85 (t, 1H, J 
2.8 Hz, C≡CH), 2.15 (t, 1H, J 2.5 Hz, C≡CH), 2.45 (dd, 1H, J 3.4 and 11.9, H5), 
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2.51 (dt, 1H, J 16.6 and 2.8 Hz, CCHH’), 2.68 (ddd, 2.8, 9.3 and 16.6 Hz, 
CCHH’), 2.86 (d, 1H, J 16.6 Hz, H3), 2.96 (ddd, 1H, J 1.2, 3.4 and 11.9 Hz, 
H5’), 3.27 (dd, 1H, J 1.2 and 16.6 Hz, H3’), 3.43 (d, 1H,J 13.0 Hz,  CHH’Ph), 
3.47 (d, 1H, J 13.0 Hz, CHH’Ph), 3.61-3.66 (m, 1H, H6), 3.77 (dd, 1H, J 2.5 and 
17.6 Hz, NCHH’), 4.58 (dd, 1H, J 2.5 and 17.6 Hz, NCHH’), 7.13-7.24 (m, 5H, 
HAr); C (100 MHz, CDCl3): 21.8 (CH2), 33.6 (CH2), 52.3 (CH2, C5), 54.9 (CH, 
C6), 57.3 (CH2, C3), 61.5 (CH2, CH2Ph), 71.0 (C, C≡C), 72.6 (C, C≡C), 78.2 
(CH, C≡CH), 80.3 (CH, C≡CH), 127.5 (CHAr), 128.4 (CHAr), 129.0 (CHAr), 
136.8 (CAr), 167.1 (C=O); max/cm
-1 (neat) 3290, 2962, 2921, 2115, 1679 
(C=O), 1417, 1251, 1183; m/z (AP+) 267 ([M+H]+, 100%); HMRS calc. for 
C17H18ON2 267.1492, found 267.1496 [M+H]
+. 
 
 
 
General procedure for the transition-metal catalysed [2+2+2] 
cyclotrimerisation reactions: 
 
 
Diethylacetylene dicarboxylate 2.112a (355 L, 377 mg, 2.26 mmol) was added 
to a stirred solution of dialkyne 1.132 (73 mg, 0.45 mmol), Cp*RuCodCl (17 mg, 
0.045 mmol) in anhydrous degassed (three cycles of freeze-pump-thaw) 
toluene (2.0 mL) under argon. The mixture was heated to reflux for 2.5 h then 
the solvent removed under vacuum. Purification of the residue by flash column 
chromatography (petroleum ether/ethyl acetate 9:1 to 0:1) yielded the tricyclic 
adduct 2.116a (104 mg, 70%) as a brown oil, hexaethyl benzene-1,2,3,4,5,6-
hexacarboxylate 2.113a (276 mg, 44%) as a pale yellow solid and 1,5-
Di(benzyl-1,2,3,4-tetracarboxylic acid tetraethyl ester)-pyrrolidin-2-one 2.215a 
(61 mg, 16%) as a dark orange oil. 
 
The percentage yield and the appearance of the compounds obtained in these 
cyclotrimerisation reactions are listed below. 
 
Compound No % yield mass (mg) appearence 
2.114a 21 32 Brown orange oil 
2.113b 22 239 Orange oil 
2.115b 17 61 Orange oil 
2.116b 34 52 Yellow oil 
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2.113g 32 426 White solid 
2.116g 1 2 Colourless oil 
2.117a 46 73 Dark brown oil 
2.118a 8 31 dark brown oil 
2.117b 28 39 Red oil 
2.118b 8 27 Dark orange oil 
2.117g 5 8 Yellow oil 
2.119a 39 56 Yellow oil 
2.120a 4 12 Yellow oil 
Table XXXVI – Yield and appearance of compounds obtained through the [2+2+2] 
cyclotrimerisation of alkynes. 
 
The 13C NMR spectrum of some cyclic products often show superimposition of 
the CH3 and OCH2 carbons, nevertheless it can be confidently stated that it is 
the right compound; all other characterisation matches the desired structure. 
 
Hexaethyl benzene-1,2,3,4,5,6-hexacarboxylate 2.113a 
 
 
Rf 0.33 (petroleum ether/ethyl acetate 7:3); mp = 64-67 ºC [lit.
203 74 ºC]; H (400 
MHz, CDCl3): 1.28 (t, 18 H, J 7.2 Hz, CH3), 4.25 (q, 12H, J 7.2 Hz, OCH2); C 
(100 MHz, CDCl3): 13.8 (CH3), 62.6 (CH2), 133.8 (C), 164.8 (CO). Data in 
agreement with literature.203 
 
 
Tetraethyl 5-((2-oxo-5-(prop-2-yn-1-yl)pyrrolidin-1-yl)methyl)benzene-
1,2,3,4-tetracarboxylate 2.114a 
 
 
Rf 0.42 (ethyl acetate/petroleum ether 7:3); H (400 MHz, CDCl3): 1.31-1.37 (m, 
12H, CH3), 1.93-2.01 (m, 1H, H4), 1.97 (t, 1H, J 2.6 Hz, C≡CH), 2.13-2.23 (m, 
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1H, H4’), 2.32-2.45 (m, 3H, H3, CHH’), 2.57-2.66 (m, 1H, H3’), 3.53-3.58 (m, 
1H, H5), 4.17 (d, 1H, J 15.8 Hz, NCHH), 4.15-4.39 (m, 8H, OCH2), 5.10 (d, 1H, 
J 15.8 Hz, NCHH’), 7.96 (s, 1H, HAr); C (100 MHz, CDCl3): 13.9 (CH3), 13.9 
(CH3), 14.1 (CH3), 23.1 (CH2, C4), 23.4 (CH2), 29.8 (CH2, C3), 41.3 (CH2), 55.4 
(CH, C5), 62.1 (CH2, OCH2), 62.2 (CH2, OCH2), 62.5 (CH2, OCH2), 62.6 (CH2, 
OCH2), 71.5 (C, C≡C), 79.0 (CH, C≡CH), 130.8 (CAr), 131.2 (CAr), 132.7 
(CHAr), 134.4 (CAr), 136.2 (CAr), 136.4 (CAr), 164.6 (C=O), 165.3 (C=O), 
166.5 (C=O), 166.6 (C=O), 175.5 (C=O); max/cm
-1 (neat) 3309, 3059, 2985, 
1727 (C=O), 1690 (C=O), 1420, 1368, 1266, 1244; m/z (AP+) 502 ([M+H]+, 
100%); HMRS calc. for C26H32NO9 502.2072, found 502.2068 [M+H]
+. 
 
 
1,5-Di(benzyl-1,2,3,4-tetracarboxylic acid tetraethyl ester)-pyrrolidin-2-one 
2.115a 
 
 
Rf 0.36 (ethyl acetate/petroleum ether 7:3) ; H (400 MHz, CDCl3): 1.24-1.31 (m, 
24 H, CH3), 1.69-1.86 (m, 2H, H4/H4’), 2.26-2.34 (m, 1H, H3), 2.41 (dd, 1H, J 
8.7 and 17.3 Hz, H3’), 2.49 (dd, 1H, J 10.3 and 13.2 Hz, CCHH’), 3.15 (dd, 1H, 
J 3.9 and 13.2 Hz, CCHH’), 3.70 (m, 1H, H5), 4.25 (d, 1H, J 13.7 Hz, NCHH’), 
4.21-4.31 (m, 16H, OCH2), 5.00 (d, 1H, J 13.7 Hz, NCHH’), 7.82 (s, 1H, HAr), 
7.88 (s, 1H, HAr); C (100 MHz, CDCl3): 13.8 (CH3), 13.9 (CH3), 14.0 (CH3), 
14.0 (CH3), 23.1 (CH2, C4), 29.2 (CH2, C3), 35.8 (CH2), 41.5 (CH2), 58.1 (CH, 
C5), 62.1 (CH2, OCH2), 62.2 (CH2, OCH2), 62.4 (CH2, OCH2), 62.4 (CH2, 
OCH2), 62.5 (CH2, OCH2), 130.9 (CAr), 131.1 (CAr), 131.2 (CAr), 131.3 (CAr), 
132.1 (CHAr), 133.7 (CAr), 133.8 (CHAr), 134.3 (CAr), 135.8 (CAr), 136.8 
(CAr), 137.0 (CAr), 137.2 (CAr), 164.5 (C=O), 164.5 (C=O), 165.4 (C=O), 165.4 
(C=O), 166.4 (C=O), 166.4 (C=O), 166.6 (C=O), 166.7 (C=O), 175.3 (C=O); 
max/cm
-1 (neat) 2983, 2940, 2908, 1722 (C=O), 1694 (C=O), 1445, 1415, 1233, 
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1196, 1177, 1156, 1101, 1018; m/z (AP+) 843 ([M+2H]+, 50%), 842 ([M+H]+, 
100%); HMRS calc. for C42H55N2O17 859.3495, found 859.3497 [M+NH4]
+. 
 
Diethyl 3-oxo-1,2,3,5,10,10a-hexahydropyrrolo[1,2-b]isoquinoline-7,8-
dicarboxylate 2.116a 
 
 
Rf 0.18 (ethyl acetate); H (400 MHz, CDCl3): 1.34 (t, 3H, J 7.1 Hz, CH3), 1.34 (t, 
3H, J 7.1 Hz, CH3), 1.78-1.86 (m, 1H, H1), 2.37-2.49 (m, 3H, H1’, H2, H2’), 2.70 
(dd, 1H, J 11.4 and 15.7 Hz, H10), 3.02 (dd, 1H, J 3.7 and 15.7 Hz, H10’), 3.72-
3.79 (m, 1H, H10a), 4.26 (d, 1H, J 18.2 Hz, H5), 4.33 (q, 2 H, J 7.1 Hz, OCH2), 
4.33 (q, 2 H, J 7.1 Hz, OCH2), 4.97 (d, 1H, J 18.2 Hz, H5’), 7.47 (s, 1H, HAr), 
7.49 (s, 1H, HAr); C (100 MHz, CDCl3): 14.1 (CH3), 14.1 (CH3), 25.1 (CH2, C1), 
29.9 (CH2, C2), 36.6 (CH2, C10), 42.3 (CH2, C5), 53.4 (CH, C10a), 61.7 (CH2, 
OCH2), 61.7 (CH2, OCH2), 127.4 (CHAr), 129.8 (CHAr), 130.6 (CAr), 130.7 
(CAr), 135.2 (CAr), 136.7 (CAr), 167.1 (C=O), 167.3 (C=O), 174.2 (C=O); 
max/cm
-1 (neat) 2982, 2940, 2908, 1718 (C=O), 1686 (C=O), 1442, 1419, 1285, 
1255, 1180, 1129, 1018; m/z (AP+) 332 ([M+H]+, 100%), 286 ([M-OCH2CH3]
+, 
90%); HMRS calc. for C18H22O9N 332.1492, found 332.1496 [M+H]
+. 
 
 
Hexamethyl benzene-1,2,3,4,5,6-hexacarboxylate 2.113b 
 
 
Rf 0.32 (ethyl acetate/petroleum ether 1:1); mp = 188-190 ºC [lit.
204 186 ºC]; H 
(400 MHz, CDCl3): 3.82 (s, 18H); C (100 MHz, CDCl3): 52.9 (CH3), 133.8 (C), 
164.8 (CO). Data in agreement with literature.204 
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1,5-Di(benzyl-1,2,3,4-tetracarboxylic acid tetramethyl ester)-pyrrolidin-2-
one 2.115b 
 
 
Rf 0.3 (ethyl acetate); H (400 MHz, CDCl3): 1.76 (m, 1H, H4), 1.88 (m, 1H, H4’), 
2.34 (m, 1H, H3), 2.46 (dd, 1H, J 8.7 and 17.3 Hz, H3’), 2.54 (dd, 1H, J 9.9 and 
13.4 Hz, CHH’), 3.15 (dd, 1H, J 4.3 and 13.4 Hz, CHH’), 3.69-3.75 (m, 1H, H5), 
3.75 (s, 3H, CH3), 3.82 (s, 3H, CH3), 3.84 (s, 3H, CH3), 3.87 (s, 3H, CH3), 3.88 
(s, 3H, CH3), 3.88 (s, 3H, CH3), 3.89 (s, 6H, CH3), 4.18 (d, 1H, J 15.9 Hz, 
NCHH’), 5.02 (d, 1H, J 15.9 Hz, NCHH’), 7.88 (s, 1H, HAr), 7.92 (s, 1H, HAr); C 
(100 MHz, CDCl3): 23.3 (CH2, C4), 29.1 (CH2, C3), 36.1 (CH2), 41.7 (CH2), 53.0 
(CH3), 53.1 (CH3), 53.1 (CH3), 53.2 (CH3), 58.0 (C5), 130.3 (CAr), 130.5 (CAr), 
130.6 (CAr), 130.7 (CAr), 132.8 (CHAr), 134.0 (CAr), 134.2 (CHAr), 134.7 
(CAr), 136.1 (CAr), 137.0 (CAr), 137.1 (CAr), 137.4 (CAr), 164.6 (C=O), 164.6 
(C=O), 165.5 (C=O), 165.6 (C=O), 166.8 (C=O), 166.9 (C=O), 167.2 (C=O), 
167.2 (C=O), 175.3 (C=O); max/cm
-1 (neat) 2950, 2850, 1723 (C=O), 1694 
(C=O), 1420, 1375, 1237, 1175, 1017; m/z (AP+) 748 ([M+NH4]
+, 100%), 731 
([M+H]+, 10%); HMRS calc. for C34H39N2O17 747.2243, found 747.2243 
[M+NH4]
+. 
 
 
Dimethyl 3-oxo-1,2,3,5,10,10a-hexahydropyrrolo[1,2-b]isoquinoline-7,8-
dicarboxylate 2.116b 
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Rf 0.12 (ethyl acetate); H (400 MHz, CDCl3): 1.78-1.86 (m, 1H, H1), 2.37-2.49 
(m, 3H, H1’, H2, H2’), 2.70 (dd, 1H, J 11.2 and 15.6 Hz, H10), 3.01 (dd, 1H, J 
3.7 and 15.6 Hz, H10’), 3.73-3.80 (m, 1H, H10a), 3.87 (s, 3H, CH3), 3.87 (s, 3H, 
CH3), 4.25 (d, 1H, J 18.3 Hz, H5), 4.97 (d, 1H, J 18.3 Hz, H5’), 7.47 (s, 1H, 
HAr), 7.49 (s, 1H, HAr); C (100 MHz, CDCl3): 25.1 (CH2, C1), 29.9 (CH2, C2), 
36.6 (CH2, C10), 42.3 (CH2, C5), 52.7 (CH3), 52.7 (CH3), 53.4 (CH, C10a), 
127.4 (CHAr), 129.8 (CHAr), 130.3 (CAr), 130.3 (CAr), 135.3 (CAr), 136.9 
(CAr), 167.6 (C=O), 167.8 (C=O), 174.2 (C=O); max/cm
-1 (neat) 2954, 2845, 
1719(C=O), 1675 (C=O), 1432, 1247, 1210, 1157, 1125; m/z (AP+) 304 
([M+H]+, 100%); HMRS calc. for C16H16O5N 302.1023, found 302.1029 [M-H]
+. 
 
 
3',4',5',6'-Tetraphenyl-1,1':2',1''-terphenyl 2.113g 
 
 
 
Rf 0.12 (ethyl acetate); mp = 458 ºC [lit.
205 462 ºC];  H (400 MHz, CDCl3): 7.24-
7.30 (m, 18H), 7.44-7.49 (m, 12H); C (100 MHz, CDCl3): 128.3, 128.4, 131.6. 
Data in agreement with literature.205 
 
 
7,8-Diphenyl-1,2,10,10a-tetrahydropyrrolo[1,2-b]isoquinolin-3(5H)-one 
2.116g 
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Rf 0.24 (ethyl acetate); H (400 MHz, CDCl3): 1.82-1.91 (m, 1H, H1), 2.40-2.54 
(m, 3H, H1, H2, H2’), 2.79 (dd, 1H, J 11.3 and 15.3 Hz, H10), 3.05 (dd, 1H, J 
3.7 and 15.3 Hz, H10’), 3.85-3.92 (m, 1H, H10a), 4.35 (d, 1H, J 17.6 Hz, H5), 
5.04 (d, 1H, J 17.6 Hz, H5’), 7.10-7.13 (m, 4H, HAr), 7.19-7.23 (m, 8H, HAr); C 
(100 MHz, CDCl3): 25.4 (CH2, C1), 30.2 (CH2, C2), 36.6 (CH2, C10), 42.4 (CH2, 
C5), 54.1 (CH, C10a), 126.6 (CHAr), 126.6 (CHAr), 127.9 (CHAr), 128.0 
(CHAr), 128.7 (CHAr), 129.8 (CHAr), 131.1 (CAr), 131.2 (CHAr), 132.5 (CAr), 
139.1 (CAr), 139.4 (CAr), 140.8 (CAr), 140.9 (CAr), 174.3 (C=O); max/cm
-1 
(neat) 2974, 2843, 1657 (C=O), 1444, 1335, 1264; m/z (AP+) 340 ([M+H]+, 
100%); HMRS calc. for C24H22ON 340.1696, found 340.1699 [M+H]
+. 
 
 
Diethyl 4-oxo-2,3,4,6,11,11a-hexahydro-1H-pyrido[1,2-b]isoquinoline-8,9-
dicarboxylate 2.117a 
 
 
 
Rf 0.27 (ethyl acetate); H (400 MHz, CDCl3): 1.32 (t, 3H, J 7.2 Hz, CH3), 1.38 (t, 
3H, J 7.2 Hz, CH3), 1.69-1.79 (m, 2H, H2, H1), 1.87-1.92 (m, 1H, H2’), 2.09-
2.16 (m, 1H, H1’), 2.38-2.50 (m, 2H, H3/H3’), 2.79-2.91 (m, 2H, H11/H11’), 
3.56-3.63 (m ,1H, H11a), 4.21 (d, 1H, J 18.3 Hz, H6), 4.32 (s, 2H, OCH2), 4.32 
(s, 2H, OCH2), 5.34 (d, 1H, J 18.3 Hz, H6’), 7.44 (s, 1H, HAr), 7.48 (s, 1H, HAr); 
C (100 MHz, CDCl3): 14.1 (CH3), 18.5 (CH2, C2), 29.1 (CH2, C1), 32.7 (CH2, 
C3), 36.6 (CH2, C11), 44.6 (CH2, C6), 53.1 (CH, C11a), 61.6 (CH2, OCH2), 
127.2 (CHAr), 128.9 (CHAr), 130.4 (CAr), 130.5 (CAr), 136.2 (CAr), 137.1 
(CAr), 167.2 (C=O), 167.4 (C=O), 169.7 (C=O); max/cm
-1 (neat) 2982, 2940, 
2904, 1718 (C=O), 1627 (C=O), 1444, 1367, 1296, 1274, 1244, 1129; m/z 
(AP+) 346 ([M+H]+, 100%); HMRS calc. for C19H22O5N1 344.1493, found 
344.1497 [M-H]+.  
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1,6-Di(benzyl-1,2,3,4-tetracarboxylic acid tetraethyl ester)-piperidin-2-one 
2.118a 
 
 
 
Rf 0.35 (ethyl acetate); H (400 MHz, CDCl3): 1.25-1.31 (m, 24H, CH3), 1.53-
1.61 (m, 2H, H5/H5’), 1.68-1.74 (m, 1H, H4), 1.91-1.97 (m, 1H, H4’), 2.42-2.50 
(m, 2H, H3/H3’), 2.76 (dd, 1H, J 10.6 and 13.6 Hz, CCHH’), 3.20 (dd, 1H, J 4.0 
and 13.6 Hz, CCHH’),   3.54-3.60 (m, 1H, H6), 4.20-4.31 (m, 17H, 
OCH2/NCHH’), 5.27 (d, 1H, J 16.4 Hz, NCHH’), 7.78 (s, 1H, HAr), 7.80 (s, 1H, 
HAr); C (100 MHz, CDCl3): 13.7 (CH3), 13.9 (CH3), 13.9 (CH3), 14.0 (CH3), 14.1 
(CH3), 17.0 (CH2, C4), 25.5 (CH2, C5), 31.8 (CH2, C3), 36.0 (CH2), 45.7 (CH2), 
57.6 (CH, C6), 62.0 (CH2, OCH2), 62.1 (CH2, OCH2), 62.3 (CH2, OCH2), 62.3 
(CH2, OCH2), 62.5 (CH2, OCH2), 130.8 (CHAr), 130.9 (CAr), 131.0 (CAr), 131.3 
(CAr), 131.4 (CAr), 133.6 (CAr), 133.8 (CAr), 134.1 (CHAr),135.4 (CAr), 136.4 
(CAr), 137.8 (CAr), 138.0 (CAr), 164.5 (C=O), 164.6 (C=O), 165.5 (C=O), 165.6 
(C=O), 166.3 (C=O), 166.5 (C=O), 166.7 (C=O), 166.8 (C=O), 170.7 (C=O); 
max/cm
-1 (neat) 2984, 2940, 2908, 1722 (C=O), 1695 (C=O), 1445, 1416, 1367, 
1234, 1196, 1178, 1155, 1101, 1018; m/z (AP+) 856 ([M+H]+, 100%); HMRS 
calc. for C43H57N2O17 873.3652, found 873.3650 [M+NH4]
+.  
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Dimethyl 4-oxo-2,3,4,6,11,11a-hexahydro-1H-pyrido[1,2-b]isoquinoline-8,9-
dicarboxylate 2.117b 
 
 
Rf 0.20 (ethyl acetate); H (400 MHz, CDCl3): 1.72-1.80 (m, 2H, H2,H1), 1.88-
1.96 (m, 1H, H2’), 2.11-2.18 (m, 1H, H1’), 2.40-2.53 (m, 2H, H3/H3’), 2.81-2.94 
(m, 2H, H11/H11’), 3.59-3.65 (m, 1H, H11a), 3.88 (s, 3H, OCH3), 3.88 (s, 3H, 
OCH3), 4.25 (d, 1H, J 18.3 Hz, H6), 5.37 (d, 1H, J 18.3 Hz, H6’), 7.46 (s, 1H, 
HAr), 7.50 (s, 1H, HAr); C (100 MHz, CDCl3): 18.5 (CH2, C2), 29.1 (CH2, C1), 
32.7 (CH2, C3), 36.6 (CH2, C11), 44.6 (CH2, C6), 52.7 (CH3), 53.0 (CH, C11a), 
127.3 (CHAr), 129.0 (CHAr), 130.1 (CAr), 130.2 (CAr), 136.4 (CAr), 137.3 
(CAr), 167.7 (C=O), 167.9 (C=O), 169.8 (C=O); max/cm
-1 (neat) 2954, 2936, 
1712 (C=O), 1639 (C=O), 1438, 1279, 1237, 1131; m/z (AP+) 318 ([M+H]+, 
100%); HMRS calc. for C17H20O5N 318.1336, found 318.1340 [M+H]
+. 
 
 
 
1,6-Di(benzyl-1,2,3,4-tetracarboxylic acid tetramethyl ester)-piperidin-2-
one 2.118b 
 
 
Rf 0.3 (ethyl acetate); H (400 MHz, CDCl3): 1.93-2.03 (m, 2H, H5/H5’), 2.07-
2.13 (m, 1H, H4), 2.25-2.37 (m, 1H, H4’), 2.77-2.93 (m, 2H, H3/H3’), 3.14 (dd, 
1H, J 10.3 and 13.7 Hz, CCHH’), 3.54 (dd, 1H, J 4.3 and 13.7 Hz, CCHH’), 
3.94-4.01 (m, 1H, H6), 4.13 (s, 3H, OCH3), 4.18 (s, 3H, OCH3), 4.19 (s, 3H, 
OCH3), 4.22 (s, 3H, OCH3), 4.22 (s, 3H, OCH3), 4.24 (s, 3H, OCH3), 4.24 (s, 
3H, OCH3), 4.57 (d, 1H, J 16.2 Hz, NCHH’), 5.64 (d, 1H, J 16.2 Hz, NCHH’), 
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8.23 (s, 1H, HAr), 8.25 (s, 1H, HAr); C (100 MHz, CDCl3): 17.0 (CH2, C4), 25.6 
(CH2, C5), 31.8 (CH2, C3), 36.1 (CH2), 45.7 (CH2), 52.2 (OCH3), 53.1 (OCH3), 
53.1 (OCH3), 53.1(OCH3), 53.2 (OCH3), 53.2 (OCH3), 53.3 (OCH3), 57.6 (CH, 
C6), 130.4 (CAr), 130.5 (CAr), 130.7 (CAr), 130.7 (CAr), 131.7 (CHAr), 134.0 
(CAr), 134.2 (CAr), 134.5 (CHAr), 135.8 (CAr), 136.8 (CAr), 138.0 (CAr), 138.2 
(CAr), 164.6 (C=O), 164.8 (C=O), 165.6 (C=O), 165.7 (C=O), 166.8 (C=O), 
167.0 (C=O), 167.3 (C=O), 167.4 (C=O), 170.7 (C=O); max/cm
-1 (neat) 2954, 
1724 (C=O), 1642 (C=O), 1439, 1330, 1239, 1200, 1156, 1106; m/z (AP+) 85 
(100%), 121 (85%), 744 ([M+H]+, 30%); HMRS calc. for C35H41N2O17 761.2400, 
found 761.2398 [M+NH4]
+.  
 
 
8,9-Diphenyl-2,3,11,11a-tetrahydro-1H-pyrido[1,2-b]isoquinolin-4(6H)-one 
2.117g 
 
Rf 0.36 (ethyl acetate); H (400 MHz, CDCl3): 1.75-1.84 (m, 2H, H2,H1), 1.93-
1.96 (m, 1H, H2’), 2.13-2.21 (m, 1H, H1’), 2.49-2.52 (m, 2H, H3/H3’), 2.86 (dd, 
1H, J 15.7 and 3.4 Hz, H11), 2.97 (dd, 1H, J 15.7 and 11.4 Hz, H11’), 3.69-3.76 
(m, 1H, H11a), 4.35 (d, 1H, J 17.6 Hz, H6), 5.39 (d, 1H, J 17.6 Hz, H6’), 7.09-
7.12 (m, 4H, HAr), 7.18-7.22 (m, 8H, HAr); C (100 MHz, CDCl3): 18.7 (CH2, 
C2), 29.3 (CH2, C1), 32.8 (CH2, C3), 36.5 (CH2, C11), 44.8 (CH2, C6), 53.6 (CH, 
C11a), 126.5 (CHAr), 126.6 (CHAr), 127.9 (CHAr), 127.9 (CHAr), 128.6 (CHAr), 
129.8 (CHAr), 130.3 (CHAr), 132.2 (CAr), 133.0 (CAr), 138.9 (CAr), 139.1 
(CAr), 140.9 (CAr), 141.1 (CAr), 169.8 (C=O); max/cm
-1 (neat) 2980, 2952, 1732 
(C=O), 1634 (C=O), 1446, 1418, 1340, 1264; m/z (AP+) 354 ([M+H]+, 100%); 
HMRS calc. for C25H22ON 352.1696, found 352.1701 [M-H]
+. 
 
 
185 
  
Diethyl 2-benzyl-4-oxo-2,3,4,6,11,11a-hexahydro-1H-pyrazino[1,2-
b]isoquinoline-8,9-dicarboxylate 1.119a 
 
 
Rf 0.28 (ethyl acetate); H (400 MHz, CDCl3): 1.34 (t, 3H, J 7.1 Hz, CH3), 1.35 (t, 
3H, J 7.1 Hz, CH3), 2.61 (dd, 1H, J 5.0 and 11.8, H1), 2.71 (dd, 1H, J 3.1 and 
16.3 Hz, H11), 2.88 (dd, 4.4 and 11.8 Hz, H1’), 3.11-.3.17 (m, 1H, H11’),  3.19 
(d, 1H, J 16.1 Hz, H3), 3.28 (d, 1H, J 16.1 Hz, H3’), 3.53 (d, 1H, J 12.9 Hz,  
CHH’Ph), 3.60 (d, 1H, J 12.9 Hz,  CHH’Ph), 3.61-3.67 (m, 1H, H11a), 4.21 (d, 
1H, J 18.0 Hz, H6), 4.33 (q, 2H, J 7.1 Hz, OCH2), 4.34 (q, 2H, J 7.1 Hz, OCH2), 
5.40 (d, 1H, J 18.0 Hz, H6’), 7.26-7.36 (m, 5H, HAr), 7.45 (s, 1H, HAr), 7.49 (s, 
1H, HAr); C (100 MHz, CDCl3): 14.1 (CH3), 34.1 (CH2, C11), 43.9 (CH2, C6), 
52.1 (CH, C11a), 54.1 (CH2, C1), 57.8 (CH2, C3), 61.6 (CH2Ph), 61.7 (OCH2), 
127.2 (CHAr), 127.7 (CHAr), 128.6 (CHAr), 130.0 (CHAr), 129.3 (CHAr), 130.4 
(CAr), 130.6 (CAr), 135.5 (CAr), 136.8 (CAr), 137.0 (CAr), 166.8 (C=O), 167.2 
(C=O), 167.4 (C=O); max/cm
-1 (neat) 3055, 2988, 1725 (C=O), 1650 (C=O), 
1421, 1264; m/z (AP+) 437 ([M+H]+, 100%); HMRS calc. for C25H28O5N2 
437.2071, found 437.2065 [M+H]+. 
 
 
1,6-Di-1,2,3,4-tetracarboxylic acid tetraethyl ester)-4-benzylpiperazin-2-one 
2.120a 
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Rf 0.53 (ethyl acetate); H (400 MHz, CDCl3): 1.19-1.25 (m, 24H, CH3), 2.37 (dd, 
1H, J 3.1 and 12.2 Hz, H5), 2.63 (d, 1H, J 12.2 Hz, H5’), 2.77 (d, 1H, J 16.9 Hz, 
H3), 3.12-3.21 (m, 2H, CCHH’), 3.26 (d, 1H, J 12.8 Hz, CHH’Ph), 3.36 (d, 1H, J 
16.9 Hz, H3’), 3.42-3.44 (m 1H, H6), 3.64 (d, 1H, J 12.8 Hz, CHH’Ph), 4.15-4.28 
(m, 17H, OCH2/NCHH’), 5.23 (d, 1H, J 16.6 Hz, NCHH’), 7.15-7.22 (m, 5H, 
HAr), 7.71 (s, 1H, HAr), 7.87 (s, 1H, HAr); C (100 MHz, CDCl3): 13.7 (CH3), 
13.9 (CH3), 13.9 (CH3), 14.0 (CH3), 14.1 (CH3), 35.8 (CH2), 45.3 (CH2), 52.1 
(CH2, C5), 56.5 (CH2, C3), 56.9 (CH, C6), 61.7 (CH2, CH2Ph), 62.0 (OCH2), 
62.1 (OCH2), 62.1 (OCH2), 62.2 (OCH2), 62.2 (OCH2), 62.4 (OCH2), 62.5 
(OCH2), 127.8 (CHAr), 128.5 (CHAr), 129.1 (CHAr), 130.6 (CHAr), 130.8 (CAr), 
130.9 (CAr), 131.4 (CAr), 131.7 (CAr), 133.8 (CAr), 133.9 (CAr), 134.9 (CHAr), 
135.3 (CAr), 136.1 (CAr), 136.3 (CAr), 137.3 (CAr), 138.0 (CAr), 164.4 (C=O), 
164.5 (C=O), 165.5 (C=O), 165.6 (C=O), 166.1 (C=O), 166.4 (C=O), 166.7 
(C=O), 166.8 (C=O), 167.8 (C=O;. max/cm
-1 (neat) 2983, 2936, 1723 (C=O), 
1658 (C=O), 1465, 1196, 1178, 1155, 1102, 1019; m/z (ES+) 947 ([M+H]+, 
100%); HMRS calc. for C49H59O17N2 947.3808, found 947.3821 [M+H]
+.  
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6.3 Experimental procedures for chapter 3 
 
4-(Dimethyl(phenyl)silyl)but-3-yn-2-ol 3.56 
 
 
Following the procedure of Brawn and co-workers:157 nBuLi (3.4 mL of 2.5 M 
solution in hexane, 8.56 mmol,) was added to a stirred solution of but-3-yn-2-ol 
3.55 (300 mg, 4.28 mmol) and dry LiCl (42 mg, 12.9 mmol) in THF (6.0 mL), at -
78 ºC under nitrogen. After 1 h, DMPSCl (741 L, 753 mg, 4.28 mmol) was 
added dropwise and the reaction was stirred overnight, warming slowly to room 
temperature. The reaction mixture was quenched with an aq. sat. solution of 
NH4Cl (6 mL), extracted with ethyl acetate (3  6 mL), dried over MgSO4, 
concentrated under vacuum and purified by flash column chromatography 
(hexane/ethyl acetate 9:1) to yield 3.56 (482 mg, 55%) as a clear oil. 
Rf 0.29 (hexane/ethyl acetate 4:2); H (500 MHz, CDCl3): 0.54 (s, 6H, CH3), 1.54 
(d, 3H, J 6.6 Hz, CH3), 3.53 (brs, 1H, OH), 4.61 (q, 1H, J 6.6 Hz, H2), 7.45-7.48 
(m, 3H, HAr), 7.75-7.76 (m, 2H, HAr); C (126 MHz, CDCl3): -0.5 (CH3), 24.5 
(CH3), 58.9 (CH, C2), 86.5 (C, C≡C), 110.0 (C, C≡C), 128.3 (CHAr), 129.8 
(CHAr), 134.0 (CHAr), 137.1 (CAr). Data in agreement with literature.157  
 
 
2-((1-Phenylprop-2-yn-1-yl)oxy)acetonitrile 3.53 
 
 
NaH (184 mg of a 60% dispersion in oil, 4.60 mmol) was added to a stirred 
solution of 1-phenylprop-2-yn-1-ol 3.58 (304 mg, 2.30 mmol) in THF (5.0 mL) at 
0 ºC under nitrogen. After 1 h, the temperature was cooled to -20 ºC and 
bromoacetonitrile (352 L, 607 mg, 5.06 mmol) was added very slowly and the 
reaction mixture stirred for 3 h at -20 ºC. Further NaH (184 mg of a 60% 
dispersion in oil, 4.60 mmol) and bromoacetonitrile (352 L, 607 mg, 5.06 
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mmol) were added and the reaction stirred overnight at room temperature. The 
reaction was quenched with an aq. sat. solution of NH4Cl (5 mL), extracted with 
ethyl acetate (3  5 mL), dried over MgSO4, concentrated under vacuum and 
purified by flash column chromatography (hexane/ethyl acetate 4:1) to yield 
3.53  (215 mg, 55 %) as a yellow oil. 
Rf 0.43 (hexane/ethyl acetate 4:1); H (500 MHz, CDCl3): 2.78 (d, 1H, J 2.4 Hz, 
H3), 4.31 (d, 1H, J 16.1 Hz, OCHH’), 4.45 (d, 1H, J 16.1 Hz, OCHH’), 5.39 (d, 
1H, J 2.4 Hz, H1), 7.38-7.42 (m, 3H, HAr), 7.51-7.53 (m, 2H, HAr); C (126 MHz, 
CDCl3): 53.2 (CH2, OCH2), 71.9 (CH, C1), 78.5 (CH, C≡CH), 79.2 (C, C≡C), 
115.9 (C, C≡N), 127.9 (CHAr), 129.1 (CHAr), 129. 7 (CHAr), 136.1 (CAr). 
max/cm
-1 (neat) 3286, 3067, 3035, 2920, 2861, 2118, 1664, 1608, 1454, 1070; 
m/z (AP+) 170 ([M-H]+, 20%), 114 (100%); HRMS calc. for C11H8NO 170.0600, 
found 170.0597 [M-H]+. 
 
 
2-((3-(Dimethyl(phenyl)silyl)-1-phenylprop-2-yn-1-yl)oxy)acetonitrile 3.59 
 
 
LHMDS (785 L of a 1.0 M solution in THF, 0.78 mmol) was added to a stirred 
solution of alkynenitrile 3.53 (133 mg, 0.78 mmol) in THF (1.5 mL), at -78 ºC 
under nitrogen. After 15 minutes, DMPSCl (132 L, 134 mg, 0.78 mmol) was 
added dropwise and the reaction mixture stirred for 15 minutes at -78 ºC. The 
reaction mixture was quenched with an aq. sat. solution of NH4Cl (5 mL), 
extracted with ethyl acetate (3  5 mL), dried over MgSO4, concentrated under 
vacuum and purified by flash column chromatography (hexane/ethyl acetate 
9:1) to yield 3.59 (157 mg, 66%) as a colourless oil. 
Rf 0.47 (hexane/ethyl acetate 19:1); H (500 MHz, CDCl3): 0.56 (s, 6H, CH3), 
4.37 (d, 1H, J 16.0 Hz, OCHH’), 4.53 (d, 1H, J 16.0 Hz, OCHH’), 5.51 (s, 1H, 
H1), 7.43-7.49 (m, 6H, HAr), 7.59-7.61 (m, 2H, HAr), 7.69-7.71 (m, 2H, HAr); C 
(126 MHz, CDCl3): -0.78 (CH3), 53.2 (CH2, OCH2), 72.7 (CH, C1), 94.2 (C, 
C≡C), 102.0 (C, C≡C), 116.1 (C, C≡N), 128.2 (CHAr), 128.4 (CHAr), 129.1 
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(CHAr), 129.6 (CHAr), 130.0 (CHAr), 134.0 (CHAr), 136.3 (CAr), 136.3 (CAr). 
max/cm
-1 (neat) 3069, 2961, 2174, 1643, 1428, 1250, 1071; m/z (AP+) 265 
(25%), 249 (100%); HRMS calc. for C19H23NOSi 323.1574, found 323.1577 
[M+NH4]
+. 
 
 
3-(But-3-yn-2-yloxy)propanenitrile 3.60 
 
 
DBU (500 L, 505 mg, 3.32 mmol) was added dropwise to a stirred solution of 
but-3-yn-2-ol 3.55 (1.2 g, 16.59 mmol) in acrylonitrile (4.4 mL, 3.52 g, 66.4 
mmol). After 1 h, the acrylonitrile was evaporated and the residue was purified 
by flash column chromatography (hexane/ethyl acetate 4:1) to yield alkynenitrile 
3.60 (1.8 g, 89%) as a colourless oil. 
Rf 0.39 (hexane/ethyl acetate 7:3); H (500 MHz, CDCl3): 1.45 (d, 1H, J 6.6 Hz, 
CH3), 2.46 (d, 1H, J 2.0 Hz, H4), 2.62 (t, 2H, J 6.5 Hz, CH2C≡N), 3.61 (dt, 1H, J 
6.5 and 9.3 Hz, OCHH’), 3.93 (dt, 1H, J 6.5 and 9.3 Hz, OCHH’), 4.22 (dq, 1H, J 
2.0 and 6.6 Hz, H2); C (126 MHz, CDCl3): 19.1 (CH2), 22.1 (CH3), 63.3 (CH2, 
OCH2), 65.9 (CH, C2), 74.0 (CH, C≡CH), 82.9 (C, C≡C), 117.9 (C, C≡N); 
max/cm
-1 (neat) 3284, 2990, 2939, 2883, 2253, 2111, 1374, 1328, 1105; m/z 
(AP+) 124 ([M+H]+, 100%); HRMS calc. for C7H10NO 124.0757, found 124.0754 
[M+H]+. 
 
 
(1-(Prop-2-yn-1-yloxy)prop-2-yn-1-yl)benzene 3.63 
 
 
NaH (631 mg of a 60% dispersion in oil, 15.78 mmol,) was added to a stirred 
solution of 1-phenylprop-2-yn-1-ol 3.58 (1.6 g, 12.14 mmol) in THF (36 mL) at 0 
ºC under nitrogen. After 1 h, propargyl bromide 2.9 (1.8 mL of a 80% solution in 
toluene, 15.78 mmol) was added dropwise and the reaction stirred for 3 h at 0 
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ºC. The reaction was quenched with an aq. sat. solution of NH4Cl (40 mL), 
extracted with ethyl acetate (3  40 mL), dried over MgSO4, concentrated under 
vacuum and purified by flash column chromatography (hexane/ethyl acetate 
4:1) to yield 3.63 (829 mg, 40%) as a pale yellow oil. 
Rf 0.44 (hexane/ethyl acetate 4:1); H (500 MHz, CDCl3): 2.50 (t, 1H, J 2.4 Hz, 
C≡CH) 2.69 (d, 1H, J 2.2 Hz, H3), 4.30 (dd, 1H, J 2.4 and 15.7 Hz, OCHH’), 
4.41 (dd, 1H, J 2.4 and 15.7 Hz, OCHH’), 5.45 (d, 1H, J 2.2 Hz, H1), 7.35-7.42 
(m, 3H, HAr), 7.56 (brd, 2H, J 7.2 Hz,  HAr); C (126 MHz, CDCl3): 55.7 (CH, 
C1), 70.0 (CH2, OCH2), 75.4 (CH, C≡CH), 76.5 (CH, C≡CH), 79.3 (C, C≡C), 
80.9 (C, C≡C), 127.8 (CHAr), 128.8 (CHAr), 129.0 (CHAr), 137.6 (CAr). Data in 
agreement with literature.206 
 
 
1-Phenylprop-2-yn-1-yl pent-4-ynoate 3.70 
 
 
DMAP (19 mg, 0.15 mmol) and NEt3 (323 L, 234 mg, 2.32 mmol) were added 
to a stirred solution of 1-phenylprop-2-yn-1-ol 3.58 (204 g, 1.54 mmol) in DCM 
(2.0 mL) at 0 ºC under nitrogen. Pent-4-ynoyl chloride (270 mg, 2.32 mmol) was 
then added very slowly and the reaction mixture was stirred at 0 ºC for 1.5 h. 
The solvent was removed under vacuum and the residue purified by flash 
column chromatography (hexane/ethyl acetate 9:1) to yield ester 3.70 (280 mg, 
85%) as a colourless oil. 
Rf 0.34 (hexane/ethyl acetate 4:1); H (500 MHz, CDCl3): 1.96 (t, 1H, J 2.0 Hz, 
C≡CH), 2.51-2.54 (m, 2H, CH2C≡C), 2.56-2.66 (m, 2H, COCHH’), 2.67 (d, 1H, J 
1.9 Hz, H3), 6.49 (d, 1H, J 1.9 Hz, H1), 7.36-7.41 (m, 3H, HAr), 7.53-7.55 (m, 
2H, HAr); C (126 MHz, CDCl3): 14.5 (CH2), 33.5 (CH2, OCH2), 65.8 (CH, C1), 
69.5 (CH, C≡CH), 75.9 (CH, C≡CH), 80.3 (C, C≡C), 82.3 (C, C≡C), 127.9 
(CHAr), 128.9 (CHAr), 129.4 (CHAr), 136.5 (CAr), 170.7 (CO); max/cm
-1 (neat) 
3303, 3055, 1741 (C=O), 1421, 1371, 1264, 1155; m/z (AP+) 213 ([M+H]+, 
25%), 120 (100%), 115 (95%); HRMS calc. for C14H13O2 213.0910, found 
213.0910 [M+H]+, C14H16NO2 230.1176, found 230.1171 [M+NH4]
+. 
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1-Phenylprop-2-yn-1-yl propiolate 3.74 
 
 
Triphenylphosphine (2.15 g, 8.19 mmol) and propiolic acid (378 L, 430 mg, 
6.14 mmol) were added to a stirred solution of 1-phenylprop-2-yn-1-ol 3.58 (541 
mg, 4.09 mmol) in THF (14 mL) under nitrogen. The reaction mixture was 
cooled to 0 ºC and DEAD (1.3 mL, 1.4 g, 8.19 mmol) was added very slowly. 
After 2 h, the solvent was removed under vacuum, diethyl ether was added and 
the solution was kept in the fridge overnight. The white solid was filtered off, the 
filtrate was concentrated under vacuum and purified by flash column 
chromatography (hexane/ethyl acetate 9:1) to yield product 3.74 (436 mg, 58%) 
as a white solid. 
Rf 0.31 (hexane/ethyl acetate 4 :1) ; mp = 49-52 ºC ; H (500 MHz, CDCl3): 2.78 
(d, 1H, J 2.1 Hz, H3), 2.97 (s, 1H, C≡CH), 6.52 (d, 1H, J 2.1 Hz, H1), 7.40-7.45 
(m, 3H, HAr), 7.57-7.59 (m, 2 H, HAr); C (126 MHz, CDCl3): 67.5 (CH, C1), 
74.3 (C, C≡C), 76.7 (CH, C≡CH), 77.1 (CH, C≡CH), 79.3 (C, C≡C), 128.2 
(CHAr), 129.1 (CHAr), 129.8 (CHAr), 135.5 (CAr), 151.7 (CO); max/cm
-1 (neat) 
3275, 3263, 3073, 2959, 2115, 1705 (C=O), 1222, 1192, 1177; m/z (AP+) 184 
[M]+, 5%; 120 (35%), 114 (100%); HRMS calc. for C12H9O2 185.0597, found 
185.0596 [M+H]+.  
 
 
N-(But-3-yn-2-yl)-2-nitrobenzenesulfonamide 3.77 
 
 
From but-3-yn-2-amine hydrochloride 3.28 
To a stirred solution of but-3-yn-2-amine hydrochloride 3.75 (243 mg, 3.52 
mmol) and NEt3 (1.5 mL, 1.1 g, 10.55 mmol) in DCM (2.0 mL) at room 
temperature was added nosyl chloride (1.2 g, 5.27 mmol). The reaction was 
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stirred for 24 h at 40 ºC, then it was quenched with water (5 mL), extracted with 
ethyl acetate (3  5 mL), dried over MgSO4, concentrated under vacuum and 
purified by flash column chromatography (hexane/ethyl acetate 1:0 to 4:1) 
affording amine 3.77 (355 mg, 96%) as a white solid. 
 
From tert-butyl but-3-yn-2-yl((2-nitrophenyl)sulfonyl)carbamate 3.85 
Tert-butyl but-3-yn-2-yl((2-nitrophenyl)sulfonyl)carbamate 3.85 (1.1 g, 3.10 
mmol) was stirred in TFA (8.6 mL, 12.8 g, 112 mmol) for 5 minutes and then 
neutralized by pouring into an aq. sat. solution of NaHCO3. The reaction mixture 
was extracted with ethyl acetate (3  200 mL), the combined organic phases 
were dried over MgSO4, concentrated under vacuum and purified by flash 
column chromatography (hexane/ethyl acetate 7:3) to afford amine 3.77 (711 
mg, 90%) as a white solid.  
Rf 0.32 (hexane/ethyl acetate 7:3); mp = 107-109 ºC ; H (500 MHz, CDCl3): 
1.51 (d, 3H, J 7.0 Hz, CH3), 2.00 (d, 1H, J 2.2 Hz, H4), 4.32-4.39 (m, 1H, H2), 
5.67 (d, 1H, J 9.4 Hz, NH), 7.75-7.78 (m, 2H, HAr), 7.90-7.92 (m, 1H, HAr), 
8.18-8.22 (m, 1H, HAr); C (126 MHz, CDCl3): 23.2 (CH3), 42.1 (CH, C2), 72.6 
(CH, C≡CH), 82.1 (C, C≡C), 125.7 (CHAr), 131.8 (CHAr), 133.1 (CHAr), 134.1 
(CHAr), 134.2 (CAr), 148.1 (CAr); max/cm
-1 (neat) 3307, 3267, 3097, 2996, 
2944, 2880, 2110, 1535, 1412, 1357, 1335, 1303, 1163, 1118; m/z (AP+) 255 
([M+H]+, 100%); HRMS calc. for C10H11N2O4S 255.0434, found 255.0436 
[M+H]+. 
 
 
 (Z)-4-((4-Methoxybenzyl)amino)but-3-en-2-one 3.90 
 
 
But-3-yn-2-one 3.78 (115 L, 100 mg, 1.47 mmol) was added to a stirred 
solution of PMB amine (254 L, 267 mg, 1.62 mmol) in DCM (5.0 mL) under 
nitrogen. After 30 minutes, NaBH3CN (129 mg, 2.06 mmol) was added 
portionwise and the reaction was stirred overnight at room temperature. The 
reaction was then quenched with an aq. sat. solution of NaHCO3 (3 mL), 
followed by NH4Cl (3 mL). The reaction mixture was extracted with DCM (3  5 
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mL), and the combined organic layers dried over MgSO4, concentrated under 
vacuum and purified by flash column chromatography (hexane/ethyl acetate 
1:1) to afford keto-enamine 3.80 (121 mg, 40%) as a brown oil. 
Rf 0.18 (hexane/ethyl acetate 1:1); H (400 MHz, CDCl3): 2.04 (s, 3H, CH3), 3.79 
(s, 3H, OCH3), 4.30 (d, 2H, J 5.6 Hz, CH2), 5.02 (d, 1H, J 7.4 Hz, H3), 6.69 (dd, 
1H, J 7.4 and 12.8 Hz, H4), 6.86 (d, 2H, J 8.7 Hz, HAr), 7.16 (d, 2H, J 8.7 Hz, 
HAr), 9.99 (brs, 1H, NH); C (126 MHz, CDCl3): 29.1 (CH3), 52.0 (CH2), 55.3 
(OCH3), 94.3 (CH, C3), 114.2 (CHAr), 128.6 (CHAr), 129.9 (CAr), 152.3 (CH, 
C4), 159.1 (CAr), 197.7 (C=O); max/cm
-1 (neat) 3225, 3020, 2957, 2935, 2897, 
2847, 1613 (C=O), 1575, 1532, 1510, 1242; m/z (AP+) 206 ([M+H]+, 80%), 121 
(100%); HRMS calc. for C12H16NO2 206.1176, found 206.1176 [M+H]
+. 
 
 
4-(Trimethylsilyl)but-3-yn-2-one 3.83 
 
 
Following the procedure of Holeman and co-workers:165 Trimethylsilylacetylene 
(719 L, 500 mg, 5.09 mmol) was added dropwise to a stirred solution of 
ethylmagnesium chloride (2.55 mL of a 2 M solution in THF, 5.09 mmol,) in THF 
(5.0 mL) at 0 ºC under nitrogen (evolution of ethane gas observed). After 20 
minutes acetic anhydride 3.81 (962 L, 1.0 g, 10.18 mmol) was added dropwise 
and the reaction mixture was allowed to warm to room temperature and stirred 
overnight. The reaction was quenched with water (5 mL) and neutralised with 
5% aq. HCl. The organic layer was washed with an aq. sat. solution of NaHCO3 
(3  5 mL), dried over MgSO4, concentrated under vacuum and purified by flash 
column chromatography (hexane/ethyl acetate 19:1) to yield 4-
(trimethylsilyl)but-3-yn-2-one 3.83 (90 mg, 13%) as a clear oil  and byproduct 
3.84  (1.1 g, 75%) as a white solid. 
Rf  0.53 (hexane/ethyl acetate 9:1); H (500 MHz, CDCl3): 0.22 (s, 9H, Si(CH3)3), 
2.32 (s, 3H, CH3); C (126 MHz, CDCl3): -0.6 (CH3), 32.7 (CH3), 97.5 (C≡C), 
102.6 (C≡C), 184.6 (C=O). Data in agreement with literature.168 
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3-Methyl-1,5-bis(trimethylsilyl)penta-1,4-diyn-3-yl acetate 3.84 
 
 
Rf 0.45 (hexane/ethyl acetate 9:1) ; mp = 34-37 ºC ; H (500 MHz, CDCl3): 0.12 
(s, 18H, Si(CH3)3), 1.82 (s, 3H, CH3), 2.01 (s, 3H, CH3); C (126 MHz, CDCl3): 
0.0 (CH3), 21.8 (CH3), 31.2 (CH3), 64.7 (C), 89.3 (C, C≡C), 102.6 (C, C≡C), 
168.1 (C=O); max/cm
-1 (neat) 3007, 2958, 2900, 2185, 1751 (C=O), 1410, 
1367, 1249, 1224, 1203; m/z (AP+) 281 ([M+H]+, 60%), 220 (100%); HRMS 
calc. for C14H25O2Si2 281.1388, found 281.1392 [M+H]
+. 
 
 
 
tert-Butyl (2-nitrophenyl)sulfonylcarbamate 
 
 
Following the procedure of Fukuyama and co-workers:207 Boc2O (2.7 g, 12.34 
mmol) was added to a stirred solution of 2-nitrobenzenesulfonamide (2.1 g, 
10.29 mmol) and NEt3 (2.2 mL, 1.6 g, 15.43 mmol) in DCM (22 mL) at room 
temperature under nitrogen. DMAP (126 mg, 1.03 mmol) was added and after 
30 minutes the reaction mixture was quenched with an aq. sat. solution of 
NH4Cl. The organic phase was extracted with diethyl ether (3  20 mL), the 
combined organic layers dried over MgSO4 and concentrated under vacuum to 
yield tert-butyl (2-nitrophenyl)sulfonylcarbamate (3.0 g, 97%) as a white solid. 
Rf 0.61 (ethyl acetate/hexane 1:1) ; mp = 191-193 ºC [lit.
208 194-196 ºC]; H 
(400 MHz, CDCl3): 1.43 (s, 9H, CH3), 7.57 (brs, 1H, NH), 7.79-7.81 (m, 2H, 
HAr), 7.86-7.87 (m, 1H, HAr), 8.33-8.37 (m, 1H, HAr); C (101 MHz, CDCl3): 
27.9 (CH3), 84.8 (C), 125.1 (CHAr), 132.4 (CHAr), 133.3 (CHAr), 134.7 (CHAr), 
147.6 (CAr), 150.1 (C=O). Data in agreement with literature.208 
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tert-Butyl but-3-yn-2-yl((2-nitrophenyl)sulfonyl)carbamate 3.85 
 
 
Triphenylphosphine (1.7 g, 6.27 mmol) and tert-butyl (2-
nitrophenyl)sulfonylcarbamate (1.5 g, 5.02 mmol) were added to a stirred 
solution of but-3-yn-2-ol 3.55 (293 mg, 4.18 mmol) in THF (14 mL) under 
nitrogen. The reaction mixture was cooled to 0 ºC and DEAD (993 L, 1.1 g, 
6.27 mmol) was added very slowly. After 2.5 h, a further 0.2 eq of tert-butyl (2-
nitrophenyl)sulfonylcarbamate (253 mg, 0.84 mmol) and triphenylphosphine 
(219 mg, 0.84mmol) were added and the reaction mixture stirred for 1 h. The 
solvent was removed under vacuum, diethyl ether was added and the solution 
was kept in the fridge overnight. The white solid was filtered off, the filtrate was 
concentrated under vacuum and purified by flash column chromatography 
(hexane/ethyl acetate 1:1) to yield 3.85 (1.5 g, 96%) as a white solid. 
Rf 0.26 (hexane/ethyl acetate 4:1); mp = 82-84 ºC ; H (400 MHz, CDCl3): 1.42 
(s, 9H, CH3), 1.75 (d, 3 H, J 7.0 Hz, CH3), 2.41 (d, 1H, J 2.5 Hz, H4), 5.28 (dq, 
1H, J 2.5 and 7.0 Hz, H2), 7.72-7.81 (m, 3H, HAr), 8.29-8.34 (m, 1H, HAr); C 
(100 MHz, CDCl3): 21.8 (CH3), 27.9 (CH3), 46.0 (CH, C2), 71.4 (C, C≡C), 82.0 
(CH, C≡CH), 85.7 (C), 124.6 (CHAr), 132.0 (CHAr), 133.0 (CHAr), 133.7 (CAr), 
134.2 (CHAr), 147.9 (CAr), 149.7 (C=O); max/cm
-1 (neat) 3282, 3110, 3082, 
2990, 2940, 2122, 1732 (C=O), 1544, 1366, 1251, 1125; m/z (AP+) 355 
([M+H]+, 30%), 299 ([M-C(CH3)3]
+, 100%); HRMS calc. for C15H19O6N2S 
355.0958, found 355.0961 [M+H]+. 
 
 
N-(But-3-yn-2-yl)-N-(cyanomethyl)-2-nitrobenzenesulfonamide 3.86 
 
 
NaH (142 mg of a 60% dispersion in oil, 3.56 mmol,) was added to a stirred 
solution of amine 3.77 (696 mg, 2.74 mmol) in DMF (11 mL), at 0 ºC under 
nitrogen. After 1 h, 2-bromoacetonitrile (286 L, 493 mg, 4.11 mmol) was added 
dropwise and the reaction mixture was stirred for an additional 30 minutes. The 
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reaction was quenched with an aq. sat. solution of NH4Cl (20 mL), extracted 
with ethyl acetate (3  20 mL), the combined organic layers were dried over 
MgSO4, concentrated under vacuum and purified by flash column 
chromatography (hexane/ethyl acetate 7:3) to yield 3.86  (743 mg, 93%) as a 
yellow oil. 
Rf 0.32 (ethyl acetate/hexane 2:3); H (500 MHz, CDCl3): 1.62 (d, 3H, J 7.0 Hz, 
CH3), 2.43 (d, 1H, J 2.0 Hz, H4), 4.34 (d, 1H, J 18.5 Hz, NCHH’), 4.47 (d, 1H, J 
18.5 Hz, NCHH’),  4.95 (dq, 1H, J 2.0 and 7.0 Hz, H2), 7.73-7.80 (m, 3H, HAr), 
8.10-8.12 (dd, 1H, J 1.6 and 7.3 Hz, HAr); C (126 MHz, CDCl3): 21.6 (CH3), 
32.0 (CH2), 47.1 (CH, C2), 75.6 (CH, C≡CH), 79.6 (C, C≡C), 115.9 (C, C≡N), 
125.1 (CHAr), 131.5 (CHAr), 132.1 (CAr), 132.7 (CHAr), 135.0 (CHAr), 148.2 
(CAr); max/cm
-1 (neat) 3288, 3003, 2964, 2944, 2116, 1541, 1372, 1350, 1335, 
1156; m/z (AP+) 294 ([M+H]+, 100%); HRMS calc. for C12H11N3O4SNa 
316.0362, found 316.0364 [M+Na]+. 
 
 
N-(But-3-yn-2-yl)-2-nitro-N-(prop-2-yn-1-yl)benzenesulfonamide 3.89 
 
 
NaH (82 mg of a 60% dispersion in oil, 2.05 mmol) was added to a stirred 
solution of amine 3.77 (401 mg, 1.58 mmol) in DMF (6.6 mL), at 0 ºC under 
nitrogen. After 1 h propargyl bromide (527 L of an 80% solution in toluene, 
4.73 mmol) was added dropwise and the reaction mixture stirred for 7.5 h. The 
reaction was quenched with an aq. sat. solution of NH4Cl (10 mL), extracted 
with ethyl acetate (3  10 mL), and the combined organic layers dried over 
MgSO4, concentrated under vacuum and purified by flash column 
chromatography (hexane/ethyl acetate 4:2) to yield 3.89 (418 mg, 91%) as a 
yellow oil. 
Rf 0.35 (ethyl acetate/hexane 7:3); H (400 MHz, CDCl3): 1.63 (d, 3H, J 7.0 Hz, 
CH3), 2.19 (t, 1H, J 2.5 Hz, C≡CH), 2.35 (d, 1H, J 2.3 Hz, H4), 4.18 (dd, 1H, J 
2.5 and 18.6 Hz, NCHH’), 4.35 (dd, 1H, J 2.5 and 18.6 Hz, NCHH’),  4.94 (dq, 
1H, J 2.3 and 7.0 Hz, H2), 7.67-7.74 (m, 3H, HAr), 8.11-8.14 (dd, 1H, J 1.6 and 
7.3 Hz, HAr); C (100 MHz, CDCl3): 22.1 (CH3), 34.0 (CH2), 47.0 (CH, C2), 73.3 
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(CH, C≡CH), 74.2 (CH, C≡CH), 74.5 (C, C≡C), 80.9 (C, C≡C), 124.6 (CHAr), 
131.2 (CHAr), 132.2 (CHAr), 133.2 (CAr), 134.2 (CHAr), 148.3 (CAr); max/cm
-1 
(neat) 3304, 3286, 3096, 2998, 2940, 2918, 2114, 1539, 1445, 1369, 1351, 
1338, 1153; m/z (AP+) 293 ([M+H]+, 100%); HRMS calc. for C13H13N2O4S 
293.0591, found 293.0593 [M+H]+. 
 
 
N-(But-3-yn-2-yl)-N-((2-nitrophenyl)sulfonyl)pent-4-ynamide 3.90 
 
 
NaH (40.9 mg of a 60% dispersion in oil, 1.02 mmol) was added to a stirred 
solution of amine 3.30 (200 mg, 0.79 mmol) in THF (3.0 mL), at 0 ºC under 
nitrogen. After 1 h pent-4-ynoyl chloride (138 mg, 1.18 mmol) was added and 
the reaction mixture stirred for 8 h at 0 ºC. The reaction mixture was quenched 
with an aq. sat. solution of NH4Cl (5 mL), extracted with DCM (3  5 mL), and 
the combined organic layers dried over MgSO4, concentrated under vacuum 
and purified by flash column chromatography (hexane/ethyl acetate 4:2) to yield 
3.90 (103 mg, 39%) as a colourless oil and RSM 3.77 (90 mg, 45%). 
Rf 0.34 (hexane/ethyl acetate 7:3); H (500 MHz, CDCl3): 1.72 (d, 3H, J 6.8 Hz, 
CH3), 1.95 (t, 1H, J 2.7 Hz, C≡CH), 2.39 (d, 1H, J 2.5 Hz, H4), 2.50-2.55 (m, 
2H, CH2C≡C), 2.91 (dt, 1H, J 17.4 and 7.3 Hz, COCHH’), 3.16 (dt, 1H, J 17.4 
and 7.3 Hz, COCHH’), 5.24 (dq, 1H, J 2.5 and 6.8 Hz, H2), 7.78-7.81 (m, 2H, 
HAr), 7.86-7.88 (m, 1H, HAr),  8.30-8.32 (m, 1H, HAr); C (126 MHz, CDCl3): 
14.4 (CH3), 22.0 (CH2, CH2C≡CC), 37.1 (CH, C2), 45.8 (CH2, OCH2), 69.9 (CH, 
C≡CH), 73.5 (CH, C≡CH), 81.7 (C, C≡C), 82.4 (C, C≡C), 125.4 (CHAr), 132.9 
(CHAr), 133.1 (CHAr), 133.2 (CAr), 135.2 (CHAr), 148.1 (CAr), 171.8 (C=O); 
max/cm
-1 (neat) 3298, 3275, 3020, 2982, 2941, 2167, 1659 (C=O), 1539, 1421, 
1370, 1150; m/z (AP+) 335 ([M+H]+, 100%); HRMS calc. for C15H15N2O5S 
335.0712, found 335.0714 [M+H]+. 
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General procedure for the transition-metal catalysed [2+2+2] 
cyclotrimerisation reactions: 
 
CpCo(CO)2 (11 L, 15 mg, 0.08 mmol) was added to a stirred solution of amine 
3.86 (120 mg, 0.41 mmol) and diphenylacetylene 2.113g (219 mg, 1.23 mmol) 
in anhydrous chlorobenzene (2.3 mL, 0.18 M). The reaction was performed in a 
closed vessel with microwave irradiation at 150 ºC (300 W) for 15 minutes. The 
solvent was removed under vacuum and the residue purified by flash column 
chromatography (hexane/ethyl acetate 7:3) to yield bicycle 3.91g (22 mg, 11%) 
as a orange oil and RSM 3.86 (54mg, 54%). 
 
The percentage yield and the appearance of the compounds obtained in these 
cyclotrimerisation reactions are listed below. 
 
Compound No % yield mass (mg) Appearence 
3.94 37 62 Dark yellow oil 
3.96 6 9 Dark yellow oil 
3.97 12 12 Dark yellow oil 
3.98 50 46 Yellow oil 
3.99 20 20 Brown oil 
3.100 29 30 Brown oil 
3.101 12 31 Brown oil 
3.105 4 14 Yellow oil 
3.107g 70 104 Yellow oil 
3. 107h 4 5 Yellow oil 
3. 107a 12 18 Dark yellow oil 
3. 109a 61 141 Brown oil 
3. 107i 16 126 Dark yellow oil 
3. 109i 21 76 Brown oil 
3. 107k 9 15 Yellow oil 
3.110g 97 109 Yellow oil 
3.110k 
(1:1 isomer mix.) 
8 7 Yellow oil 
3.111a 31 34 Yellow oil 
3.112a 34 37 Yellow oil 
3.111b 30 49 Yellow oil 
3.112b 29 48 Yellow oil 
3.111d 20 38 Yellow oil 
3.112d 21 39 Yellow oil 
3.111e 27 50 Yellow oil 
3.112e 28 52 Yellow oil 
3.112f 28 60 Yellow oil 
3.121 15 12 Yellow oil 
Table XXXVII – Yield and appearance of compounds obtained through the 
[2+2+2] cyclotrimerisation of alkynes. 
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5-Methyl-6-((2-nitrophenyl)sulfonyl)-2,3-diphenyl-6,7-dihydro-5H-
pyrrolo[3,4-b]pyridine 3.91g 
 
 
Rf 0.31 (hexane/ethyl acetate 2:3); H (500 MHz, CDCl3): 1.71 (d, 3H, J 6.5 Hz, 
CH3), 4.86 (d, 1H, J 14.6 Hz, H7), 4.90 (dd, 1H, J 2.2 and 14.6 Hz, H7’), 5.47 
(dq, 1H, J 2.2 and 6.5, H5), 7.12-7.15 (m, 2H, HAr), 7.20-7.30 (m, 8H, HAr), 
7.53 (s, 1H, HAr), 7.62-7.65 (m, 1H, HAr), 7.67-7.73 (m, 2H, HAr), 8.08-8.10 (m, 
1H, HAr); C (126 MHz, CDCl3): 23.9 (CH3), 54.0 (CH2, C7), 61.3 (CH, C5), 
124.5 (CHAr), 127.7 (CHAr), 128.2 (CHAr), 128.3 (CHAr), 128.7 (CHAr), 129.8 
(CHAr), 130.1 (CHAr), 131.1 (CHAr), 131.9 (CHAr), 132.1 (CAr), 133.1 (CHAr), 
133.9 (CAr), 134.1 (CHAr),  136.0 (CAr), 139.7 (CAr), 139.7 (CAr), 154.5 (CAr), 
158.1 (CAr); max/cm
-1 (neat) 3056, 2988, 2928, 1546, 1432, 1354, 1264, 1167; 
m/z (AP+) 472 ([M+H]+, 100%); HRMS calc. for C26H22N2O4S 472.1326, found 
472.1314 [M+H]+. 
 
 
1-Methyl-2-((2-nitrophenyl)sulfonyl)-5,6-diphenylisoindoline 3.94 
 
 
Rf 0.41 (hexane/ethyl acetate 7:3); H (500 MHz, CDCl3): 1.69 (d, 3H, J 6.1 Hz, 
CH3), 4.90 (dd, 1H, J 1.6 and 14.0 Hz, H3), 4.94 (d, 1H, J 14.0 Hz, H3’), 5.38 (q, 
1H, J 6.1, H1), 7.08-7.11 (m, 4H, HAr), 7.19-7.22 (m, 6H, HAr), 7.23 (s, 1H, 
HAr), 7.28 (s, 1H, HAr), 7.62-7.65 (m, 1H, HAr), 7.68-7.73 (m, 2H, HAr), 8.04-
8.07 (m, 1H, HAr); C (126 MHz, CDCl3): 23.8 (CH3), 53.8 (C3), 62.5 (C1), 124.5 
(CHAr), 124.6 (CHAr), 124.8 (CHAr), 127.0 (CHAr), 128.2 (CHAr), 130.0 
(CHAr), 130.6 (CHAr), 131.9 (CHAr), 132.5 (CAr), 133.9 (CHAr), 134.1 (CAr),  
141.0 (CAr), 141.0 (CAr), 141.1 (CAr), 141.1 (CAr), 141.2 (CAr), 148.8 (CAr); 
max/cm
-1 (neat) 3104, 3029, 2929, 2854, 1539, 1479, 1371, 1355, 1170; m/z 
(AP+) 471 [M+H]+, 100%; HRMS calc. for C27H23N2O4S 471.1373, found 
471.1365 [M+H]+. 
200 
  
6-(4-Fluorophenyl)-3-methyl-2-((2-nitrophenyl)sulfonyl)-2,3-dihydro-1H-
pyrrolo[3,4-c]pyridine 3.6 
 
Rf 0.47 (hexane/ethyl acetate 1:1); H (400 MHz, CDCl3): 1.65 (d, 3H, J 6.3 Hz, 
CH3), 4.85 (dd, 1H, J 1.8 and 15.2 Hz, H1), 4.94 (d, 1H, J 15.2 Hz, H1’), 5.37 
(dq, 1H, J 1.8 and 6.3, H3), 7.12-7.17 (m, 2H, HAr), 7.56 (s, 1H, H7), 7.63-7.65 
(m, 1H, HAr), 7.70-7.73 (m, 2H, HAr), 7.91-7.94 (m, 2H, HAr), 8.05-8.08 (m, 1H, 
HAr). 8.51 (s, 1H, H4); C (101 MHz, CDCl3): 23.4 (CH3), 53.3 (CH2, C1), 60.7 
(CH, C3), 114.1 (CHAr, C7), 115.8 (d, J 21.6 Hz, CHAr), 124.4 (CHAr), 128.8 
(d, J 8.4 Hz, CHAr), 130.6 (CHAr), 131.8 (CHAr), 132.2 (CAr), 134.0 (CHAr), 
134.9 (d, J 3.2 Hz, CAr), 136.0 (CAr), 143.9 (CHAr, C4), 145.3 (CAr), 156.2 
(CAr), 162.4 (CAr), 164.9 (CAr); max/cm
-1 (neat) 3083, 2918, 2850, 1614, 1602, 
1536, 1513, 1475, 1366, 1339, 1300, 1212, 1157, 1135, 1096; m/z (AP+) 414 
([M+H]+, 100%); HRMS calc. for C20H16N3O4FS 414.0918, found 414.0915 
[M+H]+. 
 
 
6-(4-Fluorophenyl)-1-methyl-2-((2-nitrophenyl)sulfonyl)-2,3-dihydro-1H-
pyrrolo[3,4-c]pyridine 3.97 
 
 
Rf 0.27 (hexane/ethyl acetate 1:1); H (400 MHz, CDCl3): 1.65 (d, 3H, J 6.4 Hz, 
CH3), 4.83-4.96 (m, 2H, H3, H3’), 5.36 (q, 1H, J 6.4, H1), 7.12-7.18 (m, 2H, 
HAr), 7.49 (s, 1H, H7), 7.62-7.65 (m, 1H, HAr), 7.68-7.75 (m, 2H, HAr), 7.91-
7.96 (m, 2H, HAr), 8.05-8.07 (m, 1H, HAr). 8.56 (s, 1H, H4); C (101 MHz, 
CDCl3): 23.0 (CH3), 51.7 (CH2, C3), 62.0 (CH, C1), 113.9 (CHAr, C7), 115.8 (d, 
J 21.6 Hz, CHAr), 124.4 (CHAr), 128.8 (d, J 8.4 Hz, CHAr), 129.4 (CAr), 130.6 
(CHAr), 131.8 (CHAr), 132.0 (CAr), 134.0 (CHAr), 135.0 (d, J 3.1 Hz, CAr), 
144.0 (CHAr, C4), 151.7 (CAr), 156.3 (CAr), 162.4 (CAr), 164.9 (CAr); max/cm
-1 
(neat) 3075, 2920, 2849, 1614, 1601, 1539, 1487, 1372, 1353, 1341, 1215, 
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1170, 1125, 1083; m/z (AP+) 414 ([M+H]+, 100%); HRMS calc. for 
C20H16N3O4FS 414.0918, found 414.0915 [M+H]
+. 
 
 
2,3,5-Triphenyl-5,7-dihydrofuro[3,4-b]pyridine 3.98 
 
 
Rf 0.21 (hexane/ethyl acetate 9:1); H (500 MHz, CDCl3): 5.31 (d, 1H, J 13.4 Hz, 
H7), 5.43 (dd, 1H, J 1.2 and 13.4 Hz, H7’), 6.32 (s, 1H, H5), 7.11-7.12 (m, 2H, 
HAr), 7.23-7.26 (m, 6H, HAr), 7.34-7.36 (m, 2H, HAr), 7.39-7.44 (m, 6H, HAr); 
C (126 MHz, CDCl3): 73.1 (CH2, C7), 85.1 (CH, C5), 127.0 (CHAr), 127.5 
(CHAr), 128.1 (CHAr), 128.2 (CHAr), 128.5 (CHAr), 128.7 (CHAr), 129.0 
(CHAr), 129.9 (CHAr), 130.2 (CHAr), 133.0 (CHAr), 134.1 (CAr), 135.4 (CAr),  
140.1 (CAr), 140.1 (CAr), 141.5 (CAr), 157.8 (CAr), 159.6 (CAr); max/cm
-1 
(neat) 3055, 3030, 2852, 1602, 1556, 1493, 1449, 1429, 1398, 1354, 1038, 
1025; m/z (AP+) 350 ([M+H]+, 100%); HRMS calc. for C25H19NO 350.1539, 
found 350.1537 [M+H]+. 
 
 
5-Phenyl-2,3-bis(trimethylsilyl)-5,7-dihydrofuro[3,4-b]pyridine 3.99 
 
 
Rf 0.24 (hexane/ethyl acetate 4:1); H (500 MHz, CDCl3): 0.32 (s, 9H, CH3), 0.39 
(s, 9H, CH3), 5.17 (d, 1H, J 13.1 Hz, H7), 5.30 (dd, 1H, J 2.1 and 13.1 Hz, H7’), 
6.19 (s, 1H, H5), 7.30-7.39 (m, 5H, HAr), 7.48 (s, 1H, HAr); C (126 MHz, 
CDCl3): 1.5 (CH3), 1.6 (CH3), 73.4 (CH2, C7), 85.3 (CH, C5), 127.0 (CHAr), 
128.4 (CHAr), 128.9 (CHAr), 132.4 (CAr), 134.9 (CHAr), 139.4 (CAr), 141.8 
(CAr), 159.5 (CAr), 174.0 (CAr); max/cm
-1 (neat) 2955, 2900, 1596, 1578, 1449, 
1250; m/z (AP+) 340 ([M-H]+, 40%), 286 (100%); HRMS calc. for C19H27N1OSi2 
340.1547, found 340.1546 [M-H]+.  
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Diethyl 5-phenyl-5,7-dihydrofuro[3,4-b]pyridine-2,3-dicarboxylate 3.5100 
 
 
Rf 0.46 (hexane/ethyl acetate 7:3); H (500 MHz, CDCl3): 1.34 (t, 3H, J 7.1 Hz, 
CH3), 1.42 (t, 3H, J 7.2 Hz, CH3), 4.31-4.38 (m, 2H, OCH2), 4.47 (q, 2H, J 7.2 
Hz, OCH2), 5.23 (dd, 1H, J 1.6 and 14.5 Hz, H7), 5.36 (dd, 1H, J 2.3 and 14.5 
Hz, H7’), 6.25 (s, 1H, H5), 7.31-7.33 (m, 2H, HAr), 7.36-7.42 (m, 3H, HAr), 7.83 
(s, 1H, HAr); C (126 MHz, CDCl3): 14.2 (CH3), 14.3 (CH3), 62.4 (OCH2), 62.7 
(OCH2), 72.8 (CH2, C7), 84.8 (CH, C5), 125.7 (CAr), 127.0 (CHAr), 129.1 
(CHAr), 129.2 (CHAr), 132.3 (CHAr), 137.2 (CAr), 140.4 (CAr), 152.0 (CAr), 
163.8 (C), 165.3 (C=O), 166.5 (C=O); max/cm
-1 (neat) 3055, 2985, 2865, 1726 
(C=O), 1606, 1571, 1422, 1372, 1265; m/z (AP+) 342 ([M+H]+, 100%); HRMS 
calc. for C19H20NzO5 342.1336, found 342.1338 [M+H]
+. 
 
 
Tetraethyl 6-((phenyl(2,3,4,5-
tetrakis(ethoxycarbonyl)phenyl)methoxy)methyl)pyridine-2,3,4,5-
tetracarboxylate 3.101 
 
 
Rf 0.18 (hexane/ethyl acetate 7:3); H (500 MHz, CDCl3): 1.12 (t, 3H, J 7.1 Hz, 
CH3), 1.16 (t, 3H, J 7.2 Hz, CH3), 1.30-1.39 (m, 18H, CH3), 3.93-4.04 (m, 2H, 
OCH2), 4.09-4.22 (m, 2H, OCH2), 4.25-4.43 (m, 12H, OCH2), 4.79 (d, 1H, J 12.2 
Hz, OCHH’), 4.82 (d, 1H, J 12.2 Hz, OCHH’), 5.85 (s, 1H, CH), 7.22-7.29 (m, 
5H, CHAr), 8.26 (s, 1H, CHAr); C (126 MHz, CDCl3):13.8 (CH3), 13.9 (CH3), 
14.0 (CH3), 14.0 (CH3), 14.1 (CH3), 14.2 (CH3), 14.2 (CH3), 14.3 (CH3), 62.2 
(CH2), 62.3 (CH2), 62.4 (CH2), 62.6 (CH2), 62.6 (CH2), 62.8 (CH2), 62.9 (CH2), 
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63.0 (CH2), 71.2 (CH2), 80.2 (CH), 127.6 (CAr), 128.0 (CHAr), 128.5 (CHAr), 
128.7 (CHAr), 129.2 (CAr), 130.7 (CAr), 131.0 (CHAr), 131.3 (CAr), 134.4 
(CAr), 135.6 (CAr), 139.1 (CAr), 140.7 (CAr), 141.7 (CAr), 148.1 (CAr), 157.7 
(CAr), 164.2 (C=O), 164.5 (C=O), 164.9 (C=O), 165.1 (C=O), 165.2 (C=O), 
165.7 (C=O), 166.5 (C=O), 167.0 (C=O); max/cm
-1 (neat) 2984, 2940, 2904, 
1726 (C=O), 1567, 1227, 1190, 1094, 1016; m/z (AP+) 852 ([M+H]+, 100%); 
HRMS calc. for C43H50NO17 852.3073, found 852.3064 [M+H]
+. 
 
 
4-(Dimethyl(phenyl)silyl)-2,5-diphenyl-5,7-dihydrofuro[3,4-b]pyridine 3.105 
 
 
Rf 0.54 (hexane/ethyl acetate 9:1); H (500 MHz, CDCl3): 0.07 (s, 3H, CH3), 0.33 
(s, 3H, CH3), 5.11 (d, 1H, J 13.4 Hz, H7), 5.25 (dd, 1H, J 2.1 and 13.4 Hz, H7’), 
5.92 (d, 1H, J 2.1 Hz, H5), 6.91 (d, 2H, J 7.0 Hz, HAr), 7.23-7.36 (m, 7H, HAr), 
7.40-7.51 (m, 4H, CHAr), 7.74 (s, 1H, HAr), 7.97 (d, 2H, J 7.3 Hz, HAr); C (126 
MHz, CDCl3): -3.0 (CH3), -1.9 (CH3), 72.0 (CH2, C7), 85.9 (CH, C5), 126.2 
(CHAr, C3), 127.3 (CHAr), 128.3 (CHAr), 128.8 (CHAr), 129.0 (CHAr), 129.0 
(CHAr), 129.0 (CHAr), 129.2 (CHAr), 129.9 (CHAr), 134.4 (CHAr), 136.0 (CAr), 
138.1 (CAr), 139.6 (CAr), 141.1 (CAr), 144.2 (CAr), 156.9 (CAr), 160.5 (CAr); 
max/cm
-1 (neat) 2953, 2998, 1592, 1574, 1450, 1248; m/z (ES+) 408 [M+H]+, 
100%. The sample decomposed before HRMS could be obtained. 
 
 
5-Methyl-2,3-diphenyl-7,8-dihydro-5H-pyrano[4,3-b]pyridine 3.107g 
 
Rf 0.34 (hexane/ethyl acetate 4:2); H (500 MHz, CDCl3): 1.60 (d, 3H, J 6.5 Hz, 
CH3), 3.00 (td, 1H, J 17.1 and 3.0 Hz, H8), 3.24-3.32 (m, 1H, H8’), 3.97 (ddd, 
1H, J 3.8, 10.5 and 11.5 Hz, H7), 4.33 (ddd, 1H, J 3.0, 5.9 and 11.5 Hz, H7’), 
4.93 (q, 1H, J 6.5 Hz, H5), 7.13-7.17 (m, 2H, HAr), 7.21-7.28 (m, 6H, HAr), 
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7.31-7.35 (m, 2H, HAr), 7.42 (s, 1H, H4); C (126 MHz, CDCl3): 21.6 (CH3), 32.4 
(CH2, C8), 64.4 (CH2, C7), 72.0 (CH, C5), 127.3 (CHAr), 127.9 (CHAr), 128.2 
(CHAr), 128.5 (CHAr), 129.8 (CHAr), 130.1 (CHAr) 133.7 (CAr), 134.3 (CAr), 
135.2 (CHAr, C4), 140.1 (CAr), 140.1 (CAr), 152.7 (CAr), 155.4 (CAr); max/cm
-1 
(neat) 3056, 2974, 2932, 2852, 1545, 1449, 1428, 1372, 1113; m/z (AP+) 302 
([M+H]+, 100%); HRMS calc. for C21H20NO 302.1540, found 302.1539 [M+H]
+.  
 
5-Methyl-2,3-bis(trimethylsilyl)-7,8-dihydro-5H-pyrano[4,3-b]pyridine 
3.107h 
 
 
Rf 0.52 (hexane/ethyl acetate 9:1); H (500 MHz, CDCl3): 0.35 (s, 9H, CH3), 0.36 
(s, 9H, CH3), 1.51 (d, 3H, J 6.5 Hz, CH3), 2.84 (dt, 1H, J 17.0 and 2.9 Hz, H8), 
3.10-3.18 (m, 1H, H8’), 3.88 (ddd, 1H, J 3.8, 10.9 and 11.5 Hz, H7), 4.24 (ddd, 
1H, J 2.9, 5.9 and 11.5 Hz, H7’), 4.81 (q, 1H, J 6.5 Hz, H5), 7.48 (s, 1H, H4); C 
(126 MHz, CDCl3): 1.3 (CH3), 1.5 (CH3), 21.4 (CH3), 32.6 (CH2, C8), 64.6 (CH2, 
C7), 72.0 (CH, C5), 132.2 (CAr) 137.1 (CHAr, C4), 138.3 (CAr), 152.4 (CAr), 
171.5 (CAr); max/cm
-1 (neat) 3051, 2960, 1535, 1420, 1373, 1264; m/z (ES+) 
326 (100%), 294 ([M+H]+, 25%), 292 [M-H]+, 70%. The sample decomposed 
before HRMS could be obtained. 
 
Diethyl 5-methyl-7,8-dihydro-5H-pyrano[4,3-b]pyridine-2,3-dicarboxylate 
3.107a 
 
 
Rf 0.45 (hexane/ethyl acetate 7:3); H (500 MHz, CDCl3): 1.37 (t, 3H, J 7.2 Hz, 
CH3), 1.40 (t, 3H, J 7.2 Hz, CH3), 1.57 (d, 3H, J 6.6 Hz, CH3), 2.94-2.99 (m, 1H, 
H8), 3.19-3.26 (m, 1H, H8’), 3.88 (td, 1H, J 3.8, 11.5, H7), 4.27 (ddd, 1H, J 2.9, 
6.0 and 11.5 Hz, H7’), 4.37 (q, 1H, J 7.2 Hz, OCH2), 4.45 (q, 1H, J 7.2 Hz, 
OCH2), 4.86 (q, 1H, J 6.6 Hz, H5), 7.92 (s, 1H, H4); C (126 MHz, CDCl3): 14.2 
(CH3), 14.3 (CH3), 21.3 (CH3), 32.6 (CH2, C8), 62.1 (OCH2), 62.4 (OCH2), 63.6 
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(CH2, C7), 71.8 (CH, C5), 134.0 (CHAr, C4), 134.4 (CAr), 136.6 (CAr), 149.9 
(CAr), 157.6 (CAr), 165.2 (C=O), 166.8 (C=O); max/cm
-1 (neat) 2999, 2978, 
2867, 1741 (C=O), 1607, 1565, 1427, 1370, 1261; m/z (AP+) 294 [M+H]+, 
100%; HRMS calc. for C15H20NO5 294.1336, found 294.1338 [M+H]
+. 
 
Tetraethyl 5-(1-(2-cyanoethoxy)ethyl)benzene-1,2,3,4-tetracarboxylate 
3.109a 
 
 
Rf 0.22 (hexane/ethyl acetate 7:3); H (500 MHz, CDCl3): 1.30-1.37 (m, 12H, 
CH3), 1.47 (d, 1H, J 6.4 Hz, CH3), 2.55 (t, 2H, J 6.2 Hz, CH2C≡N), 3.42-3.50 (m, 
2H, OCHH’), 4.28 (q, 2H, J 7.2 Hz, OCH2), 4.27-4.37 (m, 6H, OCH2), 4.66 (q, 
1H, J 6.4 Hz, CH), 8.18 (s, 1H, HAr); C (126 MHz, CDCl3): 14.0 (CH3), 14.2 
(CH3), 14.3 (CH3), 19.1 (CH2, CH2CN), 23.4 (CH3), 62.3 (OCH2), 62.4 (OCH2), 
62.5 (OCH2), 62.7 (OCH2), 63.9 (CH2), 75.4 (CH), 117.8 (C, C≡N), 130.4 
(CHAr), 130.5 (CAr), 131.7 (CAr), 134.7 (CAr), 135.5 (CAr), 143.3 (CAr), 164.8 
(C=O), 165.5 (C=O), 166.8 (C=O), 167.0 (C=O); max/cm
-1 (neat) 2983, 2939, 
2904, 2252, 1725 (C=O), 1235, 1194, 1178, 1156, 1099, 1019; m/z (AP+) 464 
([M+H]+, 100%); HRMS calc. for C23H33N2O9 481.2191, found 481.2185 
[M+NH4]
+. 
 
Di-tert-butyl 5-methyl-7,8-dihydro-5H-pyrano[4,3-b]pyridine-2,3-
dicarboxylate 3.107i 
 
 
Rf 0.49 (hexane/ethyl acetate 7:3); H (500 MHz, CDCl3): 1.57 (d, 3H, J 6.6 Hz, 
CH3), 1.58 (s, 6H, CH3), 1.60 (s, 6H, CH3), 1.62 (s, 6H, CH3), 2.91-2.96 (m, 1H, 
H8), 3.16-3.24 (m, 1H, H8’), 3.82-3.89 (m, 1H, H7), 4.23-4.29 (m, 1H, H7’), 
4.82-4.86 (m, 1H, H5), 7.74 (s, 1H, H4); C (126 MHz, CDCl3): 21.4 (CH3), 28.2 
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(CH3), 28.3 (CH3), 28.4 (CH3), 32.6 (CH2, C8), 63.8 (CH2, C7), 71.8 (CH, C5), 
82.7 (C), 83.1 (C), 133.6 (CAr), 133.9 (CHAr, C4), 135.8 (CAr), 150.8 (CAr), 
156.8 (CAr), 164.5 (C=O), 166.1 (C=O); max/cm
-1 (neat) 2979, 2935, 1718 
(C=O), 1368, 1302, 1278, 1245, 1170, 1118, 1094; m/z (AP+) 348 ([M-H]+, 
40%), 270 100%; 238 ([M-(2tBu)+H]+, 80%); HRMS calc. for C19H28NO5 
350.1962, found 350.1964 [M+H]+. 
 
 
Tetra-tert-butyl 5-(1-(2-cyanoethoxy)ethyl)benzene-1,2,3,4-tetracarboxylate 
3.109i 
 
 
Rf 0.57 (hexane/ethyl acetate 7:3); H (500 MHz, CDCl3): 1.48 (d, 1H, J 6.4 Hz, 
CH3), 1.55 (s, 9H, C(CH3)3), 1.57 (s, 9H, C(CH3)3), 1.58 (s, 9H, C(CH3)3), 1.59 
(s, 9H, C(CH3)3), 2.49-2.59 (m, 2H, CH2CN), 3.41-3.48 (m, 2H, OCHH), 4.71 (q, 
1H, J 6.4 Hz, CH), 7.84 (s, 1H, HAr); C (126 MHz, CDCl3): 19.2 (CH2, CH2CN), 
24.1 (CH3), 28.2 (CH3), 28.2 (CH3), 28.3 (CH3), 28.4 (CH3), 63.8 (CH2), 75.6 
(CH), 82.8 (C), 83.3 (C), 84.0 (C), 84.1 (C), 117.8 (C, C≡N), 127.8 (CHAr), 
133.5 (CAr), 133.7 (CAr), 134.0 (CAr), 134.6 (CAr), 142.0 (CAr), 164.7 (C=O), 
165.8 (C=O), 166.0 (C=O), 166.1 (C=O); max/cm
-1 (neat) 2981, 2935, 2253, 
1718 (C=O), 1368, 1251, 1184, 1107; m/z (AP+) 576 ([M+H]+, 5%),  354 (50%), 
294 (100%); HRMS calc. for C31H49N2O9 593.3433, found 593.3439 [M+NH4]
+. 
 
 
5-Methyl-2-(triisopropylsilyl)-7,8-dihydro-5H-pyrano[4,3-b]pyridine 3.107k 
 
 
Rf 0.54 (hexane/ethyl acetate 9:1); H (400 MHz, CDCl3): 1.09 (d, 9H, CH3), 
1.11 (d 9H, CH3) 1.41-1.48 (m, 3H, CH), 1.52 (d, 3H, J 6.5 Hz, CH3), 2.88 (td, 
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1H, J 16.8 and 3.2 Hz, H8), 3.17 (ddd, 1H, J 6.0, 10.4 and 16.8 Hz, H8’), 3.90 
(ddd, 1H, J 3.9, 10.5 and 11.5 Hz, H7), 4.25 (ddd, 1H, J 2.9, 6.0 and 11.5 Hz, 
H7’), 4.82 (q, 1H, J 6.5 Hz, H5), 7.22 (d, 1H, J 7.8 Hz, HAr), 7.75 (d, 1H, J 7.8 
Hz, HAr); C (100 MHz, CDCl3): 11.2 (CH), 18.9 (CH3), 21.4 (CH3), 33.0 (CH2, 
C8), 64.5 (CH2, C7), 72.1 (CH, C5), 128.5 (CHAr), 129.5 (CHAr), 133.3 (CAr), 
153.6 (CAr), 162.9 (CAr); max/cm
-1 (neat) 3059, 2944, 2896, 2865, 1463, 1373, 
1264; m/z (AP+) 306 ([M+H]+, 100%). The sample decomposed before HRMS 
could be obtained. 
 
 
Tri-isopropyl(phenylethynyl)silane 
 
 
 
Ethyl magnesium chloride (8.3 mL of a 2 M solution in THF, 16.6 mmol) was 
added dropwise to a stirred solution of phenyl acetylene (1.7 mL, 1.6 g, 15.48 
mmol) in THF (17.0 mL) at -78 ºC under nitrogen. After 1 h, TIPSCl (2.3 mL, 2.1 
g, 11.1 mmol) was added very slowly. The reaction mixture was allowed to 
warm to rt temperature and then heated under reflux overnight. The reaction 
was quenched with an aq. sat. solution of NH4Cl (20 mL), extracted with ethyl 
acetate (3  20 mL), and the combined organic layers dried over MgSO4, 
concentrated under vacuum and purified by flash column chromatography 
(hexane) to yield (2.1 g, 75%) as a colourless liquid. 
Rf 0.78 (hexane), H (500 MHz, CDCl3): 1.19 (brs, 18H, CH3), 1.21 (brs, 3H, 
CH3), 7.33-7.34 (m, 3H, HAr), 7.52-7.54 (m, 2H, HAr). C (126 MHz, CDCl3): 
11.6 (CH), 18.9 (CH3), 90.6 (C, C≡C), 107.4 (C, C≡C), 123.8 (CAr), 128.4 
(CHAr), 128.5 (CHAr), 132.3 (CHAr); max/cm
-1 (neat) 2942, 2864, 2156, 1488, 
1462, 1218; m/z (AP+) 517 ([dimer]+, 100%), 259 ([M+H]+, 15%),  217 ([M-
CH(CH3)2]
+, 70%); HRMS calc. for C17H30NSi 276.2142, found 276.2145 
[M+NH4]
+. 
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1,5,6-Triphenyl-1,3-dihydroisobenzofuran 3.110g 
 
 
Rf 0.57 (hexane/ethyl acetate 4:1); H (500 MHz, CDCl3): 5.32 (d, 1H, J 12.3 Hz, 
H3), 5.46 (dd, 1H, J 2.1 and 12.3 Hz, H3’), 6.27 (brs, 1H, H1), 7.07-7.09 (m, 2H, 
HAr), 7.11 (s, 1H, HAr), 7.15-7.18 (m, 5H, HAr), 7.20-7.23 (m, 3H, HAr), 7.32-
7.34 (m, 1H, HAr), 7.36-7.41 (m, 3H, HAr), 7.43-7.45 (m, 2H, HAr); C (126 
MHz, CDCl3): 73.4 (CH2, C3), 86.4 (CH, C1), 123.2 (CHAr), 124.5 (CHAr), 
126.8 (CHAr), 126.8 (CHAr), 127.2 (CHAr), 128.1 (CHAr), 128.2 (CHAr), 128.4 
(CHAr), 128.9 (CHAr), 130.1(CHAr), 138.8 (CAr), 140.6 (CAr), 140.7 (CAr), 
141.6 (CAr), 141.6 (CAr), 141.8 (CAr), 142.2 (CAr); max/cm
-1 (neat) 3063, 3026, 
2921, 2850, 1601, 1493, 1473, 1447, 1402, 1349, 1265; m/z (AP+) 349 ([M+H]+, 
100%); HRMS calc. for C26H21O 349.1587, found 3349.1585 [M+H]
+. 
 
 
1,5- and 1,6-Diphenyl-1,3-dihydroisobenzofuran 3.110k 
 
 
Rf 0.28 (hexane/ethyl acetate 9:1); H (500 MHz, CDCl3): 5.26 (d, 1H, J 12.1 Hz, 
CH), 5.28 (d, 1H, J 11.3 Hz, CH), 5.40 (dd, 1H, J 2.3 and 12.2 Hz, CH), 5.41 
(dd, 1H, J 2.1 and 12.1 Hz, CH), 6.22 (brs, 2H, CH), 7.11 (d, 1H, J 7.9 Hz, HAr), 
7.24 (s, 1H, HAr), 7.31-7.47 (m, 18H, HAr), 7.51-7.54 (m, 4H, HAr), 7.57-7.59 
(m, 2H, HAr); C (126 MHz, CDCl3): 73.4 (CH2), 73.5 (CH2), 86.3 (CH), 86.5 
(CH), 119.9 (CHAr), 121.3 (CHAr), 121.5 (CHAr), 122.8 (CHAr), 127.1 (CHAr), 
127.2 (CHAr), 127.2 (CHAr), 127.3 (CHAr), 127.4 (CHAr), 127.5 (CHAr), 127.6 
(CHAr), 127.6 (CHAr), 128.4 (CHAr), 128.4 (CHAr), 128.8 (CHAr), 129.0 
(CHAr), 129.0 (CHAr), 138.5 (CAr), 140.2 (CAr), 141.1 (CAr), 141.2 (CAr), 
141.2 (CAr), 141.4 (CAr), 142.2 (CAr), 142.3 (CAr), 143.1 (CAr); max/cm
-1 
(neat) 3021, 2857, 2870, 1613, 1484, 1456, 1320, 1271; m/z (ES+) 271 ([M-
H]+,100%); HRMS calc. for C20H20NO 273.1539, found 273.1536 [M+H]
+. 
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6-(4-Fluorophenyl)-3-phenyl-1,3-dihydrofuro[3,4-c]pyridine 3.111a 
 
 
Rf 0.33 (hexane/ethyl acetate 4:1); H (400 MHz, CDCl3): 5.23 (d, 1H, J 13.5 Hz, 
H1), 5.36 (dd, 1H, J 2.2 and 13.5 Hz, H1’), 6.27 (brs, 1H, H3), 7.15 (t, 2H, J 8.7 
Hz, HAr), 7.33-7.41 (m, 5H, HAr), 7.62 (s, 1H, H7), 7.94-7.97 (m, 2H, HAr), 8.39 
(s, 1H, H4); C (100 MHz, CDCl3): 72.8 (CH2, C1), 84.7 (CH, C3), 113.1 (CHAr, 
C7), 116.0 (d, J 21.7 Hz, CHAr), 127.0 (CHAr), 128.8 (CHAr), 129.0 (CHAr), 
129.1 (d, J 8.5 Hz, CHAr), 135.5 (d, J 3.1 Hz, CAr), 141.1 (CAr), 144.1 (CHAr, 
C4), 150.3 (CAr), 156.1 (CAr), 162.8 (CAr), 164.8 (CAr); max/cm
-1 (neat) 3035, 
2863, 1600, 1511, 1477, 1456, 1417, 1383, 1212, 1154; m/z (AP+) 292 ([M+H]+, 
100%); HRMS calc. for C19H15NOF 292.1132, found 292.1131 [M+H]
+. 
 
 
 
6-(4-Fluorophenyl)-1-phenyl-1,3-dihydrofuro[3,4-c]pyridine 3.112a 
 
 
Rf 0.21 (hexane/ethyl acetate 4:1); H (500 MHz, CDCl3): 5.29 (d, 1H, J 12.5 Hz, 
H3), 5.43 (d, 1H, J 12.5 Hz, H3’), 6.18 (s, 1H, H1), 7.09-7.13 (m, 2H, HAr), 7.35-
7.41 (m, 6H, HAr, H7), 7.88-7.92 (m, 2H, HAr), 8.65 (s, 1H, H4); C (126 MHz, 
CDCl3): 71.7 (CH2, C3), 86.0 (CH, C1), 114.2 (CHAr, C7), 115.9 (d, J 21.7 Hz, 
CHAr), 127.2 (CHAr), 128.9 (CHAr), 129.0 (CHAr), 129.1 (CHAr), 135.5 (d, J 
3.1 Hz, CAr), 140.7 (CAr), 142.9 (CHAr, C4), 152.8 (CAr), 156.2 (CAr), 162.7 
(CAr), 164.7 (CAr); max/cm
-1 (neat) 3063, 3027, 2856, 1599, 1512, 1475, 1224, 
1156; m/z (AP+) 292 ([M+H]+, 100%); HRMS calc. for C19H15NOF 292.1132, 
found 292.1132 [M+H]+. 
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3,6-Diphenyl-1,3-dihydrofuro[3,4-c]pyridine 3.111b 
 
 
Rf 0.30 (hexane/ethyl acetate 4:1); H (500 MHz, CDCl3): 5.24 (d, 1H, J 13.5 Hz, 
H1), 5.37 (dd, 1H, J 2.1 and 13.5 Hz, H1’), 6.28 (brs, 1H, H3), 7.33-7.44 (m, 6H, 
HAr), 7.48 (t, 2H, J 7.4 Hz, HAr),7.67 (s, 1H, H7), 7.98 (d, 2H, J 7.4 Hz, HAr), 
8.42 (s, 1H, H4); C (126 MHz, CDCl3): 72.8 (CH2, C1), 84.8 (CH, C3), 113.4 
(CHAr, C7), 127.1 (CHAr), 127.3 (CHAr), 128.8 (CHAr), 129.0 (CHAr), 129.3 
(CHAr), 136.9 (CAr), 139.3 (CAr), 141.2 (CAr), 144.1 (CHAr, C4), 150.2 (CAr), 
157.1 (CAr); max/cm
-1 (neat) 3061, 2919, 2853, 1605, 1565, 1474, 1449, 1385, 
1042, 1024; m/z (AP+) 274 ([M+H]+, 100%); HRMS calc. for C19H16NO 
2274.1226, found 274.1229 [M+H]+. 
 
  
 
1,6-Diphenyl-1,3-dihydrofuro[3,4-c]pyridine 3.112b 
 
 
Rf 0.17 (hexane/ethyl acetate 4:1); H (500 MHz, CDCl3): 5.29 (d, 1H, J 12.5 Hz, 
H3), 5.43 (dd, 1H, J 2.2 and 12.5 Hz, H3’), 6.19 (brs, 1H, H1), 7.33-7.45 (m, 9H, 
Har, H7), 7.92 (d, 2H, J 7.1 Hz, HAr), 8.68 (s, 1H, H4); C (126 MHz, CDCl3): 
71.7 (CH2, C3), 86.0 (CH, C1), 114.5 (CHAr, C7), 127.2 (CHAr), 127.3 (CHAr), 
128.8 (CHAr), 129.0 (CHAr), 129.1 (CHAr), 129.2 (CHAr), 134.0 (CAr), 139.4 
(CAr), 140.7 (CAr), 143.0 (CHAr, C4), 152.7 (CAr), 157.3 (CAr); max/cm
-1 (neat) 
3028, 2919, 2848, 1612, 1563, 1474, 1454, 1336, 1017; m/z (AP+) 274 ([M+H]+, 
100%); HRMS calc. for C19H16NO 2274.1226, found 274.1229 [M+H]
+. 
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6-(1H-Indol-3-yl)-3-phenyl-1,3-dihydrofuro[3,4-c]pyridine 3.111d 
 
 
Rf 0.43 (hexane/ethyl acetate 1:1); H (500 MHz, CD3COCD3): 5.19 (d, 1H, J 
13.4 Hz, H1), 5.36 (dd, 1H, J 1.8 and 13.4 Hz, H1’), 6.26 (brs, 1H, H3), 7.13-
7.20 (m, 2H, HAr), 7.31-7.34 (m, 1H, HAr), 7.39 (t, 2H, J 7.5 Hz, HAr), 7.44-7.49 
(m, 3H, HAr), 7.84 (s, 1H, H7), 8.05 (d, 1H, J 2.3 Hz, HAr), 8.36 (s, 1H, H4), 
8.95 (d, 1H, J 8.0 Hz, HAr), 10.64 (brs, 1H, NH); C (126 MHz, CD3COCD3): 
72.4 (CH2, C1), 84.3 (CH, C3), 111.8 (CHAr), 112.1 (CHAr, C7), 116.7 (CAr), 
120.3 (CHAr), 122.0 (CHAr), 122.1 (CHAr), 125.6 (CHAr), 126.0 (CAr), 126.7 
(CHAr), 128.1 (CHAr), 128.7 (CHAr), 134.9 (CAr), 137.7 (CAr), 142.8 (CAr), 
143.4 (CHAr, C4), 149.5 (CAr), 155.0 (CAr); max/cm
-1 (neat) 3170, 2964, 2921, 
2851, 1613, 1547, 1449, 1242, 1020; m/z (AP+) 313 ([M+H]+, 100%); HRMS 
calc. for C21H17N2O 313.1346, found 313.1340 [M+H]
+. 
 
 
6-(1H-Indol-3-yl)-1-phenyl-1,3-dihydrofuro[3,4-c]pyridine 3.112d 
 
 
Rf 0.23 (hexane/ethyl acetate 1:1); H (500 MHz, CD3COCD3): 5.22 (d, 1H, J 
12.2 Hz, H3), 5.40 (dd, 1H, J 1.9 and 12.2 Hz, H3’), 6.19 (brs, 1H, H1), 7.12-
7.18 (m, 2H, HAr), 7.30-7.33 (m, 1H, HAr), 7.38 (t, 2H, J 7.6 Hz, HAr), 7.45 (d, 
3H, J 7.5 Hz, HAr), 7.54 (s, 1H, H7), 7.96 (d, 1H, J 1.9 Hz, HAr), 8.50 (d, 1H, J 
7.8 Hz, HAr), 8.66 (s, 1H, H4), 10.59 (brs, 1H, NH); C (126 MHz, CD3COCD3): 
71.4 (CH2, C3), 85.4 (CH, C1), 111.8 (CHAr), 112.9 (CHAr, C7), 116.6 (CAr), 
120.3 (CHAr), 122.1 (CHAr), 122.2 (CHAr), 125.4 (CHAr), 126.0 (CAr), 126.9 
(CHAr), 128.2 (CHAr), 128.8 (CHAr), 131.5 (CAr), 137.6 (CAr), 142.2 (CAr), 
142.6 (CHAr, C4), 152.2 (CAr), 155.1 (CAr); max/cm
-1 (neat) 3305, 3132, 3062, 
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2925, 2856, 1613, 1543, 1448, 1266, 124, 1004; m/z (AP+) 313 ([M+H]+, 
100%); HRMS calc. for C21H17N2O 313.1335, found 313.1340 [M+H]
+. 
 
 
6-(3-Methoxyphenyl)-3-phenyl-1,3-dihydrofuro[3,4-c]pyridine 3.111e 
 
 
Rf 0.32 (hexane/ethyl acetate 4:1); H (500 MHz, CDCl3): 3.78 (s, 3H, CH3), 4.17 
(s, 2H, CH2Ar),  5.10 (d, 1H, J 13.7 Hz, H1), 5.23 (dd, 1H, J 1.9 and 13.7 Hz, 
H1’), 6.20 (brs, 1H, H3), 6.78-6.84 (m, 3H, HAr), 7.06 (s, 1H, H7),7.24 (t, 1H, J 
7.9 Hz, HAr), 7.23-7.34 (m, 5H, HAr), 8.28 (s, 1H, H4); C (126 MHz, CDCl3): 
44.7 (CH2, CH2Ar), 55.4 (CH3), 72.6 (CH2, C1), 84.7 (CH, C3), 112.1 (CHAr), 
115.2 (CHAr), 115.9 (CHAr, C7), 121.8 (CHAr), 127.0 (CHAr), 128.7 (CHAr), 
129.0 (CHAr), 130.0 (CHAr), 136.1 (CAr), 141.0 (CAr), 141.3 (CAr), 143.6 
(CHAr, C4), 150.0 (CAr), 160.0 (CAr), 160.2 (CAr); max/cm
-1 (neat) 3055, 2937, 
2837, 1599, 1584, 1489, 1454, 1393, 1260, 1041; m/z (AP+) 318 ([M+H]+, 
70%); HRMS calc. for C21H20NO2 318.1500, found 318.1492 [M+H]
+. 
6-(3-Methoxybenzyl)-1-phenyl-1,3-dihydrofuro[3,4-c]pyridine 3.112e 
 
 
Rf 0.16 (hexane/ethyl acetate 4:1); H (500 MHz, CDCl3): 3.74 (s, 3H, CH3), 4.06 
(d, 1H, 14.7 Hz, CHH’Ph), 4.14 (d, 1H, 14.7 Hz, CHH’Ph), 5.20 (d, 1H, J 12.3 
Hz, H3), 5.35 (dd, 1H, J 2.4 and 12.3 Hz, H3’), 6.08 (brs, 1H, H1), 6.73-6.81 (m, 
3H, HAr), 6.89 (s, 1H, H7), 7.19 (t, 1H, J 7.3 Hz, HAr), 7.26-7.39 (m, 5H, HAr), 
8.53 (s, 1H, H4); C (126 MHz, CDCl3): 44.7 (CH2, CH2Ph), 55.4 (CH3), 71.6 
(CH2, C3), 85.8 (CH, C1), 112.1 (CHAr), 114.8 (CHAr), 117.1 (CHAr, C7), 121.6 
(CHAr), 127.1 (CHAr), 128.7 (CHAr), 129.0 (CHAr), 129.8 (CHAr), 133.2 (CAr), 
140.8 (CAr), 141.2 (CAr), 142.6 (CHAr, C4), 152.4 (CAr), 160.0 (CAr), 160.1 
(CAr); max/cm
-1 (neat) 3053, 2924, 2837, 1598, 1488, 1263, 1149, 1040; m/z 
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(AP+) 318 ([M+H]+, 100%); HRMS calc. for C21H20NO2 318.1489, found 
318.1491 [M+H]+. 
 
 
1-Phenyl-6-(3-(trifluoromethyl)benzyl)-1,3-dihydrofuro[3,4-c]pyridine 3.112f 
 
 
Rf 0.26 (hexane/ethyl acetate 4:1); H (500 MHz, CDCl3): 4.33 (s, 2H, CH2Ar), 
5.22 (d, 2H, J 12.3 Hz, H3), 5.35 (dd, 1H, J 2.3 and 12.3 Hz, H3’), 6.09 (brs, 1H, 
H1), 6.82 (s, 1H, H7), 7.25-7.37 (m, 7H, HAr), 7.43 (t, 1H, J 7.5 Hz, HAr), 7.64 
(d, 1H, J 7.7 Hz, HAr), 8.54 (s, 1H, H4); C (126 MHz CDCl3): 40.6 (CH2, 
CH2Ar), 71.6 (CH2, C3), 85.7 (CH, C1), 117.4 (CHAr, C7), 123.6 (C), 125.8 
(CAr), 126.2 (q, J 5.8 Hz, CHAr), 126.8 (CHAr), 127.0 (CHAr), 128.8 (CHAr), 
129.0 (CHAr), 132.1 (d, J 4.1 Hz, CHAr), 133.5 (CAr), 137.8 (CAr), 140.6 (CAr), 
142.6 (CHAr, C4), 152.5 (CAr), 159.0 (CAr); max/cm
-1 (neat) 3054, 2988, 2861, 
1609, 1483, 1455, 1396, 1313, 1264, 1120; m/z (AP+) 372 (90%), 370 (100%), 
356 ([M+H]+, 80%); HRMS calc. for C21H17NOF3 356.1257, found 356.1253 
[M+H]+. 
 
 
Diethyl 3-oxo-1-phenyl-1,3,4,5-tetrahydrobenzo[c]oxepine-7,8-
dicarboxylate 3.121 
 
 
Rf 0.48 (ethyl acetate); H (500 MHz, CDCl3): 1.29 (t, 3H, J 7.1 Hz, CH3), 1.37 (t, 
3H, J 7.1 Hz, CH3), 2.81-2.87 (m, 1H, H5) 3.07-3.12 (m, 1H, H5’), 3.15-3.21 (m, 
1H, H4), 3.33-3.34 (m, 1H, H4’), 4.28 (q, 2H, J 7.1 Hz, OCH2), 4.37 (q, 2H, J 7.1 
Hz, OCH2), 6.65 (s, 1H, H1), 7.24 (s, 1H, HAr), 7.30 (d, 2H, J 7.3 Hz, HAr), 
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7.39-7.44 (m, 3H, HAr), 7.58 (s, 1H, HAr); C (126 MHz, CDCl3): 14.2 (CH3), 
14.3 (CH3), 28.6 (CH2, C5), 33.2 (CH2, C4), 62.0 (OCH2), 62.1 (OCH2), 80.4 
(CH, C1), 127.4 (CHAr), 129.1 (CHAr), 129.2 (CHAr), 130.1 (CAr), 130.5 
(CHAr), 130.9 (CHAr), 133.3 (CAr), 138.0 (CAr), 139.2 (CAr), 141.4 (CAr), 
166.7 (C=O), 167.4 (C=O), 172.5 (C=O); max/cm
-1 (neat) 3059, 2984, 1718 
(C=O), 1449, 1368, 1265; m/z (AP+) 383 ([M+H]+, 100%); HRMS calc. for 
C22H23O6 383.1500, found 383.1490 [M+H]
+. 
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6.4 Experimental procedure for chapter 4 
 
Following the procedure of Mosmann:209 1 × 104 cells/ml were inoculated into 
each well of a 96-well plate and incubated overnight at 37 °C in a humidified 
atmosphere containing 5% CO2. All the compounds were dissolved in DMSO 
and then diluted in complete cell culture medium to give final test concentrations 
of 5 and 50 µM and making sure that the maximum final DMSO concentration 
was not greater than 0.1%. Medium was removed from each well and replaced 
with compound or control solutions, and the plates then incubated for a further 
96 h. After 96 h culture medium was removed and 200 µL of 0.5 mg.ml-1 MTT 
solution  in complete medium added to each well. Following a further 4 h 
incubation, the solution was removed from each well and 150 µL of DMSO 
added to solubilise the formazan crystals resulting from MTT conversion. 
Absorbance values for the resulting solutions were read at 550 nm on a 
microplate reader and cell survival calculated from the ratio of absorbance of 
treated cells to control cells. Results were expressed in terms of IC50 values 
(concentration of compound required to kill 50% of cells) and all experiments 
were performed in triplicate. 
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